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Abstract 
 
 
Generic medications are those medicines manufactured by a pharmaceutical company without 
a license from the company that has first invented and patented the same drug, when the related 
patent and other exclusivity rights have expired. Only studies of bioequivalence are requested 
as requirements to introduce a new generic medication in clinics, making easier and financially 
attractive for many pharmaceutical companies to participate in this typology of market.  
Organised criminality is strongly attracted by this market both for the high profitability, and 
for the high similarity to the production and trafficking of illegal controlled substances 
associated to the extreme difficulties faced by the law enforcement authorities in effectively 
investigating the online market, because of its anonymity. 
A significant paradigm continuously frequented in pharmacology is the confliction between 
views on generic medications that can be used interchangeably with the original medicines. 
Several clinical studies conducted in certain medical areas have shown as the generic 
medications present an overlapping therapeutic equivalence to the original ones. On the 
contrary, for certain other generics, both pharmacokinetics and pharmacodynamics issue have 
been reported. Also, in some cases issues on the stability of generics have been raised.  
Despite the numerous research articles and reviews published on the matter of clinical 
equivalence among generic and original medications, no study to the scientific community has 
been presented on an analytical evaluation of the chemical composition of the different generic 
drugs that could shed some lights on the reason of the different clinical performances reported.  
The main aim of this research was to develop a non-destructive quick qualitative 
analytical methodology to be able to discriminate differences in the chemical composition from 
generic medicines that have been reported not presenting similar therapeutic equivalence in 
clinical comparison studies, obtained from authorised pharmacies and non-authorised online 
sellers.  
From the cardio-vascular area, digoxin (with the related cardiac glycosides digitoxin and 
digoxigenin) and amlodipine (in its different salts maleate, mesylate and besylate used in 
therapies). In the gastroenterology area, omeprazole both in its racemic and isomeric forms, 
have been selected as samples to be analysed. In the antihistamine area, cetirizine, in its racemic 
and isomeric forms, equally for the same reasons as before, have been considered. As starting 
analytical approaches, voltammetry, FT-IR, Raman spectroscopies and NMR have been 
considered and a statistical data analysis approach of the analytical data obtained based on 
Abstract 
!
!
!
8!
multivariate analysis such as principal component analysis, cross validation, correlation scatter 
plots and factor loadings has been implemented. 
This work has matched the aims initially set, generating novel methods of analysis to 
investigate differences in the chemical composition within different groups of generic 
medications. This study has led to the creation and interpretation of new knowledge, through a 
systematic acquisition and understanding of a substantial body of scientific literature and 
through original research, and adjusting the project design in the light of unforeseen problems, 
conceptualizing, designing and implementing the research project for the generation of novel 
knowledge. 
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Preamble 
 
 
Generic substitution has become common practise amongst healthcare professionals since 
generic medications can be used interchangeably with the original medicines. A significant 
paradigm continuously frequented in pharmacology is the confliction between views on 
generic medications. There is a substantial amount of clinical comparison studies that report 
how some generic medications show marked different therapeutic outcomes. There are 
concerns in the healthcare sector, as well as among patients, that not all only generic 
preparations are not equally clinically effective but also that their quality could be questioned, 
considering the risk of illegal introduction of fraudulent medications in the conventional chain 
of supply. Therefore, there is the need to develop a non-destructive quick qualitative analytical 
methodology to be able to discriminate differences in the chemical composition of similar 
medications from generic medicines, in order to adopt a flagging system able to give 
information on the nature of the medications tested. 
In order to facilitate the reader an outline of the thesis is presented here below: 
Chapter 1 gives the the outline of the thesis with introduction on the generic medication past 
and current situation, with a mention to the problematic of the counterfeiting criminal activities 
that revolve around the use of generic medicine.  
Chapter 2 presents the aims and objectives of the research project. 
Chapter 3 describes the analytical methods employed, giving an overview of their theoretical 
basis and of the medications analysed, chosen among the ones that have been reported 
presenting bioequivalence issues. 
Chapters 4 to 7 present specific studies conducted using voltammetry, Raman and FT-IR 
spectroscopies on cardiac glycosides, calcium channel blocker, proton pump inhibitors, 
antipsychotic and anti-allergic medications aimed to find the optimal analytical conditions to 
set a flagging analytical system. It also introduces the statistical analysis of the data set obtained 
by these different analytical approaches. 
Chapter 8 gives the conclusions of the research and presents the gains and limitations of the 
work.  
Chapter 9 provides links to scope for future work. 
 
CHAPTER 1                                                                                                                                Introduction  
 10 
1. INTRODUCTION 
 
 
1.1. Generic and branded medications  
 
1.1.1. Definition of generic medications 
According to the definition given by the World Health Organisation (WHO), generic 
medications, or complementary equivalent medications, are those medicines 
manufactured by a pharmaceutical company without a license from the company that 
has first invented and patented the drug, when the related patent and other exclusivity 
rights have expired [1].  
The assessment of the therapeutic equivalence between a generic medicine and the 
original one is based on the concept of bioequivalence. Two or more products are 
recognised as bioequivalent when, administrated at the same dose with the same 
formulation, reach the same site of action with the similar rate and extension [2].  
Two pharmaceutical products are classified as therapeutically equivalent when they 
have the same clinical effect and safety profile [3]. 
Pharmaceutical equivalence is related to the same amount of the same Active 
Pharmaceutical Ingredient (API), in the same formulation, for the same route of 
administration, with comparable standard. Bioavailability is related to pharmacokinetics 
and pharmacodynamics characteristics of the comparing products. Pharmacokinetics 
parameters obtained from blood sample of volunteers involved in cross-over 
comparison studies are also considered when studying the bioequivalence. The 
pharmacokinetics is calculated as the area under the curve of the plasma drug 
concentration versus time (AUC) where peak concentration (Cmax), time to peak (tmax), 
absorption lag time (tlag) are the main parameters used to evaluate the bioavailability 
between different products. Particularly the peak concentration is used to assess the 
absorption rate, and the AUC is the feature used to evaluate the extend of drug 
absorption [4] 
The foundation at the base of the model of bioequivalence is that if the different drugs 
are characterised as identical or similar, within a specified range, they will have same 
level of safety and therapeutic efficacy [5]. The FDA considers bioequivalent products 
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whose areas under the drug concentration is within 90 % confidence interval for the 
ratio sample versus reference. Another parameter taken into consideration is the 
maximum drug plasma concentrations which must fall between 80 and 125% [6].  
When pharmacokinetic parameters are not obtainable because the medications 
specifically act on topic areas, for instance in case of comparison of the bioavailability 
of inhalers, pharmacodynamics features are compared [7]. 
Complementary equivalent medications are subjected to individual policies depending 
on the country of delivery and following different pharmaceutical regulations, even if 
produced by the same company. They are world wide labelled with a generic 
international non proprietary name (INN) adopted by the WHO [8]. The concept behind 
the introduction of a standard international name recognised worldwide is to guarantee 
recognisability and reducing prescribing errors. The INN for medication has been 
introduced by WHO in 1953. 
Bioequivalence studies between innovator product and its generic alternative allows 
marginal chemical differences in the chemical structure of the drugs to be tested, for 
example the generic medications can be present as different salts or ester moieties [6].  
Polymorphism is the aptitude of certain solid compounds to exist in more than one 
crystalline form. Although chemically identical, the polymorphs have dissimilar 
structural matrix which produce differences in their chemical-physical features such as 
hygroscopy, refractive index, melting point, spectral vibrational transitions, density. 
More than half of the active pharmaceutical ingredients are reported to present more 
than one polymorphic form [8,9]. 
These polymorphic forms of a drug differ in the physicochemical properties like 
dissolution and solubility, chemical and physical stability, flowability and 
hygroscopicity. These forms also differ in various important pharmaceutical outcomes 
such as drug efficacy, bioavailability, and even toxicity. Polymorphic studies are 
important as a particular polymorph can be responsible for a particular property which 
might not be exhibited by any other form. 
The stereochemistry of the polymorphs is also a crucial parameter. The molecular 
dissymmetry and chirality associated is now being employed in the pharmaceutical drug 
development. Each optically active compound has different pharmacological activity 
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and it has been proved that chirality with dissymmetry, directly affects the 
pharmacological activity [10]. 
Consequently, it is critical to perform suitable polymorphic selection for each active 
pharmaceutical ingredient (API) and select the most stable polymorph for the product 
development. The most stable polymorph should be employed in the marketed 
formulation to prevent polymorphic alterations during manufacturing, delivery, or 
storage. In general, the selected polymorph should be thermodynamically stable during 
the drug development process and remain stable during the manufacturing process too 
[11]. In this context, various federal agencies require the appropriate description of the 
solid state of the API employed in the formulation [12]. 
Furthermore, on the regulatory aspect, currently there are concerns in reference to the 
clarity of the guidelines dealing with the polymorphic transitions of the API as well as 
the potential excipients [13]. 
Pharmaceutical companies introduce their products into the market under well-covered 
patents, in order guarantee the condition to generate income from the commercialization 
of their findings. Having the right of exclusivity on that medication allows the inventor 
company to avoid competitors to enter the same market with the same product for a 
certain period of time [14]. 
The cost for the introduction in the market of a new medication takes into consideration 
all the phases incurred in the drug development of the product, from the initial research 
and development, to the safety and efficiency studies, the manufacturing, regulatory 
approval and the patenting cost. In 2014, it was estimated that the average of such a cost 
was 2.6 billion American dollars [15]. Because of this level of financial commitment in 
the developing of new medications, the focus on recoup of the incurred costs and the 
expected profit is paramount. 
During the period of validity of the patent, sometimes in the range of 20 years, the 
company benefits from a period of exclusivity. In this period the return and profitability 
is maximized covering even the costs incurred in the drug discovery and research of 
other drugs that have not been successful at any stage of the development path.  
Generic medications when introduced into the market are sold at a considerably lower 
price than the original one. However, despite the lower price, the profit margins in the 
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complementary equivalent medications market are considerable, because of the fewer 
expenses incurred, not having had the burden of initial drug development. 
 
 
1.1.2. History of generic medications 
The use of generic medications is an old well-known alternative to the original ones, but 
it is only since the first decade of the 80s that have become known worldwide by the 
public. In fact, one of the first references of the use of generic medications, with the 
legal issues related to them, can be tracked down to the beginning of 20th Century when 
Bayer had to protect its most important drug, Aspirin, from the replicas produced 
intensively by other companies [16]. During the first period of co-existence in the 
market of both original and generic drugs, the regulatory affairs office of the FDA in 
America and the equivalent office worldwide were not particularly strict in applying the 
standards to accept generic medication for clinical use. The main safety test was 
essentially post-market, when the patients could report side and unexpected effects. The 
devastating drama of the Thalidomide overlooked usage forced a change in the 
regulation [13]. Thalidomide was introduced in the market in 1957 as over the counter 
available medication to treat the morning sickness in pregnant women. Shortly after the 
first years of use, around 10000 new births with malformation of limbs were reported all 
over the world [14]. 
As a result of such a scandal, in 1962, the FDA modified the related act for new 
admitted medications, strengthen the testing processes for authorization [15]. The safety 
and effectiveness control of new medications was then raised at a much higher standard, 
both for the original and for the complementary equivalent medications manufacturers. 
The pharmaceutical companies had to face lengthier and extremely expensive research 
and development studies before being able to introduce brand new drugs in the market. 
At this stage, because of the high cost, not many pharmaceutical company interested in 
producing generic medications were actually engaged in this market sector, being 
financially unrewarding.  
In 1984 a new law, known as the Hatch-Waxman Act [15] changed some of the 
requirements requested to the generic medicines, making it financially convenient to 
produce complementary equivalent medications. Within the Hatch-Waxman Act 
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conditions, the pharmaceutical companies producing generic medications are no longer 
requested to repeat the the long lasting and costly pre-clinical and clinical tests, already 
done by the original company when initially produced the innovator branded 
medication. From 1984, within the Hatch-Waxman Act regulations, only studies of 
bioequivalence are requested [16]. Essentially, within these new regulations, to obtain 
the authorization to introduce a new complementary equivalent medication into the 
market, a generic manufacturer needs only to prove that its new generic product 
contains the same active pharmaceutical ingredients (API), have the same strength, use 
the same formulation and use the same route of administration [17] of the original 
branded used as reference. This change of the entry requirements attracted more 
pharmaceutical companies in this line of business, changing dramatically the therapeutic 
habits in the last decade.  
 
 
1.1.3. Patent protection  
A patent is the legal right of temporary exclusive exploitation of an invention hold by 
the inventor without having competitors to exert any commercial pressure by copying 
the invention itself [18]. The duration of legal protection varies among the different 
countries, being usually between 15 to 20 years. An invention to be able to be patented 
must meet specific requirements. Novelty is the main feature of a patent, being 
necessary that the invention is for the first time available to the public. Another main 
feature of an invention is that it must not be obvious for the technical expert of the 
sector. It must not be a simple straightforward implementation of the current technical 
knowledge but must retain a level of inventiveness, the so called ‘inventive step’, that 
place the invention is an adequate distance beyond or above the state of the art" [18]. 
Finally, the invention must have an industrial application, being able to be replicated in 
the manufacturing sites and having a market where to be sold [19]. 
Considering the high cost involved in pharmaceutical research and development, 
patenting is the preferred way to protect the investment and guarantee the expected 
financial return. When the protection period ends, the original inventor loses its 
exclusivity rights and other actors can be able to exploit the invention. Nevertheless, not 
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all the countries have patent laws enforced and in some states medications are not 
considered patentable.  
In the pharmaceutical sector, the main types of patents cover the product, the process, 
and the formulation. The patent on the product, covers the active pharmaceutical 
ingredient as a new medication, and it is the most important but also the less frequent. 
The patent can cover the process to obtain the specific product or only the process to be 
used for the preparation of different products. The claim could be on the formulation of 
the the medication, i.e. on the end product not only on the API. This can include the 
excipients and the coating agents. Finally, the method of use can be also claimed in the 
patent, covering the new use of a drug to cure a medical condition. It is worth to remark 
that not all the categories of patents are recognised in all countries. 
 
 
1.1.4. Financial implications in the switch from branded to generic medications 
Switching from innovative brand to generic medications can halve the cost paid directly 
or indirectly by the patients. Particularly in developing countries with low and middle 
income the switch from innovative to generic medication generates great savings [20]. 
In China, it has been estimated that 370 million US dollars could be saved changing 
only four medications from originator to generic ones, with a potential saving of 65% 
[21]. In certain developing countries, for some medications, the gap in cost between 
branded and generic medication can even be more than ten-fold [22]. 
In the United Kingdom, the cost of prescribing in primary care has increased 4 times 
over the past 40 years, from two billion pounds in 1976 to 8 billion pounds in 2013 
[23]. These figures are related to the increase in the volume of prescribed medication as 
a whole but it suggests a conversion in the prescription habits of the prescribers from 
originator to generic medications, with the relative changes in prices [24]. It has also 
been reported that the number of prescription of branded medications in the last 40 
years has dropped by 33%. This change in habits on prescribing and dispensing 
complementary equivalent medications over branded ones has had an overwhelming 
effect on the productivity (measured as the ratio of the debit against the credit) of the 
prescribing budget in primary care [23]. Such increase is the result of the combination 
of the increased volume of generic medications prescribed and impact of new the 
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Pharmaceutical Price Regulation Scheme policies on costs for generic medicines [24]. 
On these basis, the NHS has saved approximatively 7 billion pounds in the last 40 
years. Currently the ratio of generic medications prescribed is around 84% of the total 
of medications prescribed yearly. Certain medications, for different reasonable reasons, 
are still prescribed as brands, with an average cost 7 times higher than the equivalent 
generic drug [23, 24].  
In 2007, the yearly prescription cost in the USA amounted to over 280 billion US 
dollars, raising the focus on the use of complementary equivalent medications in order 
to condense the financial impact on public funds [25,26]. In this country, generic 
medications represent approximatively 66% of the total medications prescribed 
annually, but account for less than 13% of the total cost [27]. It has been reported that a 
further exchanging of prescribing habits from original to generic drugs could lead to a 
continued reduction by 11% per year in the total USA financial budget for medication 
[28]. Particularly, in the cardiovascular clinical area, a reduction of 25% it is expected 
by the generic switching of the hypertension medications [29]. 
 
 
1.1.5. Perception of the use of generic medications from the patients 
The increase of the volume of a multitude of generic medications manufactured by 
different companies for the same branded medicine causes perplexity within the general 
public [30]. 
It has been reported that spread feelings of uncertainty amongst both general public and 
health professionals on the equivalence in quality between branded and generic 
medications occur [31]. Specifically, the bioequivalence has been questioned in terms of 
generic substitution, in reference to the different industrialized processes and 
pharmaceutical technologies adopted. As a matter of fact, the efficacy of the method to 
test the bioequivalence and the concept of bioequivalence itself has been disputed. 
Furthermore, amid different countries, there are slight different approaches to test 
bioequivalence and this lack of international harmonization represents also an element 
to doubt about the results obtained [32]. 
Furthermore, in countries where the patent protection in the pharmaceutical business is 
not implemented, a reduced inclination to use generic medication prescribing and lack 
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of financial incentives for pharmacies to dispense generic drug have been observed. 
This is giving the impression to the general public that generic medications are 
considered as poor quality medications [33]. 
In a study conducted on adult individuals in Columbia (USA) to assess patients’ 
awareness on generics, patients acknowledged that complementary equivalent 
medications are as safe as the reference branded and financially beneficial [34]. 
Nevertheless, despite the fact that 56% of the population interviewed agreed that more 
generic drugs should be adopted in therapeutic treatments, only 38% actually prefers to 
take complementary equivalent medications for themselves. In the USA, it has been 
reported that the usage of generic medications is inconsistent and that there are patterns 
of different use amongst different social groups. For instance, the perception of 
equivalence between generic and brand-named medications is lower in poorer 
communities, in younger generations and in patients who receive a regular care from 
specialists [35-37]. 
 
 
1.2.  Clinical studies on therapeutic equivalence of generic medications  
The idea that bioequivalence characteristics of two medicines are the ones to be taken 
into consideration to assess their therapeutic equivalence is generally accepted [38, 39]. 
For many years, the assessment of the bioequivalence has been used as official test to 
allow the introduction of new medications in clinical usage [39, 40]. However, in some 
circumstances when the formulation tested is not the same than the final formulation to 
be used clinically some more additional bioequivalence studied are necessary to 
demonstrate clinical equivalence [40].  
The issue on the compliance with the bioequivalence requirements for a medication to 
be classified as a generic medicine relies on the fact that the tolerance accepted is not 
strict enough in case of medicines with a narrow therapeutic index or with an elevated 
intra subject and inter subject variability [38-41]. 
Based on a review that took into consideration three decades of literature referred to the 
effect of generic substitution on extended areas of therapy, a change in the modality to 
test the therapeutic equivalence of medications and a switch from measurements of 
average bioequivalence to individual and population bioequivalence has been proposed 
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[41]. The concept that bioequivalence is comparable to therapeutic equivalence has 
raised many criticisms. It has been reported that the tests for the approval of generics 
are not as stringent as the ones to allow the first introduction in therapy of new branded 
medications and that the level of the clinical equivalence tests among generics in 
comparison with the reference branded product is not acceptable [42]. 
Clinicians have identified a number of therapeutic areas where generic substitution 
ought to be applied carefully. In some particular areas of therapies, those concerns were 
so high that several comparison studies to check the interchangeability among generics 
and branded have been performed and published. Some of these studies have 
demonstrated the therapeutic equivalence amongst generic medications and original 
one, but some others have raised doubts about their similarity in clinical efficacies.  
In the following paragraphs, it has reported an essential panorama of those medications 
where interchangeability has been proved and where strong concerns have been raised. 
 
 
1.2.1. Clinical areas where therapeutic efficacy has been confirmed 
 
1.2.1.1. Osteoporosis   
Osteoporosis is a pathology characterised by a demineralization of of the bone structure 
leading to a reduction in density with a resulting decay of the mechanic features of the 
skeleton [43].  
Osteoporosis is the first cause of bone fractures in the elderly [44, 45]. The 
demineralization occurs without any substantial symptoms and the breakage can 
consequently occur unexpected [46]. About 65-70% of population over 80 years old 
seems to be suffering of such condition [47-50]. Alendronic acid is a drug, belonging to 
the family of bisphosphonates, used in UK as first line of treatment [51] to inhibit the 
resorption of mineral from bone operated by the osteoclast cells.  
Extensive studies on the efficacy of bisphosphonate have been produced [52-61]. 
Alendronic acid has shown to reduce significantly the breakage of bones [54-56] by 
improving bone mass and lower bone turnover [55-61].  
The methods to assess the efficacy of on the mineralization of bone tissue is based on 
physical assessment of the mechanical properties of the bones such as bone mineral 
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density [62], X-Ray measurement [66], measurement of telopeptide in the cross linked 
structure of collagen [67]. In several studies [68-75] different branded and generic of 
alendronate medications have been compared in order to assess their efficacy and safety 
for patients. Different trials have been performed over significative period of time and 
different treatments on different test groups treated with the different manufactured 
alendronate tablets, at the standard dosage of 70mg once a week. Their bone mineral 
density was measured at different bone areas, more often on the lumbar spine, hip, and 
femoral neck. During and at the end of the test period of treatment, the bone mineral 
density for all patients was significantly higher than the values at the beginning. In this 
area of therapy, the generic medications have shown to be interchangeable.  
 
1.2.1.2. Hypercholesterolaemia  
Cholesterol is one of the main lipids that is used by cells to synthetize their membranes 
[76]. Cholesterol is insoluble in water and therefore needs to be transporter all over the 
body through the blood stream linked to lipoproteins. Despite the fact that this molecule 
is directly involved in the mechanism of production of cell membranes, a high 
concentration in the blood, hypercholesterolemia, is associated with pathology such as 
atherosclerosis, and particularly in the heart, coronary heart diseases [77-79]. 
Hypercholesterolemia is caused by two separate factors: genetic and life-style. A survey 
on the rate of population over 20 years old affected by hypercholesterolemia, shown as 
in 2010, around 13% presented blood level over the normal range [76]. When changes 
in life-style do not succeed in reducing the cholesterol level, a drug therapy is required. 
First line of treatment for anti-hypercholesterolemia is a group of medications called 
statins. They inhibit the HMG-CoA reductase, an enzyme involved in the biosynthesis 
of cholesterol. Different studies have been completed to ascertain the efficacy of such 
medications [77, 78]. Other studies have been performed to test the interchangeability 
of generic statins [79-90]. It has been highlighted the fact that replacement in therapy 
with generic statins represent a cost saving choice, being reassured on the efficacy, 
having the generic statins shown similar therapeutic efficacy to the referenced branded 
medications. 
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1.2.2. Clinical areas where therapeutic efficacy has not been confirmed 
 
1.2.2.1. Glaucoma  
Glaucoma is a group of ophthalmic conditions characterised by an increased intra ocular 
pressure (above 30mmHg) that stresses the optic nerve, damaging the connection 
between eyes and brain and leading to a loss of peripheral vision [91]. Open angle 
glaucoma is the most common, followed by the closed angle glaucoma and normal 
tension glaucoma [92]. In open angle glaucoma, the trabecular meshwork, is obstructed, 
allowing less fluid to leave the eye, increasing therefore the local pressure. This 
condition progresses gradually over time with no apparent symptomatology. It 
represents the 80-90-% of all the glaucoma conditions [91]. With closed-angle 
glaucoma, such a canal is still open but very narrowly, reducing the fluid drainage. This 
second type of glaucoma can develop slowly or rapidly. Normal angle glaucoma is less 
known, being characterised by a damaged optical nerve not associated to any high intra 
ocular pressure. 
Globally, this pathology affects currently over 67 million people, with a predicted raise 
to 80 million in 2020, 74% of which will be open angle glaucoma [93].  In the USA, the 
overall population affected by this condition is about 2 million, being more common in 
older generations. 
In glaucoma conditions, the main therapeutic goal is lowering the ocular hypertension. 
Topical treatment, with the use of eye drops, is the preferred therapy, being 
prostaglandin analogues the first line treatment recommended. Prostaglandin analogues, 
such as latanoprost, bimatoprost and travoprost, increase the outflow of the intra ocular 
liquid. Beta blockers, such as timolol, reduce the production of the intra ocular humor. 
Carbonic anhydrase inhibitors, such as dorzolamide, reduce the secretion of intra ocular 
liquid [94,95]. 
Studies on the interchangibility of latanoprost and combined dorzolamide-timolol 
generic medications in comparison with the relative branded equivalent have been 
performed [96-98]. Concern has been raised on the ability to obtain the same magnitude 
of results when switching from original medication to the equivalent generic ones. 
The concentration of active ingredients and preservatives in 2 different generic and 
branded eye drops of dorzolamide and timolol and latanoprost, has also been monitored 
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using liquid chromatography in tandem with mass spectrometry (LC-MS). The bottles 
of eye drops have been tested and then stored at 25 °C for 30 days and then re-tested 
again. After this length of time, latanoprost in the branded product was still 94% of the 
original starting value while in both the generic eye drops the concentration dropped to 
less than 78%. Furthermore, the particulate counts of both dorzolamide-timolol and 
latanoprost generic had a significative increase in particulate material and in some cases 
long string-like contaminants were spotted. 
 
1.2.2.2. Gastro Esophageal Reflux Disease 
Gastro Esophageal Reflux Disease (GERD) is a condition in which an excess of gastric 
acid overtakes the stomach sack and reverses up into the esophagus, irritating its 
epithelium [99]. This is due to a not efficient closure of the lower esophageal sphincter 
that allows the passage of acid coming up from the underneath stomach. The esophageal 
epithelium is different than the gastric mucosa, being particularly sensitive to acid 
aggression. Factors that can trigger GERD are several [100, 101], the most recurrent 
ones are hiatal hernia, obesity, increased production of gastrin due for instance to a high 
level of calcium in the blood stream or to Zollinger-Ellison syndrome. Other factors are 
related to life-style and side effects of certain classes of medications. 
GERD affects between 10 to 20% of western population [102], with daily episodes 
affecting 4-7% of the population. The incidence of the condition is higher in developed 
countries and lowering in African and Asian developing countries [103]. 
First line treatment for GERD addresses the use of Proton Pump Inhibitory (PPI) [104]. 
This class of medications inhibit specifically the proton-potassium ATPase pump in the 
stomach parietal cells, blocking the final step of acid production. The therapeutic action 
of omeprazole, the most common remedy, appears in an hour after administration and 
lasts up to three days [105]. Other medications used for GERD are H2 antagonist, such 
as ranitidine, and antacids [106]. 
Several studies have assessed the therapeutic effect of PPI [107-109] highlighting the 
efficacy of the results with relatively non relevant contraindication. 
High concerns have been raised by different clinical studies about the interchangeability 
of PPI among generic and branded medications, Comparison studies [110-112] have 
suggested that the acid suppressive action of generic PPIs are not necessarily 
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comparable, reflecting different clinical results, with the concept that bioequivalence 
not necessarily imply same therapeutic efficacy [113]. 
 
1.2.2.3. Bacterial infections  
Antibiotics are a group of medications that are used to treat or prevent bacterial 
infections [114] by killing or preventing the growth of bacteria. Antibiotics are divided 
in different classes according to their mechanism of action and specific typology of 
infections they can treat. Nowadays, the majority of antibiotics are produced altering 
partially in manufacturer plants natural products [115]. 
Rifaximin branded and generic have been tested in a study of pharmacokinetics 
analyzing through HPLC-MS plasma and urine samples after set time from 
administration of the antibiotics. The results obtained showed remarkable differences in 
Cmax and AUC between original and generic medications, highlighting a different 
bioavailability [116].   
A review of articles related to the comparison of effectiveness of generic antibiotics 
suggests that there is a concern on the claims of therapeutic equivalence in this class of 
medications. Particularly for intravenous antibiotics, it has raised alarm on different 
level of impurity found. Also, pharmacokinetics and pharmacodynamics correlations 
have been reported being different in the comparison within same groups of generic 
antibiotics [117]. 
 
1.2.2.4. Cardio Vascular Diseases  
Cardiovascular disease (CVD) is a large class of conditions that affect either the 
myocardial muscle and peripheral vessels or both. CVD represent the principal cause of 
death internationally [118]. Coronary artery disease, such as angina, myocardial 
infarction and stroke represent a cause of death for 80% of the male population and 75% 
in females [119]. Age is one of the main parameter to influence the epidemiology of 
these conditions. In USA, while cardiovascular disease affects 11% of the population 
aged between 20 and 40 years old, in the range of age between 60 and 80 years old the 
rate raises to 70 % [120]. In the western countries the average age of death from CVD is 
around 80 while in the developing countries it is around 68 [121]. CVD incidence is 
also sex related, occurring seven to ten years earlier in male population as compared to 
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women [122]. In a survey of nearly 50 articles, different classes of medications used in 
CVD have been taken into consideration to study the efficacy of complementary 
equivalent medications versus the reference brad-name medicines. Beta blockers, 
diuretics, calcium channel blockers, antiplatelet agents, statins, angiotensin converting 
enzyme inhibitors, alpha blocker have been compared. The results indicated a no 
evidence of superiority of branded medications over the generic ones but diverse 
therapeutic outcomes obtained with the different generics. More than half of articles 
analysed indicated a negative view on the interchangeability of medicines [123]. 
 
1.2.2.5. Allergic reactions  
Antihistamine medications try to inhibit and suppress seasonal and perennial allergic 
reactions, such as allergic dermatitis, urticarial, rhinitis and ocular allergy without 
exerting a major effect on the autonomic central level [122]. Cetirizine and loratadine 
are relative recent antihistamines, defined as a second generation tricyclic antihistamine, 
with an effective long-acting selective peripheral H1-receptor antagonist activity, with a 
consequently reduced sedation activity. Tablets of different generics of loratadine [122] 
and desloratadine [123] were submitted to pharmacopoeial and non-pharmacopoeial 
tests, such as friability, disintegration, solubility and mechanical tests in order to 
evaluate and compare their response. Only two over six different generics proved to 
produce comparable results both for loratadine and for desloratadine probably to 
different polymorphs and formulation used.  
 
 
1.3. Counterfeit medications  
 
1.3.1. Introduction  
Counterfeiting of medications is a serious and rapid growing danger for the patient’s 
health and the pharmaceutical industry around the globe [124-126]. Fraudulent 
medications range from products without any active therapeutic ingredients to those 
with unsafe toxicological contents.They can be not only replicas of branded medicinal 
but also of generic medications or over-the-counter products as well as faked appliances 
or diagnostic tools [127-130]. 
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According to the World Health Organization (WHO) designation [128] a counterfeit 
drug is a pharmaceutical item whose original descriptions have been purposely modified 
for deception intentions.  
Furthermore, in May 2017, during the seventieth world health assembly, it has been 
agreed to adopt the definition of ‘Substandard and Falsified medical products’ as 
official term to be used by the member states [129]. Within this definition it has been 
incorporated the classification of ‘substandard’ and ‘falsified’. Substandard defines 
those official medical products that lack of reaching the required standards of quality 
and/or to meet the necessary specifications. Falsified identifies those medical products 
that intentionally give false information on their nature, origin and structure. 
The forgeries are extremely diverse and can encompass the adulteration of a product; 
the deceptive replication of an original product; the alteration of the related packaging 
[131-133].  
To the class of Substandard and Falsified medical products belong also the items that:  
-have an original composition in terms of active ingredient and excipients of the 
genuine pharmaceutical agent, appropriately boxed and stamped but illegitimately 
introduced in a country; 
-items composed of the same constituents of the referenced medicine with original 
packaging but different amount of ingredients;  
-products which do not contain any active pharmaceutical ingredient notwithstanding 
looking identical and with original look-like packaging; 
-items visually similar to the genuine ones, with original boxing but containing unsafe 
ingredients in place of the genuine components;  
-products with fraudulent boxing but original active ingredient;  
-items with fake boxing but with dissimilar composition of active ingredients [134-136]. 
The forging of drugs could similarly be extended to: 
-item being initially original but whose boxing was altered declaring a superior amount 
of active ingredient than the actual quantity in order to be marketed with a higher price.  
-original products but expired can also be located inside boxes that show a posterior 
expire date [137-140]. 
Counterfeiting of medications is a quite obscured problem whose capacity is very hard 
to measure [141, 142], mostly when considering the adversities that the officials and 
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professional often face in discriminating a counterfeit drug from a genuine one. Based 
on a WHO report [142], counterfeit medicinal count internationally for nearly 10 per 
cent of the whole amount of medicines sold in the world. Nations like Australia, 
Canada, Japan, USA, New Zealand and those within the European Union are exposed 
only marginally to this phenomenon, reporting a very low share of counterfeit 
medicines of no more than 1% of the market value [143-146]. Nevertheless, the 
substantial volume of counterfeit medications incidents reported by developed states 
proves that this condition is extended to both industrialised [143-148] and less 
industrialised countries [149-157]. 
Predominantly in Africa [158-161], and marginally in Asia [162-164] and in Central 
and Southern America, forged medications sales range from 10% to more than 30% of 
the national legal market [145-165]. In the developing economies of many of the 
previous soviet block it is estimated an impact of the fraudulent medications of more 
than 20% of the national legal market [165-168]. FDA reported an 800 % surge in the 
incidence of counterfeit drugs in the interval 2000-2006 [169] in USA. 
On December 2008, the Directorate General of Taxation and Customs Union of the 
European Commission (TAXUD) reported on the outcomes of the MEDI-FAKE action 
[127, 168, 170]. This was an operation conducted throughout the external area of the 
European Union and performed by the customs services of all the member states and 
coordinated by TAXUD. The operation accomplished a remarkable result, leading to a 
confiscation of 34 million illegitimate medications in two months’ time. The fake 
medications ranged from antibiotics to anti-cancer, anti-malarial, anti-cholesterol 
medicines, painkillers, medications for erectile dysfunction [170]. 
In 2006, in the Russian federation, the federal health service stated that 10 % of all 
medications on the Russian market were fraudulent [167]. More recently, these share 
surged to 20 %, caused by a fast growing import of such products. In other countries of 
the area, such as Ukraine, this seems to be even worse with an estimated 40 % of the 
medications involved in the Ukrainian market being forged [166]. 
In 2005, in Peru, the local health authority, the general directorate of medicines, 
supplies and drugs (DIGEMID) of the department of health, confiscated 460000 
fraudulent medicines and out of date genuine medications [171]. 
In the same year, 2005, in Dominican Republic, the local department of health stated 
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that 50 % of national pharmacies in the country functioned illegally, having found some 
medications had expired over 10 years before. Furthermore, the authorities reported 10 
% of the drugs that were imported in the country were fraudulent [172]. 
The same year, in Kenya an unplanned inspection operated by the National Quality 
Laboratories and the Pharmacy and Poison Board disclosed that around 30 % of the 
medicines were fraudulent [173, 174]. Some of the solid counterfeit medications 
contained chalk powder and some of the liquid faked syrups bottles were only full of 
water, being marketed as genuine medications.  
In 2004, in Nigeria, the ebony state task force on fraudulent and altered medications, 
stated that around 48 % of different items and medicines introduced into the country 
were substandard falsified goods [175-179]. Within this group of false medications, 19 
% present a different composition with respect the original one; 16% have a dangerous 
or incorrect components such as chalk powder; 60 % lack of any active ingredients at all 
[172]. In India, as reported by the associated chamber of commerce and industry 
(Assocham) [183] 20 % of the drugs imported are fraudulent. that 38% of the medicines 
used in Indian national hospitals are counterfeit. Based on to two government 
investigations performed by the Cambodian ministry of health and the WHO [180, 181] 
the volume of purchased forged medicinal is in constant progressive increasing. In 
2000, in Bangkok national drug-testing laboratories reported that 3.5% of the analysed 
antibiotics and analgesics specimens resulted to be forged, with a content inferior to 
60% of the stated quantity of active principle ingredient reported on the packages. The 
same investigation was repeated in 2003 and the results shown an increased rate to 11% 
[172]. As a reaction to this results, in 2010, the inter ministerial committee (IMC), 
created with the purpose to contrast fraudulent and substandard medications import 
directed an operation that led 65% of illegitimate pharmacies to be shut down and five 
producers to stop from importing their altered goods in the country [172, 182]. 
All these are examples of a wide spread problem where countries are fighting a lonely 
war where health services and ministries are not collaborating internationally for fear to 
widespread panic in the population and lack of trust in the pharmaceutical systems.  
Among the main medications introduced in developing countries, anti malarial 
medications have been heavily targeted by counterfeiters, exploiting the high incidence 
of these pathology in African and Asian regions [182-201]. Between 1999 and 2004, in 
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South East Asia the ratio of fraudulent over the counter antimalarial medications 
boosted from 38% to 53% [184].  
Fake antibiotics [202-206] and anti viral medications of different typology [236-239] 
have are also entered dramatically the market of the same countries. 
 
 
1.3.2. Manufacturing and distribution of medications 
The manufacturing procedure and the production of medications is particularly intricate 
but it can be fractioned into two principal stages: the primary manufacturing stage and 
the secondary manufacturing stage [207]. The first stage basically is related to the 
manufacturing of the active pharmaceutical ingredient (API), which is the main 
substance with therapeutic characteristics. The second stage is related to the production 
of the end product, by incorporating the API in a mix of specific excipients that allow 
the API to be delivered to the wanted anatomical region and to act in a desired manner. 
When the end product is finalized the distribution stage is started. The distribution is 
itself divided in two stages: primary and secondary distribution. The primary 
distribution is the one relative to the delivering to the bigger warehouse directly from 
the manufacturers. The secondary distribution is the one operated from the bigger 
warehouse to intermediate distributors which in turns distribute to the final retailers, 
usually the pharmacies [207]. In certain circumstances, when there is an urgent need to 
supply a specific patient with a medication, the manufacturers sell straightforwardly to 
the pharmacies. In this case the medication is intended to be used by the specific patient 
and cannot re-enter the distribution chain [207, 208]. 
The manufactures may also decide to destine part of the medications produced for 
charity. The distributors usually do not deal with the full range of items of a single 
pharmaceutical company. They receive specific items of different manufacturers from 
different bigger distributors. The products can then be delivered to a final retailer or to 
another intermediate distributor, and restarting the process. 
The business reason of all these intermediary distributions is the possibility to lower the 
final retail price of the item and being then beneficial to the final buyer. This is made 
possible, for instance, when intermediator obtain medications at lower prices when the 
product originates from surplus in production or storage [208]. 
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The small dimension of the intermediate distributors allows them to be more flexible 
and ready to the changes in market demand. This is useful especially when there is a 
request of high volume of medications in a specific period of the year, for instance 
vaccines used in immunization campaigns. Thanks to this ability to respond quickly to 
the changes in the market demands, the intermediate distributors can counteract the 
larger distributors’ shortages when a sudden and unforeseen surge in the demand of a 
particular medications occurs.  
In different countries there could be different prices policies that make the cost of 
specific medication being different. This condition originates the phenomenon of the 
parallel import. Distributors buy the medication in the areas where the price is lower 
and sell it at increased price in other countries where the cost is higher [208]. 
This extreme intricacy of the distribution chain creates the conditions for the entry of 
fraudulent products [209]. 
Because of this complexity, the tracking of the drug journeys in the distribution chain 
from the initial manufacturer to the patients become very complicated.  
Needless to say, the higher the number of intermediate distributors in the distribution 
chain the higher the complexity in chasing the journey of the medications and the 
possible infiltration in the official chain of illicit operations. Fraudulent medicinal might 
therefore be introduced into the distribution chain at virtually all levels in various modes 
[209]. For example, some of the elements that make the process weak, can be: the 
complication of the delivery process; the limited and infrequently implemented 
checking control during the distribution and re-packaging phases; shipping 
documentation that can be effortlessly altered [208, 209]. 
The effect of parallel import and the use of the internet as an international distribution 
network significantly facilitate the entry of forged medications in the official channels 
of distribution [209]. Furthermore, business operation processes put in place by some 
intermediaries, critically show how their conduct may enable the trade of fraudulent 
medications. Throughout the entire shipping activity, each intermediary distributor 
habitually masks the references of the previous suppliers on the shipping documentation 
to preclude their clients the possibility to bypass them on further transactions [210]. 
This practice is called ‘neutralization’ and it is used therefore by many distributors in 
order to defend their business interests and exclude as many competitors as possible 
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from the distribution chain [214, 228]. Furthermore, this procedure also hides all the 
previous shipping history of the product and, concealing any traces that can refer back 
to its origin, making in fact impossible to track back the drug.  
Obviously, not knowing the origin of the medication within the distribution chain 
means not having elements to discriminate its quality. Notwithstanding the safety 
actions put in place to protect the legitimate supply chain, fraudulent medications might 
still find their way into the official distribution chain also because of intermediaries’ 
behavior [214]. Some intermediaries may have a direct accountability as they 
deliberately disguise or merely disregard the actual source of the medication or medical 
device they market [234]. The ‘One Touch’ strips incident is a good example of how the 
role of unscrupulous intermediaries in the medicines distributor chain played an 
important key role [215]. In 2006, America imported from China fraudulent blood test 
strips, used to check glucose level in diabetic patients. They have been produced 
without applying the official production standards of manufacturing and they were then 
introduced through Canada to the USA. Such adulterated strips had also been found in 
significant volumes in 35 other countries worldwide particularly in Europe and Middle 
East.  During the trial, the intermediary under investigation claimed that the company 
had only commercialised this product because they wanted to attain a more competitive 
lower prices and that they supposed the fraudulent strips were only lower priced parallel 
market products [215]. 
When legitimate medications travel in different countries and many distributors and 
retailers are involved, more complications to the identification of fraudulent 
pharmaceuticals arise. The repackaging procedure occur throughout the whole official 
distribution and shipment processes. They are necessary steps to guarantee that the 
container and instructions relative to a drug are understandable to the final patient. This 
process can be fulfilled directly by the importers, if specifically authorised, or by 
authorized companies [207]. The original container not only serves as an informative 
tool but also guarantees the originality of the medication if anti-counterfeiting features 
within the packages or labelling are applied [229]. After the opening of the product and 
the subsequent repackage these remedies might become inadequate. Furthermore, the 
code number used to identify a batch of drugs, important in case of a batch recall, every 
time that a repackage occurs, it is reprinted, creating the possibility for genuine mistakes 
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and illicit actions in the reprinting phase. Needless to say, this procedure offers huge 
chances of introducing counterfeit drugs into the official distribution channels. This 
recurrent change-hands procedure might be applied to conceal forged medications 
origin, making tracking nearly impossible. Additionally, there are further issues related 
to repackaging. In fact, the original packages should be disposed once they are switched 
with the new ones, otherwise they might be re-utilised by counterfeiters in order to be 
used as original packages for fake contents [236]. 
Other risks connected with repackaging may also be related to the possibility of alter the 
information on the original boxes. Two of the most common practices of falsification of 
packages are: the alteration of the quantity of active pharmaceutical ingredients 
(claiming more than was on the original information); the modification of the expiry 
date, allowing the distribution of out of date medicinal [231]. 
Another area exposed to risk of counterfeiting is the potential use of rejected hospital 
medications. This activity could be realised when the medication package does not 
present any anti counterfeiting protection system. In the case in which the unused 
hospital medication package still contains the medicinal, it could be remarketed while 
the original box can be used as a container for a forged medication [234]. 
 
 
1.3.3. Parallel import 
Parallel import is related to a medication that after having previously been distributed 
through the different phases of the conventional distribution chain, it is bought by the 
major distributors and introduced into the parallel distribution chain with the intention 
of relocating the product into a new more convenient market using of parallel 
intermediate distributors [208, 209]. 
Parallel import, while is a lawful commercial practice in all the European Union, raises 
large criticisms related to its effective role on the infiltration of forged product in the 
official distribution chain [167, 217]. Parallel trade may simplify the entering of 
fraudulent medications entering in the official market in several different ways. 
Nevertheless, it is possible to group those ways in 3 main factors that characterise the 
parallel import distribution chain: the amount of commercial operators involved in the 
distribution of the goods; the volume of transfers of the same good in the delivery 
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system; the number of repackaging that the same good is exposed to [208-214]. All 
these three stages of the distribution chain represent weak points that can easily allow 
the access of fraudulent products when a definite regulatory system of control is 
lacking. Both parallel and intermediary distributors operate at the secondary distribution 
level. Parallel traders necessitate a license in order to operate in this area of business but 
it is not required any form of agreement with the manufacturer. This characteristic is 
similar for midway wholesalers who also do not have a predetermined contract with the 
manufactures. Midway wholesalers exploit fast changes in the market demands for a 
medication, subsidizing the increase of exchanges between the various stakeholders. As 
a result, before reaching the final user, the medication may be transferred several times 
[217-220]. Not having any sort of contract with the initial manufacturer of the 
medications, the intermediary distributors within the secondary distribution chain can 
have the possibility to buy the medications at a reduced price and resell it where the 
higher demand allows a growing profit. Such relocations, for the same product, can 
occur numerous times [220, 225-228]. On average, it is noted that a drug may be 
subjected to a multiple number of transactions and therefore such extension of level of 
transactions make a quality control approach on the originality of the goods extremely 
complicated. At the current time, it has been reported that there is no official method of 
validating the license of parallel distributors [244-247] Furthermore, the intermediary 
distributors have no obligation to keep a record of the batch number that identify the 
medications and allows tracking through all the transitional passages. In 2007, in the 
United Kingdom, 40000 packs of tablets were confiscated by the Medicines and 
Healthcare product Regulatory Agency (MHRA) [254, 255]. The fraudulent 
medications confiscated were allegedly anti-cancer, anti-psychotic and anticoagulant 
medications. These counterfeit medications had been boxed in France, manufactured in 
China, transported to Singapore, and subsequently to France, transferred to a parallel 
importer in Luxemburg and then finally sold them to other UK parallel importers. One 
of these British parallel distributor noticed some suspected alterations and contacted the 
manufacturer, which alerted the MHRA, leading to the confiscation [254, 255]. 
Based on a report from WHO [247, 254, 256], half of the medications traded on the 
internet sites are fakes.  This peculiar market attracts people affected from different type 
of conditions, particularly those that are seen as taboos such as psychological and sexual 
CHAPTER 1                                                                                                                                Introduction  
 32 
conditions. Pfizer conducted a study on a sample of 935 men, over 35 years of age, 
using regularly the internet market [216]. The outcomes showed that half of the 
examined people purchased online medications without a regular prescription, 67% for 
erectile dysfunction medications. 60% of the surveyed men also declared if they had 
known that the medications they were buying online were forged, they might not 
conclude the purchase. 
The Food and Drug Administration released a study related to the effect of the internet 
market on the diffusion of the counterfeit medications. In this operation, the FDA 
studied a particular batch of counterfeit medicines available to buy on the internet [207, 
213]. This product was advertised as produced in Canada but was actually coming from 
27 different countries. The spam emails used to advertise the product were sent from an 
address licensed in Russia; the server for the website was located in China; the payee 
phone number was located in UK; the card payments processed in Australia and the 
product posted from US. Because of the single market regulation within the European 
Union, when a distributor obtains goods from an illegal internet source, can allow the 
spreading of the counterfeit product all over the European territory [208]. 
Counterfeiters usually penetrate the official distribution using as leverage the needs of 
the intermediary distributors to obtain goods at the lower possible price to maximize 
their profit. Once the products are introduced in the official distribution chain, they can 
therefore be marketed as all the other medications obtained from accredited 
manufacturer and it will be almost impossible to trace their origin [209-212]. 
 
 
1.3.4. The internet market 
The anonymous nature of the online market makes  the investigations performed by the 
law enforcement authorities significantly more difficult and consequently less effective 
[233], attracting the interest of criminals organizations to operate in this sector. In 2010, 
some unaware British higher education institutions were involved in a counterfeit 
medication scam involving the use of the ac.uk domains [235]. Counterfeiters exploited 
software flows in an extensively used technology named PHP utilized to make websites 
more interactive. Spammers injected a code associated with terms of the products they 
were trying to sell, such as Viagra, Cialis and other notorious names. Every time a 
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person looked for such medications online, British universities and colleges web 
addresses pop up, giving a sense of reassuring from such established institutions. Once 
the online buyer clicked on the links, they were immediately re-directed to the related 
online fake pharmacy. Those UK universities and colleges became unknowingly 
accomplices of such criminals.  
 
 
1.3.5. Geographical distribution of medicine counterfeiting 
According to the socio-economic conditions, in developed and less developed countries 
it is possible to identify diverse market choices operated by counterfeiters in respect of 
the distribution of different categories of fake medicines. This market variation is 
subjected to the different demands for specific medicines that exist in a given socio-
economic context and highlight the professional level of organization of the groups 
behind this trade [151, 152]. 
In developed countries, such as West European countries, United States of America, 
Canada, the trading of counterfeit medication predominantly involves products that are 
lifestyle-related [188]. These so called lifestyle medications include pharmaceutical 
agents against erectile dysfunction, weight loss products, fake steroids, product that 
slow down the aging process. The trafficking of fake medication in less developed 
countries, normally is related to medications used to treat serious illnesses, such as 
different kind of antibiotics, vaccines anti-malaria and anti retro-viral for HIV. The 
diversity in the categories in counterfeit medications between these two general 
different areas reflect the specific marketing strategy implemented by traffickers [188-
192]. Counterfeiters select only medications with the highest market share where the 
margin of profit are expected to be higher. In the developing countries the demand of 
certain medications is constantly high due to the constant exposure of the population to 
serious disease or epidemic catastrophes, making this market very appealing for the 
counterfeiters. The market area of developing countries is characterised by the high cost 
of the medications used to combat infections and other local typical diseases and at the 
same time by low supply of such products from the legitimate distribution chain [199-
203]. 
The worldwide market of the counterfeit medications is remarkably very similar to its 
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legitimate counterpart. Thanks to the extensive networks, it permits a drug to be 
manufactured in a country that is very distant and not necessarily closely related to the 
ones of the final marketing [189-192]. 
 
 
1.3.6. Organised criminality involved in medicine counterfeiting 
The reason behind the stringent interconnection between medicine counterfeiting and 
other forms of organized criminality can rely on the fact that there is an extensive 
similarity of between them [127, 128] For instance, organized crime involved in the 
production of narcotics, can use the same equipment to manufacture forged medicine. 
Different cases of cross-contamination have been reported, showing as the same 
clandestine laboratories used for the processing of narcotics have been used for the 
preparation of counterfeit medicines. For example, counterfeit antimalarial medications, 
seized in South East Asia have shown to contain traces of safrole [245]. This substance 
is a carcinogenic precursor to 3,4 Methylene Dioxy Meth Amphetamine (MDMA), 
better known as ecstasy, to substantiate the fact that the production of the forged 
medication has been performed in a plant used for manufacturing of ecstasy as well. A 
similar incident happened in a batch of counterfeit paracetamol elixir containing 
diethylene glycol derived from a contaminated manufacturing site that caused renal 
failure with fatal outcomes for the patient [246]. 
On this basis, it is clear that counterfeiting is a part of a more articulate organized 
criminality, which operates in an interconnect net of illegal operations. Unlawful 
distribution chains and trafficking itineraries already used traditionally for the 
movement of narcotics, as long as their manufacturing plants, can be used by 
counterfeiters to avoid investing in a new set of these infrastructures already 
established, and therefore maximize their profit [247-248]. 
One of the reason behind the success of the expansion of the illicit trafficking of 
counterfeit medications is indubitably the high demand of such products. Nevertheless, 
a distinction needs to be done. For an extensive range of forged medications, it is 
possible to consider valid the principle that wants the demand of such products being 
originated by the needs for medications that are not locally easily available through the 
traditional channels. 
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 Another main reason that trigger the demand of forged medication is financial, because 
of the different cost of a medication available in pharmacies and the same obtainable 
from the alternative illegal ones. 
However, in the case of fraudulent medications, the market requests that counterfeiters 
exploit is not only the one related to the illicit demands previously mentioned. When 
there is an increasing request of a medication, for various clinical reasons, in the 
legitimate distribution channels, counterfeiters operate intensively trying to enter in 
these official channels with their forged medications, being these the area of business 
that guarantee the highest level of profitability [248-250]. 
In 2010, in Peru, the commercialization of counterfeit medications generated 75 billion 
USD in the world, an increase of 92% with respect 2005 [171]. The Peru’s association 
of pharmaceutical laboratories affirms that the value of sale of fraudulent medications in 
Peru has increased from 40 million US dollar in 2002 to a 66milion US dollar in 2006 
[171]. 
The Kenyan association of pharmaceutical industry has reported that counterfeit drugs 
represent an estimated 130milion US dollar annually in sales in the country [174, 175]. 
The level of profitability of fraudulent medications commercialization has been 
projected being correspondent or even higher to that of the narco-trafficking [227]. For 
criminals involved in this area, the risks involved in trafficking in counterfeit 
medications is considerably lower, because worldwide the laws in this matter are either 
nonexistent or particularly severe [244]. Sentences in the majority of the countries are 
also less strict, only pecuniary, when compared with other serious crimes, which could 
involve long term detention. The lack of a strong and articulated reaction to this 
phenomenon from the law enforcement side is perhaps due to an initial impression that 
the occurrence of general counterfeiting was associated only to luxury products and for 
this reason did not create sufficient alarms to instigate an adequate reaction by law 
enforcement officials [244-247]. 
Medicine counterfeiting exploits the ability to produce a very low-cost product that, 
resembling the original one, can be sold with an incredibly higher final price counting 
on a well established organized criminal structure and a favorable environment. The 
participation of organized criminal groups in counterfeiting of fake medications has 
expanded the volume of medications copied, transforming the phenomenon into a large 
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trade illegal activity. According to WHO [248, 250], every year fraudulent anti-malarial 
and anti tuberculosis medications kill 700000 people and, from the same report, 200000 
lives per year could be saved if malaria was treated without using counterfeit 
medications. In 1995, in Nigeria, almost 50000 people suffering from meningitis were 
treated with counterfeit vaccines, received as a gift by a country considered safe, and 
2500 of them ultimately died. In 2001, China reported that 192000 dead occurred from 
the use of counterfeit medicines being administered instead those genuine ones [248, 
250]. The ratio profit versus risks is particularly high and this represent the main reason 
at the basis of the commitment of the criminal organization in this line of illegal 
activity. 
 
 
1.4. Literature review  
The cost for the introduction of a new medication in the market, taking into 
consideration the overall phases incurred in the drug development of the product, was 
estimated averaged 2.6 billion American dollars in 2014. Generic medications are sold 
at a significantly lower price than the original one, but, nevertheless, not having 
incurred in the exceptional cost of the initial drug development phase, the lower price 
warrants considerable profit margins.  
Within the Hatch-Waxman Act regulations produced in 1984, which regulates in the 
USA the entry requirements for the pharmaceutical companies to introduce a new 
generic medication, only studies of bioequivalence are requested, making easier and 
financially attractive for many pharmaceutical companies to participate in this typology 
of market. A consistent number of generic medications produced by a spread amount of 
manufacturers have permeated the therapeutic market world-wide.  
Switching from the original brand to generic medications can considerably reducing the 
burden on the health assistance. It has been estimated that in the United Kingdom, the 
NHS has saved approximatively 7 billion Sterling in the last 40 years. 
Health professionals and member of the public have expressed doubts on the real 
equivalence in quality and clinical efficacy between branded and generic medications. 
Spread feelings of uncertainty have arisen on these issues and the need for some more 
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robust bioequivalence studied to demonstrate clinical equivalence among generic and 
original correspondent medications has been expressed. 
Over the last decades, a vast amount of literature has been produced on the matter of the 
therapeutic equivalence of generic medications to the relative brand-name ones.  
Health professionals have recognized certain clinical areas where generic interchange 
needs to be applied carefully. In some particular therapeutic areas, the issue of generic 
substitutions raised so many concerns that numerous comparison studies to check the 
interchangeability among generics and branded have been generated. Several clinical 
studies conducted in certain medical areas have shown as the generic medications 
present an overlapping therapeutic equivalence to the original ones. For certain 
generics, both pharmacokinetics and pharmacodynamics issue have been reported. Also, 
in some cases issues on the stability of generics have been raised. In some of these areas 
a strong recommendation on the use of generic medications is encouraged, in light of 
the enormous financial advantages in using the generic against the original ones, 
helping to support the so much constrained budgets of the health sector in several 
countries worldwide. 
Some of these studies have demonstrated the therapeutic equivalence amongst generic 
medications and original one, such as for osteoporosis and hypercholesterolaemia. 
Clinical areas where therapeutic efficacy has not been confirmed were ophtalmology, 
gastroenterology, antibiotics, cardio-vascular diseases, antiallergics. 
Medicines counterfeit is an international grave and rapid growing danger for the 
patient’s health and the pharmaceutical industry around the globe, both in industrialised 
and less industrialised countries. 
Medications counterfeiting can embrace not only replicas of branded drugs but also of 
generic medications or over-the-counter products and also extended to faked appliances 
or diagnostic tools.  
Primarily in Africa, and marginally in Asia and in Central and Southern America, 
counterfeit medications sales range from 10% to more than 30% of the national legal 
market. In many countries originated from the previous soviet bloc, the impact of the 
fraudulent medications is of more than 20% of the national legal market.  
In the interval of time between 2000 and 2006, FDA reported an 800 % increase in the 
incidence of counterfeit drugs in the United States. 
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The effect of parallel import and the use of the internet market as a global distribution 
channel considerably facilitate the entry of fraudulent medicines in the official networks 
of distribution. 
The law enforcement authorities face extreme difficulties in effectively investigating the 
organised crime perpetrated in the online market, because of its anonymity. 
Organised criminality is strongly involved in this market because of the similarity of 
medicine counterfeiting and other more traditional forms of crime. For instance, 
organized crime involved in the production of narcotics, can use the same equipment to 
manufacture forged medicine but with a ratio profit versus risks extremely convenient, 
being the medicine counterfeiting in many countries not severely prosecuted. 
Despite the numerous research articles and reviews published on the matter of clinical 
equivalence among generic and original medications, no study to the scientific 
community has been presented on an analytical evaluation of the chemical composition 
of the different generic drugs that could shed some lights on the reason of the different 
clinical performances reported.  
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2. Aims and objectives of the study 
 
From the considerations drawn in the literature review, it is clear that the different 
compositions in a formulation, the kind of medications being used (generic or branded) 
and the source of these are important from a clinical or therapeutically point of view 
given the impact on the patient response. This is particularly important in clinical areas 
where doubts on the therapeutic equivalence of generic medications have been raised. 
 
The main aim of this research is to develop non-destructive quick qualitative analytical 
methodologies to be able to recognise differences in the chemical composition 
originated both from impurities in the formulation of the bulk agents and/or from 
instability of the active principal ingredient in generic medicines originated from the 
same brand-name medications and also obtained from different sources which could 
potentially provide counterfeit products. The scope of this study is to produce a flagging 
analytical tool able to quickly detect if a sample belongs to a class of approved generic 
medication or not. 
 
This main aim can be broken down into the following objectives: 
 
-To investigate generic medications that have been reported not presenting similar 
therapeutic equivalence in clinical comparison studies. From the results obtained 
through the bibliographic research, different drugs belonging to different therapeutic 
areas have been selected as specimens to be investigated. From the cardio-vascular area, 
digoxin (with the related cardiac glycosides digitoxin and digoxigenin) and amlodipine 
(in its different salts maleate, mesylate and besylate used in therapies) have been chosen 
because involved in investigations enquiring their clinical efficacies when used as 
generic medications. In the gastroenterology area, omeprazole both in its racemic and 
enantiomeric forms, have been selected as samples to be analysed since they have raised 
serious concerns about their generic medications’ clinical efficacy. In the antihistamine 
area, cetirizine, in its racemic and isomeric forms, equally for the same reasons as 
before, have been considered. 
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-To select methods of analysis on these aforementioned generic drugs that can lead to 
significant and fast results. As starting analytical approaches, voltammetry, FT-IR, 
Raman and 1H-NMR spectroscopies  have been considered. 
 
-To develop a statistical data analysis approach of the analytical data obtained based on 
multivariate analysis such as principal component analysis, cross validation, correlation 
scatter plots and factor loadings. 
 
-To identify the analytical methods that present best responses among the previous 
taken into consideration on the basis of the results obtained. 
 
-To expand the method of analysis to other generic medications: to apply the analytical 
and statistical method to other medicines and optimise the setting of such analytical 
approach. 
 
-To apply the optimised method to medicines obtained from internet market to verify 
the authenticity of such medications. 
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3. GENERAL THEORETICAL PRINCIPLES OF THE ANALYTICAL       
TECHNIQUES ADOPTED IN THIS STUDY 
 
 
3.1. Electrochemistry 
Electrochemistry is the section of physical chemistry that investigates the correlation 
between identifiable chemical change and electricity. It is a measurable and quantitative 
occurrence with electricity considered an outcome of a particular chemical change. 
Voltammetry and Polarography are electrochemical methods based on the measurements 
of current i and potential V in chambers where electrolytic processes occur. Voltammetry 
measures the changes of current i as a function of the applied potential V and the diagrams 
that represent those variations are called voltammograms. The potential is modified 
continuously or at regular interval, being the independent variable, and the current is 
measured as the dependent variable. To perform a voltammetric investigation at least two 
electrodes are required. One electrode, called the working electrode, applies the desired 
potential in the desired conditions and interacts directly with the analyte.  Furthermore, it 
assists the transfer of electric charge to and from the analyte. A second electrode is 
necessary to complete the electrolytic cell. This second electrode is characterised by a 
known potential, essential to correlate to the one of the of the working electrode.  The 
second electrode needs to counterweight the electric charge that is added or removed by 
the working electrode during the execution of the experiment. This feature results to be 
particularly difficult to maintain, being particularly problematic for an electrode to 
provide a constant potential while passing current to counter redox reactions at the 
working electrode. To overcome this issue, the traditional original setting has been 
improved introducing a third electrode, the auxiliary electrode, dividing the supply of 
electrons and the provision of a reference potential executed by these two distinct 
electrodes, the reference electrode remains the half cell with a definite reduction potential 
and its only role remains to act as reference in measuring and controlling the potential of 
the working electrode. Thus, the reference electrode is not involved in passing any current 
during the electrolytic process. It is the auxiliary electrode that produces all the current 
necessary to balance the current registered at the working electrode. To realise this 
current, the auxiliary electrode fluctuates to extreme potentials at the extremes of the 
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solvent window, where it oxidizes or reduces the solvent or supporting electrolyte. These 
three electrodes, the working, reference, and auxiliary electrodes represent the set up of 
the current voltammetric apparatuses. In electrochemistry, the analytical signal is the 
current i, normally a faradaic current, which drifts through the cell during the electrolytic 
process of the analyte at the working electrode. The analyte may be a cation, an anion or 
a neutral molecule. The inventor of this technique, Jaroslav Heyrovsky, introduced as the 
working electrode a dropping mercury electrode. This type of electrode consists of a 
thick-walled glass capillary from which the mercury descents in drops into the sample 
solution, pushed by the pressure of a column of mercury. The recorded current-potential 
curves polarograms and introduced the term polarography. The term voltammetry derives 
from volt-am(pere)metry and it is different by the term voltametry (spelled with one m) 
which is indicated by IUPAC as a controlled current potentiometric measurement. The 
meanings of polarography and voltammetry are often used in the reverse sense or are used 
inaccurately. According to the IUPAC definitions, the term polarography should be used 
when the current-potential curves are registered by using a liquid working electrode 
whose surface can be renewed periodically or continuously (eg drops). This comprises 
the classic dropping mercury drop electrode (DME) and the successively improved static 
mercury drop electrode (SMDE) technique. Voltammetric analysis embraces all the 
techniques in which the current potential measurements are performed at a stationary and 
fixed working electrode, irrespective of its material structure. These comprise the thin 
mercury film electrode (TMFE), the hanging mercury drop electrode (HMDE), the glassy 
carbon electrodes (GCE) and carbon paste electrode (CPE). Working electrodes made of 
noble metals (such as platinum and gold) are used less recurrently. Different analytical 
approaches are addressed to the definitions of voltammetry and of polarography: these 
different methods vary in the way the measurement is performed and the procedure of 
electric potential in the determination activity. 
In the classic case in Direct Current Polarography (DCP), the analysis is based on 
the measuring of the current that flows through the DME used as working electrode 
during a linear direct voltage modification. The counter electrode is routinely an electrode 
of the second category, such as an AgCl electrode or calomel, which contrarily to the 
more recent measuring settings, is at the same time the reference electrode. On closer 
observation it is possible to recognise that the current passing through the working 
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electrode is created by two elements. One is the Faradaic current iF, which is based on 
the reduction or oxidation of the analyte, according to the redox reaction occurring. The 
second element is the capacitive current iC, which is originated by the charging and 
discharging of the electrochemical double layer on the surface of the working electrode. 
For the majority of the polarographic analysis, while the faradaic current provides the 
analytical signal, the capacitive current represents the background noise interference.  
In real terms analytical situation, the capacitive current, potential dependent, can increase 
up to 10-7 A and is then within the range of the Faradaic diffusion current iD of an analyte 
solution with 10-5 mol/L. When iC has the same value as iF (iF/iC=1), then the analytical 
signal can no longer be detached from the interference signal. The detection limit for 
direct current polarographic determinations is, therefore, restricted by this signal-noise 
ratio related to the connection between the measuring signal and interference signal. The 
maximum value for iF is the diffusion current iD and it is achieved when all the analyte 
conveyed to the surface of the mercury drop by diffusion have been reduced or oxidised. 
The correlation between the concentration of the analyte and the diffusion current is 
described by the Ilkovic equation: 
 iD = 0.607×)*2 ×2,3 ×./×016  
where: 
iD: diffusion current 
n: number of electrons exchanged in the charge-transfer reaction 
D: diffusion coefficient of the analyte 
M: Hg flow rate 
td: dropping time of the Hg drop 
Ca: analyte’s concentration 
 
A higher sensitivity for a Polarographic measurements is only possible if the ratio iF/iC 
can be increased by other measuring techniques, weather by increasing iF or decreasing 
iC. Developments of this analytical technique aiming to reduce the capacitive current 
resulted in sampled DC polarography and to the pulse methods. Optimisations aiming to 
expand the faradaic current led to stripping voltammetry. In this last variant, the analyte 
is accumulated electrolytically at a stationary working electrode before being 
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voltammetrically determined. The adoption of the use of a static mercury drop electrode 
(SMDE) instead of the dropping mercury electrode DME and the introduction of digital 
instruments and has dramatically improved he performance of both voltammetric and 
polarografic methods. 
Stripping voltammetry approaches are the highest performant electrochemical techniques 
for trace analysis and species analysis. The uncommon high selectivity and sensitivity are 
permitted by the accumulation of the analyte before its determination and that both 
accumulation and determination are electrochemical procedures whose advancement can 
be influenced. Determinations by stripping voltammetry are commonly more sensitive by 
a factor of 103 to 105 when compared to traditional polarographic analysis. The detection 
limits are usually between 10-9 to 10-11mol/L, being in some instances even 10-12mol/L. 
This values indicate that stripping methods are placed amongst the most sensitive analytic 
technique existing. In stripping methods, both the accumulation and the determination 
processes occur at the same electrode without the need to change vessels. This determines 
that the incidence of the systematic errors caused by contamination or evaporation can be 
maintained at a very low level. The term stripping is related to the fact that during the 
determination process, the accumulated analyte is stripped from the working electrode. 
The accumulation process always occurs at constant potential leading to the accumulation 
potential (Eacc). The accumulation process taking place at a stationary mercury drop, 
mercury film, graphite or noble metal electrode occurs for a controlled period, called the 
accumulation time (tacc). The sample is accumulated electrolytically as a metal, or in 
alternative weather as a sparingly soluble mercury compound or adsorptively as a 
complex compound. The stripping of the deposed analyte species from the working 
electrode is the most important analytical step, and it is based on the oxidation or 
reduction process. In the typical instance where analyte is accumulated as an amalgam at 
the Hg drop or Hg film electrode, the determination occurs to be the reverse process to 
the accumulation, and this feature is where the term inverse voltammetry originates from.  
The term Anodic Stripping Voltammetry (ASV) is used where the determination of the 
accumulated product is not related to the oxidation process of the analyte but to its 
reduction. Anodic Stripping Voltammetry (ASV) is effective in determination of the 
metals which are able to dissolve in mercury with the formation of amalgams or which 
can be deposited electrolytically at noble metal or carbon electrodes. Cathodic stripping 
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Voltammetry (CSV) is adopted for the determination of organic and inorganic anions and 
varies from ASV both in the determination process and in the accumulation procedure. 
During the accumulation process, the sample is deposited anodically as a thinly soluble 
mercury salt or cathodically as an intermetallic compound at the electrode surface. 
The combination of voltammetric accumulation and determination is defined as 
Adsorptive Stripping Voltammetry (AdSV) if the sample can be accumulated in an 
appropriate form by adsorption on the surface of the electrode and then voltammetrically 
determined by oxidation or reduction processes. Adsorptive accumulation is an important 
advantage to electrolysis because it makes stripping voltammetry applicable even for 
those analytes that cannot be accumulated or determined because of their lack of amalgam 
formation or irreversible electrode reactions at the mercury electrodes. Elements such as 
Aluminium, Iron, Cobalt, Nickel, Titanium, Chromium, etc. may therefore be traced by 
Adsorptive Stripping Voltammetry. Furthermore, Adsorptive Stripping Voltammetry is 
also applicable for the trace analysis of many organic compounds. It is worth to notice 
that while organic analytes with surface-active features are adsorbed directly at the 
electrode surface, traces of elements need firstly to be transformed into thinly adsorbable 
and soluble complexes. The determination procedures are related either to the reduction 
of the central atom, the reduction of ligands of the complex compound, or the catalytic 
hydrogen production. The determination limits of Adsorptive Stripping Voltammetry are 
in the range of nanograms per litre, making this technique’s sensitivity even higher than 
anodic stripping voltammetry. The superior sensitivity of the Adsorptive Stripping 
Voltammetry is originated by the fact that the adsorbed analyte rests on the electrode 
surface while in anodic stripping voltammetry the accumulated metal diffuses into the Hg 
drop or Hg film. Consequently, the sample concentration available for the stripping 
process at the electrode surface, known as local accumulation factor, following adsorptive 
accumulation, is higher than the analyte concentration after electrolysis and amalgam 
synthesis. 
 
 
3.2. Raman and Infra-Red Spectroscopies 
An incident light beam interacting with a material can be absorbed, reflected, refracted, 
scattered or cannot interact at all, passing through it. When the level of energy of the 
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photon impacting with the material is correspondent to the to the difference between the 
ground state and the excited state of the molecules forming the impacted material, the 
absorbed photon causes a promotion to the higher electronic energy excited state of the 
molecules. Absorption spectroscopy measures this change in energetic level detecting the 
loss of energy of the out coming light after the impact with the sample material. 
Nevertheless, the light can also be impacting with the material and scatter from it. In this 
instance, the photon does not need to be at an energy level able to cover the difference of 
two energy level of the sample. This scattered light can be detected registering the 
scattered light at an angle to the direction of the incident light. When the incident beam 
photon has a energy level different from the electronic transition level of the sample 
material, not causing in this way any electronic transition, the efficiency rises at the fourth 
power of the energy of the incident light. Scattering is an analytical method widely used 
for the determination of different physical properties of materials, such as particle size 
and size distribution. Amongst the different scattering technique, Raman scattering is the 
principal analytical approach for molecular identification. One main way to characterise 
light is though its  wavelength (λ), but, since spectroscopy is related to the interaction 
between incident beam light and energy states of the sample material, frequency (ν) or 
wavenumber are the principle feature then into consideration, being directly related to 
energy. 
The condition in which light is utilised in Raman scattering and infrared absorption 
spectroscopies is quite different. In infrared absorption the analyte is exposed to a 
radiation of a broad range of wavelengths and when the specific incident light frequency 
matches the vibrational energy level of the analyte, the molecule is stimulated to a higher 
vibrational state. It is analysed the loss of energy of the incident radiation due to these 
absorptions. On the other hand, Raman scattering adopts one unique incident radiation at 
a fixed wavelength to interact with the sample material. The scattered light produced by 
the irradiated analyte is then monitored. Consequently, complementary to the infrared 
spectroscopy, Raman scattering does not demand an overlapped incident radiation to the 
energy change between the ground and excited level. In Raman scattering, the photons 
interact with the sample and alter (polarises) the electrons cloud to create a transitory state 
called a virtual state. The virtual state is unstable and the light is rapidly re-emitted. Since 
only an electrons cloud distortion occurs in scattering, the light is re-radiated with minor 
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frequency variations. This scattering re-radiation is called elastic scattering and is the 
principal process. At molecular level, this scattering process is named Rayleigh 
scattering. When nuclear motion is involved in the scattering process, energy is shifted 
from the incident light to the sample or from the molecule to the scattered light. In these 
instances, the process is deemed to be inelastic and the energy of the scattered light is 
different from the energy of the incident light by one vibrational energy unit. This is called 
Raman shift. The Raman scattering is a weak phenomenon, occurring in only one in every 
106-108 photons which scattered. In the same time, other radiation processes can occur, 
such as fluorescence and sample degradation. The majority of the molecule exist at room 
temperature in the minor energy vibrational level. The virtual states are not natural states 
of the sample but are produced when the incident light interacts with the electrons cloud 
and causes polarization. The energy of these states is therefore determined by the 
frequency of the incident light source used. The elastic Rayleigh process is the principal 
intense process being the main process of scattering. Rayleigh process does not involve 
any permanent energy change in the electron cloud and consequently the light returns to 
the same energy state. On the contrary, the Raman scattering process involves an 
absorption of energy from the ground vibrational level to a higher excited vibrational 
state. This is called Stokes scattering. Nevertheless, some molecules may be present in an 
excited state due to thermal energy. Scattering from these excited states to the ground 
state is called anti-Stokes scattering. It involves transfer of energy to the scattered photon. 
The relative intensities of the two phenomenon depend on the population of the various 
states of the molecule. Anti-Stokes scattering will be weaker than the Stokes one and will 
reduce in intensity as the frequency of the vibration surges due to reduced population of 
the excited vibrational states. Furthermore, the rise of temperature induces an increase of 
the anti-Stokes scattering relatively to Stokes scattering. Generally, Raman scattering is 
recorded only on the low energy focussing on the Stokes scattering, but sometimes anti-
Stokes scattering is desired. For instance, in the event of occurrence of fluorescence 
interference, this will appear at a lower energy than the excitation frequency and 
subsequently anti-Stokes scattering can be more beneficial to prevent or reduce 
interference. Furthermore, because of the temperature effect on this processes, the 
difference in intensities of Raman scattering in Stokes and anti-Stokes scattering can also 
be used to monitor temperature changes. Infrared absorption encompasses direct 
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excitation of the molecule exposed to an irradiant light holding exactly the energy 
differences between two state levels.  
Raman scattering requires a much more intense radiation and measures the differences in 
energy between vibrational states as a difference between the energy of the scattered 
photon and that of the incident light. The strongest Raman scattering are produced from 
vibrations of the electronic cloud that create a variation in the polarizability of the electron 
cloud round the molecule. Normally symmetric vibrations produce the widest changes 
and create the greatest scattering. The dissimilarity with infrared absorption is 
remarkable. In infrared spectroscopy the most powerful absorption is produced by a 
variation in dipole and consequent more intense asymmetric vibrations. Among all the 
vibrations existing for a molecule, not all of them can produce both infrared and Raman 
processes and the two different spectroscopies usually give relatively distinctive intensity 
patterns. As a result, the two spectroscopies are frequently complementary and adopt 
together in chemical analysis to capture a better view of the vibrational structure of a 
molecule analysed. Both Raman scattering and infrared absorption are not active in 
centro-symmetrical molecule, because of the reflection of any part of the molecule 
through the centre will reach an identical point on the opposite part. This dissimilarity is 
remarkably valuable for small molecules where a comparison of the analysis obtained 
from infrared absorption and Raman scattering can be used to discriminate between cis 
and trans forms. The highest frequencies of vibrations will be given by light molecules 
and strong bonds while the lowest frequencies will be given by heavy molecules and weak 
bonds. During the assignment of the peaks in the spectroscopy diagram to the vibrations 
of the component of the molecule, it is important to bear in mind that two or more bonds 
of similar energies positioned close together in the same molecule can interact. In these 
cases, it is the vibration of the group of atoms linked by these bonds which is observed in 
the spectrum. For instance, methylene groups present both a symmetric and an anti-
symmetric stretching rather than 2 separate stretches. Consequently, it possible to record 
different types of vibrations for the same chemical groups, because of the chemical 
surrounding and the geometry of the molecule. However, if the atoms forming a molecule 
are well separated, they can be treated separately and showing a large difference in energy 
between the vibrations in different bonds. In the assignment of the spectral peaks to the 
chemical bonds forming the structure of the molecule analised, it is possible to identify 
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energy ranges in which the characteristic frequencies of the most common groups occur, 
both in infrared absorption and Raman scattering. For instance, the interval between 4000 
and 2500cm-1 is the region where single bonds absorb. The region between 2500 and 
2000cm-1 is related to the multiple bond absorption. The 2000-1500cm-1 interval is where 
the double bonds occur. In the region below 1500cm-1 the majority of the molecules have 
intricate configurations of vibrations due to groups of atoms, usually in carbon chains, 
link by bonds of approximately the same energy level. This interval is referred to as the 
finger print region. 
Surface Enhanced Raman Spectroscopy (SERS) is a surface-sensitive technique 
that enhances Raman scattering by molecules adsorbed on rough metal surfaces or by 
nanostructures such as plasmonic-magnetic silica nanotubes. The enhancement factor can 
be as much as 1010 to 1011 which means the technique may detect single molecules. 
The exact mechanism of the enhancement effect of SERS is still a matter of debate with 
two principal theories accredited as the most probable. The electromagnetic theory 
suggests the excitation of localized surface plasmons, and can be applied regardless of 
the chemical composition of molecule being studied. This theory does not fully explain 
the magnitude of the enhancement observed in many systems.  
The chemical mechanism proposes the formation of charge-transfer complexes for many 
molecules structured with functional groups with lone pair of electrons available that 
allow the formation of bond with the rough metal absorbed. In this theory the signal 
enhancement is of chemical nature, where the excitation wavelength is resonant with the 
metal-molecule charge transfer electronic states. The chemical theory cannot explain the 
observed signal enhancement in all cases but it is broadly accepted that the charge transfer 
between metallic nanostructures and molecular species is a key issue in the underlying 
chemical enhancement mechanism in SERS. The chemical mechanism only applies in 
specific cases and probably occurs in concert with the electromagnetic mechanism. 
The Fourier Transform is a mathematical technique that convert any waveform 
into an alternate representation as the sum of sinusoidal functions. In Fourier-Transform 
Infra Red spectroscopy (FT-IR) the spectra are collected based on measurements of the 
coherence of a radiative source, using time-domain or space-domain measurements of the 
electromagnetic radiation. In the older technology, the original infrared instruments were 
of the dispersive type. These instruments separated the specific frequencies of energy 
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emitted from the infrared source by the use of a prism or grating. The detector measured 
the intensity of energy at each frequency which has passed through the analyte. This 
scanning process resulted to be rather slow. Fourier Transform Infrared (FT-IR) 
spectrometry was developed in order to overcome the time restriction met with the 
dispersive technology measuring all of the infrared frequencies simultaneously, rather 
than individually. A simple optical device, called interferometer, was developed, which 
produces a unique type of signal that embrace all of the infrared frequencies encoded into 
it. The unique signal can be measured quickly, usually on the order of seconds rather than 
several minutes as in the cases of dispersive type, and by Fourier transformation it can be 
decoded and converted into an interpretable traditional spectrum. 
 
 
3.3. Nuclear Magnetic Resonance 
Nuclear Magnetic Resonance (NMR) is a physical phenomenon where nuclei exposed to 
electromagnetic radiations produced by a determined magnetic field, are able to resonate 
with them, absorbing and re-emitting specific resonance frequency. The resonance 
frequency varies according to the intensity of the magnetic field applied and to the 
magnetic features of the isotope studied.  Particularly, the resonance frequency applied 
for a specific sample to analyse is directly proportional to the strength of the applied 
magnetic field. The resonance frequency is usually in the range of 60–1000MHz, the 
same of radio or television broadcasts. All elements’ nuclei carry a charge. When nuclei 
are exposed to certain magnetic fields may interact with them and emitting 
electromagnetic radiations. When the spins of the protons and neutrons forming these 
nuclei are not paired, the resulting whole spin of the nucleus produces a magnetic dipole 
alongside the spin axis.  The inherent scale of this dipole is a basic nuclear feature called 
the nuclear magnetic moment, µ. The internal structure of the nucleus determines the 
symmetry of the charge setting. In nuclei presenting a spherical charge distribution, the 
relative spin angular momentum number is ½. This is the case for instance for atoms like 
1H, 13C, 15N, 19F, 31P etc. In nuclei where the charge distribution is non-spherical 
(analogous to e.g. a hydrogen 3d orbital) the spin numbers are higher (for example 10B, 
14N, etc.). Nuclear Magnetic Resonance investigates quantum mechanical magnetic 
properties of the atomic nucleus, giving important information on the structural 
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architecture of crystal and non crystalline substances. NMR is also usually used in 
diagnostics, as an advanced medical imaging techniques, such as in magnetic resonance 
imaging (MRI). It is this characteristic that is used in imaging techniques; when a 
substance is located in a non-uniform magnetic field, the nuclei’ resonance frequencies 
will vary according to the location of the magnetic fields. The resolution of the imaging 
technique is directly proportional to the intensity of the magnetic field gradient. 
Developments in increasing this feature have been sought, and the use of superconductors 
has led to a considerable improvement of the imaging resolution. Other developments to 
increase the efficiency of this analytical technique have addressed improving of 
hyperpolarization and multi-dimensional multi-frequency techniques. 
The first approach to nuclear magnetic resonance spectrometry was based the 
application of continuous-wave spectroscopy (CW spectroscopy). This technique is based 
on the use of a determined fixed frequency and varying the current, and consequently the 
magnetic field, in an electromagnet in order to observe the resonant absorption signals. 
With the CW spectroscopy has been introduced the concept of "high field" and "low field" 
to indicate the low frequency and high frequency areas of investigation. CW NMR 
spectrometers often operating at 60MHz, are cheaper to maintain and operate, with 
correspondingly weaker (non-superconducting) electromagnets cooled with water rather 
than liquid helium. In these spectrometers, one radio coil runs constantly, sweeping 
through a variety of frequencies. A second perpendicular coil, devised not to absorb 
signals from the transmitter, received radiations from nuclei that reoriented in solution.  
The downside of CW spectroscopy is that it investigates the NMR signals at individual 
frequencies in progression. Because of the intrinsic weakness of the NMR signal, the 
resulting spectrum is affected by a modest signal-to-noise ratio. This feature may be 
diminished by signal averaging, performing added repeated measurements. Whereas the 
NMR signal is constant between scans and so adds linearly, the background noise adds 
more gradually. 
Fourier-transform NMR spectroscopy exposes the sample simultaneously to more 
than one frequency producing the NMR spectrum more efficiently than with the CW 
methods. The majority of NMR applications involve the full NMR spectra, where the 
intensity of the NMR radiation is function of the frequency applied. A significant 
improvement in NMR arose when short pulses of radio-frequency signals centered at the 
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middle of the NMR spectrum, started to be used. A short pulse of a given carrier 
frequency embodies a range of frequencies centered about the principal frequency, with 
the range of excitation being inversely proportional to the pulse duration.  The Fourier 
transform of a short pulse contains contributions from all the frequencies in the 
proximities of the carrier frequency. Employing this short pulse to a set of nuclear spins 
concurrently excites all the single-quantum NMR transitions, orientating the 
magnetization vector away from its stable alignment. This alternating magnetization 
vector induces an electrical signal, known as the free induction decay (FID), oscillating 
at the NMR frequency.  To acquire the frequency-domain NMR spectrum, as NMR 
absorption intensity versus NMR frequency, the time-domain signal, intensity versus 
time, must be Fourier transformed.  
Multi-dimensional nuclear magnetic resonance spectroscopy is a modification of 
Fourier-transform NMR spectroscopy where there are two or more pulses applied with a 
methodic variation of the pulse sequence as the experiment is repeated. In 
multidimensional nuclear magnetic resonance there is a succession of pulses and one or 
more variable time period. For instance, in three dimensions, two time sequences vary 
and so on.  These time intervals allow magnetization transfer between nuclei and, 
consequently, the identification of the relative nuclear-nuclear interactions.  
Solid-state NMR spectroscopy is an analytical technique complements X-ray 
crystallography, performed on molecules in a solid phase. The development of this NMR 
spectroscopy has been extremely challenging because of the reduced signal related to the 
thermal motion in the solid state, where the majority of the molecules can only present 
limited vibrations and rotations at room temperature, each in a slightly different electronic 
environment, consequently showing a distinctive NMR absorption peak.  
The sensitivity of the NMR technique depends on the intensity of the magnetic 
field and the relative magnitude of the nuclear magnetic resonance signals and over the 
decades, this technique has progressed also with the development of more powerful 
magnets. The sensitivity of nuclear magnetic resonance spectrometry is related to the 
abundance of nucleus able to magnetically resonate and, consequently, either on the 
natural concentration of such nuclides or on the possibility to artificially increase the 
experimental condition with such nuclides. In nature, the most abundant magnetically 
susceptible isotopes readily useful for nuclear magnetic resonance spectroscopy are 
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hydrogen and phosphorus. Contrarily, carbon and nitrogen have very low natural 
abundance magnetically susceptible isotopes. 
In Nuclear Magnetic Resonance, the chemical shift is the frequency at which a 
nucleus under investigation resonate, with respect the resonant frequency of a reference 
substance exposed to the same magnetic environment. This feature is used as an analytical 
signal in NMR to characterise parts of the molecule under investigation. Within the 
molecular orbitals, the currents of electrons produce magnetic fields which can affect the 
total nuclear magnetic field. The electron distribution of the same type of nucleus 
investigated differs according to the electronegativity of the groups linked to the atom 
analysed. For example, in proton NMR, if the hydrogen is attached to a more 
electronegative group, the magnetic field necessary to produce nuclear resonance will be 
less intense than the one needed in a H-H bond. The reference substance is generally a 
molecule with a hardly distorted electron distribution that produce a strong peak of 
resonance, unambiguous to identify in the NMR spectrum. Tetramethylesilane (TMS) is 
usually selected as this standard because of its peculiar chemical structure, with four 
methyl groups linked to a single Si atom. The specific geometry of this molecule make 
the all twelve atoms of hydrogen equal when resonating with magnetic radiations.  This 
leads to the production of a single and strong peak of resonance. Furthermore, in this 
molecule, the currents of electrons in the molecular orbitals of the C-H bonds are closer 
to the hydrogens than in the majority of the other organic compounds. This implies that 
these hydrogen nuclei are the most sheltered from the applied magnetic field. 
Consequently, the intensity of the magnetic field necessary to induce nuclear resonance 
has to be extremely higher than the one generally needed to induce resonance for the 
majority of the other organic molecules. These features allow to have a reference signal 
on the NMR diagram well distinguished and separated from the majority of the others. 
 
 
3.4. Chemometric 
Nowadays analytical chemistry employs equipment able to generate enormous amounts 
of data. An Infrared analysis may produce different thousands of data points as 
wavenumbers. A single analysis of Gas Chromatography coupled with Mass 
spectrometry usually generates 600K digital values that occupy around 2.5Mbytes. There 
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are two different ways to handle this huge quantity of information. The easiest way is to 
ignore the volume of the collected data. In the case of a spectroscopic analysis, for 
example, traditionally only the most representative peaks are taken into consideration for 
analytical purpose, disregarding the rest of the spectrum. In the case of Gas 
Chromatography coupled with Mass spectrometry the recording is set for a special unit 
of mass and not the full range of units of mass. Typically, quantitative analyses are 
univariate, identifying one variable, such as a peak current at one potential in an 
electrochemical measurement or the wavelength of maximum absorbance in a 
spectroscopic measurement correlated with a given sample concentration. This traditional 
approach to data analysis is incomplete and inefficient. Considering for example that a 
simple UV-Vis spectrum of an analyte containing 500 data points, with only one data 
point, such as absorbance at one wavelength, being used for quantitative purpose, after 
identification, 99.8% of the data will be discarded. On the basis of such consideration, it 
is not efficient therefore to collect data that will not be exploited. Moreover, a univariate 
approach is extremely exposed to interferents. It is almost impossible to differentiate a 
specific signal deriving from the analyte and from an interferent when both absorb at the 
one specific data point selected for the analysis. Without specific tools it has been 
impossible until recently to fully explore the total volume of data collected during an 
analysis, leaving unrevealed potentially important pieces of analytical information. On 
the other hand, the multivariate analytical approach involves the use of the multiple 
variables, such as the response at a range of potentials or wavelengths, or even over the 
entire range of data points gathered during analytical scans. With multivariate analysis it 
can be easier to identify and to remove noise when looking at the entire data points set, 
rather than focusing only on one point. Moreover, taking into account the full set of data 
points, the interferents profile will likely differ substantially from the analyte profile 
studied. Multivariate analysis increases the amount of possible information that can be 
obtained without loss. In the past, the application of multivariate models was hindered by 
the computational complexity of the data analysis. Nowadays these issues have been 
overcome with the development of dedicated software well supported by available 
personal computer. Developments in data processors computing over the past decades 
have transformed the analytical equipment in laboratories. Technological advances have 
made devices from one hand quicker, portable, and cheaper and on the other hand more 
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accurate, precise and available. Also data analysis approaches have also gained from 
innovations in technical computing, with accessible statistical software to be used with 
available powerful computers, allowing scientists to perform intricate statistical data 
analysis in relatively short period of time. Currently, the regular use of processors makes 
it possible to entirely elaborate vast data sets, with a extremely reduced loss of 
information. The range of principal goals of multivariate approach in analytical chemistry 
include data reduction, grouping, the classification of observations and the modelling of 
relationships that may exist between variables. By the intensive use of chemometric tools, 
it becomes possible to gain a deeper insight and a more complete interpretation of this 
data. The predictive feature is also an important aspect of some multivariate analysis, 
being relevant to predict whether a new investigation belongs to any pre-acquired 
qualitative groups or to evaluate some quantitative feature such as chemical 
concentration. Chemometric is defined as the the application of statistical and 
mathematical approach to the elaboration of analytical data obtained from analytical 
chemical investigation in order to gain maximum collection and extraction of useful 
information obtain increasing amounts of chemically relevant information from their 
data. Many commercial instruments are sold already with software containing algorithms 
that able to perform certain data analysis, such as Fourier transform analysis, data 
filtering, and peak recognition, automatically. 
PCA is a visual illustrative method, not based on a probabilistic model of data but 
simply aims to provide geometric representation. Amongst the different multivariate 
analysis techniques, Principal Component Analysis (PCA) is the most frequently used, 
being a starting point in the process of data mining. PCA’s main purpose is minimizing 
the dimensionality of the data. Normally, it is usual to deal with a vast amount of data 
where a number of n objects is described by a set of p variables. Those data are gathered 
in a matrix X, with n rows and p columns, with an element xij referring to an element of 
X at the ith line and the jth column. Usually, a row of matrix X matches with an 
"observation", that could be for instance a group of chemical dimensions or a diagram or, 
more commonly, an analytical curve generated from an investigation of an analyte, 
executed by an apparatus producing analytical curves as output data. A column in the 
matrix X is usually called a "variable". The generic average chemical analyses usually 
deal with multidimensional data n x p, with n and p of order of several hundreds or even 
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thousands. It is clear that with such an abundance of data, it is impossible to identify in 
this set any significant information without the support of a statistical technique such as 
PCA. Principal Component Analysis is used in diverse areas where data analysis is 
crucial, particularly in the food research laboratories and industries, where it is often used 
in combination with other multivariate procedures such as discriminant analysis. 
Principal component analysis (PCA) is a mathematical approach to data analysis that 
rearrange a set of observations of possibly correlated variables into an orthogonal 
representation set of values of linearly uncorrelated variables called principal 
components. Therefore, PCA restructures high-dimensional data points set into a low-
dimensional subspace component and a noise component. The main question in PCA is 
to how choose the number of principal components to be retained, that represent the 
dimension of the subspace. Different guidelines have been elaborated for evaluate the real 
dimensionality of the data points set. Some of these methods encompass the measurement 
of the percentage of total variation, the Kaiser’s rule, and the screen test depending on a 
subjective options. On the contrary, other criteria, are methods based on statistical 
approaches that require distributional assumptions which are usually impractical. Another 
class of rules developed in chemometric, the cross validation (CV) methods, are fairly 
objective, not needing distributional assumptions. Notwithstanding traditional criteria, 
cross validation methods are not centred on the eigenvalues of the sample covariance 
matrix but on the predictive ability of different principal component models. The essential 
common idea of the cross validation models is the use of distinctive data sets for valuation 
and authentication of each principal component model. The training set is the data fraction 
used to estimate each principal component model. Considering a p-dimensional space 
where each individual dimension is linked with a variable. In such a space, the individual 
observation is depicted by its own coordinates related to the value of variables that define 
it. Because of the complexity of the original data, an interpretable representation of all 
the initial variables results to be inaccessible. Therefore, it is essential to condense the 
initial p-dimensional space into a reduced space than p, but retaining the greatest level of 
information. This amount of information is statistically expresses by the variances. PCA 
creates new variables by the mean of a linear combination of the original variables. This 
change of variables results geometrically in a change in orthogonal axes, called principal 
components. Each newly created axis, orthogonal each other, describes a direction that 
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defines a part of the overall information. The first principal component (PC1) is the first 
axis calculated in order to represent the main pieces of information, followed by the 
second principal component (PC2), orthogonal to the PC1, which expresses a lesser 
amount of information, and so on. In PCA therefore, the p original variables from the raw 
data points set are replaced by a group of new variables, the components, which are linear 
combinations of these original variables. The variances of components are classified in 
decreasing order. The whole set of components keeps all of the original variance in the 
processing of the PCA. This change of axis allows a better geometrical representation of 
the data, without altering the dimensions of the space.  
Scores represent the coordinates of the observations on the Principal Components, 
and the relative diagrams are called score-plots. Loadings represent the influences of 
initial variables to the different components, and the relative diagrams are called loadings-
plot. They can be thought as the projection of unit vectors characterizing the variables in 
the consecutive planes of the main components. While scores give a picture of the 
observations in the space produced by the new symmetric axes, the principal components, 
loadings express the variables in the space of principal components. Observations 
adjacent to each other in the space of principal components unavoidably present 
analogous features. This contiguity in the original space brings to a near neighbouring in 
the score-plots. Equally, the variables whose unit vectors are adjoining to each other are 
defined as positively correlated, indicating that their effect on the positioning of objects 
is comparable. These neighbouring are reproduced in the projections of variables on 
loadings-plot. On the contrary, variables positioned remotely from each other are 
described as being negatively correlated. Depending on the nature of the data, loadings 
can be differentiated in two different groups. When the data contains discontinuous 
variables, the loadings are represented as a factorial plan, such as PC1 vs. PC2, showing 
each variable in the PCs space. When the data contains continuous variables, for example 
in case of spectroscopic or chromatographic data, the loadings are represented differently. 
In this case, the values of the loadings of each principal component are represented in a 
diagram with the values of the loadings of component PCi on the Y-axis and the scale 
corresponding to the experimental unit on the X-axis. 
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3.5. Validation 
Standard deviation is a statistical feature that determine the dispersion of a set of data 
from its average value, also called the expected value. It is calculated as the square root 
of variance by determining the variation between each data point relative to the average. 
When the data points are sensibly scattered away from the average value, there is higher 
deviation within the data set and the correspondent standard deviation will be high. On 
the other hand, a low standard deviation indicates that the data points tend to be close to 
the mean of the data set, while a high standard deviation indicates that the data points are 
spread out over a wider range of values. 
Relative Standard Deviation (RSD), often known as Coefficient of Variation (CV) is 
defined as the ratio of the standard deviation to the average and is expressed as a 
percentage. When RSD is high, the data set are spread out over a wide range of values, 
while when RSD is low, the data collections are tightly clustered around the mean.  
The Limit of Detection (LOD) and Limit of Quantification (LOQ) are two relevant 
features used in method validation processes. They test the performance of a describe 
analytical procedure giving information on the smallest concentration of an analyte that 
can be detected. According to the IUPAC definition, Limit of Detection is the lowest 
amount of analyte in a sample which can be be reliably distinguished from zero, but not 
necessarily quantitated as an exact value. The LOQ gives more practical information, 
being defined as the lowest concentration of an analyte in a sample that can be determined 
with acceptable precision and accuracy under the stated conditions of test. These two 
parameters can be determined in different ways, taking into account different related 
statistical features. One typical way, is two measure the two limits from the value of the 
standard deviation (SD) and slope of the calibration curve.
LOD is calculated as 3.3× 234  , where ‘s’ is the slope of calibration curve, i.e. the 
coefficient of the concentration in the equation that describe the calibration curve. The 
SD is obtained from the blank response. LOQ is calculated as 10× 234 , giving a higher 
value in concentration. In case of a linear calibration curve, it is assumed that the 
instrument response y is linearly related to the measured standard concentration x, for a 
limited range of concentration, and it can be express as a linear function y=ax+b. This 
model is used to compute the sensitivity a and the LOD and LOQ. This approach is 
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particularly applicable when the analytical method to validate is not affected by a relevant 
background noise.  
Linear regression analysis produces a mathematical model that best explains the 
collection data obtained with the minimum total residual error. In a linear representation 
of the data, like in the typical case of a calibration curve, the coefficient of determination 
r2 produces a measure of the degree to which the values of x and y are linearly correlated. 
The higher the R2 the more linearly correlated are the concentrations and the 
correspondent analytical signals of the analytical method studied. 
!
 
3.6. List of excipients present in the tablets analysed 
Excipients are chemical components of a medicinal formulation, in addition to the active 
principle ingredient, that provide the requested chemical and physical features to the final 
medicine. The functions of excipients are mainly to contribute to reach the expected 
pharmacokinetic features of the finale dosage form, such as enhancing solubility, 
facilitating drug absorption, and to facilitate the manufacturing process, for instance 
improving the powder flowability or reducing adherence forces between particles and 
machineries.  
-Anti-adherent excipients are used during the preparation of solid formulation to reduce 
the adhesion between the tablet and the press of the compression machine and also used 
to help protect tablets from sticking each other. The most commonly used is magnesium 
stearate. 
-Binders are used in the preparation of solid forms with the purpose to hold all the 
ingredients together conferring to the final product the required mechanical strength. 
Typical substances used as binders are polysaccharides and their derivatives, proteins, 
synthetic polymers. 
-Coatings protect tablet formulations from external air humidity and mask unlikable taste 
of some tablets. Typical substances used as coatings are cellulose ethers, such as 
hydroxypropyl methylcellulose (HPMC). 
-Colour is important to contribute to an easier identification of a medication and to 
improve the look and feel of medications. Typical substance used as colour agent is 
titanium oxide  
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-Disintegrant excipients facilitate the tablet dissolution in the digestive system. absorbing 
water with consequent expansion and dissolution of the solid formulation. Typical 
substances used as disintegrants are crosslinked polymers, modified starch sodium starch 
glycolate. 
-Glidants are employed to enhance powder flow by reducing inter-particles friction and 
cohesion. Typical substances used as glidants are fumed silica, talc, and magnesium 
carbonate. 
-Lubricants are excipients employed to improve manufacturing features of the solid 
formulation reducing the adherence between the tablets and the machineries. Typical 
substances used as lubricants are talc, silica, magnesium stearate or stearic acid.  
Pharmaceutical manufacturers tend not to provide information about the 
quantitative composition of the excipients used in the preparation of their medicinal 
formulations, being this considered as an industrial secret used to maintain a competitive 
advantage against the competitors. They have to reveal the qualitative list of excipients 
adopted in the preparation of a final medicines, listing them in quantitative decreasing 
order, citing the most abundant first. 
Following, the qualitative list of the excipients present in the composition of the 
tablets analysed,  according to the patient information leaflets provided by manufacturers,
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Tab.1. List of excipients obtained from the patient’s information leaflet provided. 
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4. Determination of Cardiac Glycosides by Voltammetry assays using Hanging 
Mercury Voltammetry Solid Electrodes and PCA analysis 
 
 
4.1. Introduction 
Cardiac glycosides (CG) are a family of bioactive molecules that exert an action on the 
sodium potassium ATPase pump influencing the cell metabolism. Their action is 
focused on the myocardial muscle, increasing the output force in the heart pulsing and 
reducing the rate of contractions. Cardiac glycosides are therefore particularly used in 
the treatment of cardiovascular condition such as congestive heart failure where an 
increase of the output force is required and in cardiac arrhythmias, where there is the 
need of a decreasing of the contraction rate. Nevertheless, these beneficial clinical 
effects are counteracted by a very narrow therapeutic index. The generic chemical 
structure of a cardiac glycoside is based on  a central steroid glycoside molecule linked 
to a sugar and an organic group. The steroid glycoside consists of four rings linked to 
other functional groups which are co-responsible for the biological activity. The  
solubility and pharmacokinetics profile of the cardiac glycosides are influenced by the 
specific sugar group attached. The organic groups attached to the other moiety of the 
molecule confer different structural properties and are used to classify the cardiac 
glycoside in two sub-categories, cardenolide or bufadienolide. 
Cardiac glycoside are normally obtained from Lanatoside C, a matrix glycoside present 
mainly in the leaves and seeds of Digitalis purpurea (commonly known as Foxglove) 
[1]. Certain cardiac glycosides are used for the treatment of congestive heart failure, a 
condition in which the heart is unable to pump blood efficiently around the body [2]. 
This, in turn, can cause fluid to collect in the lungs and body tissues and lead to 
congestion.  
Digoxigenin, digitoxin and digoxin (Fig.1, 2 and 3) are amongst the most representative 
cardiac glycosides used in clinical therapy and toxicology.  
Digoxigenin (Fig.1) is considered a hapten, with high immunogenicity used in 
many biochemistry applications. Haptens are small compounds that exert an immune 
response only when conjugated to a large molecule; the molecule can be one that also 
does not produce an immune response by itself, such as a protein.  
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Fig.1. Digoxigenin, chemical structure 
 
Basically, antibodies generated against haptens have higher affinities for their targets 
than other antibodies, so haptens are conjugated to other biological molecules to deliver 
immunological studies. Digoxigenin can be linked to a single species of RNA 
nucleotide triphosphate (usually uridine), and subsequently integrated into RNA as it is 
produced by the cell metabolism. When incorporated into the RNA chain, the 
digoxigenin markers can be followed with anti-digoxigenin antibodies. In a very 
analogous approach, digoxigenin may be linked to specific sugars to investigate cellular 
glycosylation mechanisms. In terms of chemical structure, digoxigenin is the aglicone 
of the digoxin, i.e. the the same structure of digoxin but with the lack of the sugar. 
Digitoxin (Fig.2) present a comparable biochemical activity to digoxin, with a 
longer half-life. Contrarily to digoxin, digitoxin is only subjected partially to renal 
excretion, being partially exposed to hepatic catabolism.  
 
 
Fig.2. Digitoxin, chemical structure 
 
It is therefore indicated more than digoxin for the treatment of cardiovascular conditions 
in patients with impaired kidney functions. Nowadays, it is not commonly used in 
clinical practice, preferring digoxin, characterised by an improved therapeutic and 
toxicological profile. 
Amongst the different cardiac glycosides, digoxin (Fig.3) represents the most 
important for its use in current clinical practice. Cardiac glycosides act as  stimulants on 
CHAPTER 4                                                                                                                     Cardiac Glycosides 
!
 
 
88 
the cardiac muscles as well as on un-striated and skeletal muscles, renal tubules and 
stray nerve centres.   
 
 
Fig.3. Digoxin, chemical structure 
 
Digoxin is utilised to solve this as it is believed to inhibit Naþ–Kþ ATPase in addition 
to activating contractile elements of muscle fibres [2]. It increases the cellular calcium 
uptake in cardiac cells and enhances Naþ–Ca2þ exchange. Determination of the 
concentration of digoxin in blood, the heart and the kidney is, therefore, vital in order to 
confirm poisoning from ingestion of this compound. Digoxin has a double interest as a 
clinical molecule but also as a potential poison that could lead to heart failure [3]. The 
therapeutic action of digoxin starts around two hours after oral administration and 15–
30 min after intravenous administration. The half-life period of digoxin via these 
methods is 1.5–2 days. Digoxin concentration in blood should be tested in order to find 
the appropriate dose for the given individual. However, digoxin has only a small 
therapeutic range of concentrations (0.5–2.0ng/mL) [1] and because of this index, 
digoxin therapy requires strict monitoring of blood levels in order to minimize toxicity 
[2-5]. Digoxin concentrations in vitro or in blood and urine samples have been 
determined previously using many techniques such as SEM [1, 6]; HPLC (with and 
without pulsed amperometric detection) [7-13]; LC-MS [14-18]; voltammetry [19,20], 
chemi-luminescence immunoassay [21] and reverse-phase thin-layer chromatography 
[22]. Digoxin tablets have been analysed using laser-induced fluorescence polarization 
[23]. Digoxin has been extensively studied using adsorptive stripping voltammetry by 
Wang et al. [19], where mercury electrodes were analysed by differential-pulse 
voltammetric analysis. The use of this technique allows a sensitivity of nanomole order. 
However, the hanging mercury drop electrode can present some shortcomings due to the 
inner mechanisms required to produce the drop. When using the hanging mercury drop 
technique the size of the drops has to be reproducible and remain unchanged to 
guarantee accurate and reproducible results. In order to achieve this, a mercury flow 
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from the Hg reservoir to the tip of the electrode is stopped at selected time intervals to 
produce a static as opposed to a growing drop. There are many factors that can lead to 
an unstable drop size. Firstly, during the filling of the mercury reservoirs, small bubbles 
of air can become trapped. Even a small bubble of air can cause serious interferences 
with the stability of the drop. Secondly, regulation of the pressure applied to the drop at 
the end of each analysis has to be accurately set up. It is important that the pressure is 
high enough to continuously replace the drop but not too high that the drop becomes 
stressed during the scan and its size changes. 
Environmental issues, due to the toxicity of Hg, must be taken into account as well. 
Although mercury can be regenerated and reused, disposal of this element poses danger 
to the operator as well as large costs for disposal treatments.  
Digitoxin and digoxigenin result to be by-products of the degradation of digoxin, which 
is currently used in cardio-vascular therapy [15]. 
The aim of this study, therefore, was to investigate the use of carbon glass, gold and 
silver electrodes to analyse digoxin tablets, generic and as branded, and the relative 
digitoxin and digoxigenin released by the degradation of the original digoxin, and 
compare the results with those obtained from Hg electrode. 
In order to perform this study on the final pharmaceutical formulations, a preliminary 
voltammetric study was focused on the standards of the three cardiac glycosides,  
assessing the possibility to develop an analytical method able to investigate 
quantitatively the three cardiac glycosides pure standards in four different buffered 
acidic environment, resulting in pH5, 7.4, 10 and 11, using the traditional voltammetry 
based on mercury electrode and then comparing the results obtained with the outcomes 
resulting from voltammetric analyses of the same glycosides pure standard using solid 
electrodes, such as carbon glass, gold and silver electrodes. 
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4.2. Materials and Methods 
 
4.2.1. Materials 
-Digoxigenin (CAS No.: 129273-26-3, IUPAC name (3β, 5β, 12β) -3, 12, 14- 
Trihydroxycard-20 (22) -enolid; 
-Digitoxin ( Cas No.: 71-63-6,  IUPAC name (3β, 5β) -3- {[2, 6- Dideoxy-β-D- ribo- 
hexopyranosyl- (1->4)-2, 6- dideoxy-β-D- ribo-hexopyranosyl- (1->4)- 2,6- dideoxy-β-
D- ribo- hexopyranosyl] oxy} -14-hydroxycard- 20 (22)- enolide; 
-Digoxin (CAS No.: 20830-75-5, IUPAC  name 3- [(3S, 5R, 8R, 9S, 10S, 12R, 13S, 
14S, 17R) -3- [(2R, 4S, 5S, 6R) -5- [(2S, 4S, 5S, 6R) -5- [(2S, 4S, 5S, 6R) -4,5- 
dihydroxy-6-methyloxan -2- yl] oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-
methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 
15, 16, 17- tetradecahydrocyclopenta [a] phenanthren -17- yl] -2H-f uran -5 - one; 
-Alumina (Aluminum oxide Al2O3, CAS No.: 1344-28-1, 150 mesh); 
- Silica (Silicon dioxide amorphous CAS No.: 112945-52-5, fumed, particle size 
0.007µm) 
 were all obtained from Sigma Aldrich, UK.  
Methanol, (CH3OH, CAS No.: 67-56-1) was obtained from Fischer Scientific, UK. 
Sodium Acetate Trihydrate (CH3COONa · 3H2O, CAS No.: 6131-90-4), Sodium 
Hydroxide (NaOH, CAS No.: 1310-73-2), Sodium phosphate dibasic dodecahydrate 
(Na2HPO4 · 12H2O, CAS No.:10039-32-4), Sodium phosphate monobasic dihydrate 
(NaH2PO4 · 2H2O, CAS No.: 13472-35-0), Sodium Carbonate (Na2CO3, CAS No.: 497-
19-8)  and Sodium hydrogen carbonate (NaHCO3, CAS No.: 144-55-8) were obtained 
from Fischer International, UK. Glacial Acetic Acid (CH3COOH, CAS No.: 64-19-7) 
was obtained from BDH Acids HP, USA. Gold and silver electrodes were obtained 
from Metrohm, UK.  
Digoxigenin, Digitoxin and Digoxin stock solutions were prepared by dissolving the 
relative cardiac glycoside in methanol at a range of concentrations around 100µg/mL. 
These  stock solutions were stored in the dark at 4°C. 
The pH5 buffer was prepared using glacial acetic acid (0.2M) and CH3COONa · 3H2O 
(0.2M) at a ratio of 30:70 v/v.  
CHAPTER 4                                                                                                                     Cardiac Glycosides 
!
 
 
91 
The pH=7.4 buffer was prepared using Na2HPO4 · 12H2O (0.2M) and NaH2PO4 · 2H2O 
(0.2M) at a ratio of 81:19 v/v.  
The pH=10 buffer was prepared using Na2CO3 (0.1M) and NaHCO3 (0.1M) at a ratio of 
60:40 v/v.  
The pH=11 buffer was prepared using NaOH (0.005M) solution (Fischer International, 
UK). 
 
4.2.2. Methods 
Voltammograms were obtained using a 757 VA Computrace Metrohm connected to a 
Compaq deskpro personal computer. The reference electrode was Ag/AgCl (KCl 3M). 
The working electrode was a valve-controlled hanging mercury drop electrode 
(HMDE). Platinum electrodes were used as auxiliary electrode. To perform 
voltammetry analyses using HMDE electrode, 10mL of a selected buffer solution was 
poured into the measuring cell. Consequently, using the method of standard addition to 
build the correspondent calibration curve, it was added with different aliquots of 200µL 
of stock solution. The resulting solution, each time before the following addition, were 
deoxygenated by a flow of nitrogen for 8 minutes. In the cyclic voltammetric analyses, 
an accumulation potential of -0.9V was applied. 3 cyclic voltammetry scans were 
performed after each addition , with a RedOx potential range of +2V to -2V. The sweep 
rate was kept at 0.05V/s and the voltage step at 0.0059V. All data were obtained at 
25°C. In the voltammetric analyses using solid electrodes, to perform cyclic 
voltammetry analyses, 10mL of a selected buffer solution was poured into the 
measuring cell with an aliquot of cardiac glycoside stock solutions to reach varying 
concentrations from 3.9- 14.8µg/mL. The resulting solutions were deoxygenated by a 
flow of nitrogen for 5 minutes. No accumulation potential was applied. 3 cyclic 
voltammetry scans were performed on each buffer solution, with a RedOx potential 
range of +2V to -2V. The sweep rate was kept at 0.05V/s and the voltage step at 
0.0059V. All data was obtained at 25°C.The working solid carbon glass, gold and silver 
working electrodes also acted as stirrer. Platinum electrodes were used as auxiliary 
electrode. Before each new analysis and after the last of the set, each electrode was 
cleaned in order to remove traces of any electro-active substances that may be present.  
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First, the electrode was removed from the apparatus and washed under a flow of 
deionised water. Next, a single drop of deionised water and a spatula tip sized amount 
of alumina was then mixed in a petri dish to make a paste. The tip of the electrode was 
then cleaned in this paste by making 10 circular rotations in each direction, three times, 
as well as a ten figure of 8 movements in each direction, three times. The top of the 
electrode was then washed under a flow of deionised water before finally being 
sonicated in deionised water for 3 minutes. 
 
 
4.3. Results and Discussion 
The selected three cardiac glycosides have been analysed by hanging mercury 
voltammetry in order to evaluate the possibility to use this technique for investigative 
purposes. In order to identify the effect of different environmental grade of acidity on 
the response of these analytes on the analytical technique, 4 different pHs (pH5, 7.4, 10 
and 11) have been chosen to test their voltammetric behaviour. 
 
4.3.1. Investigation of the effect of different pHs on hanging mercury voltammetry 
of digoxin 
At pH5, in the first attempt to build the calibration curve, the initial results gave 
information about the range of concentrations to adopt. At the first addition (with 1.5µg 
in 10.2mL of initial buffer) no peak was observed. At the second addition (with 3µg in 
10.4mL) a peak is observed. At the third addition (with 4.5µg in 10.6mL) an overlapped 
peak to the one already obtained is observed. It seemed, therefore, that the first addition 
(with a concentration of 1.5µg in 10.2mL equivalent to 0.147µg/mL) was under the 
detectable limit of our system, while at the third addition (with a concentration of 4.5µg 
in 10.6mL equivalent to 0.424µg/mL) there was a saturation condition. In Fig.4 is 
reported a typical voltammogram obtained during these analyses. We had, therefore, to 
operate within these parameters for the next attempt to build a calibration curve.  
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Fig.4. Typical mercury voltammogram of digoxin, showing a saturation condition registered at the third 
addition of aliquot of standard solution, with 4.5µg in 10.6mL 
 
The second calibration curve attempt was performed starting from 10mL buffer spiked 
with 200µL of a solution of 7.5µg/mL and then making the following addition with 
200µL of a less concentrated solution (1µg/mL, equivalent to 0.2µg) in order to avoid to 
reach saturation conditions. 
After the first peak (conc 1.7µg in 10.2mL equivalent to 0.167µg/mL), the following 
addition seemed to lead to an immediate saturation. It was then decided to restrict again 
the range, this time between 0.15-0.167µg/mL. 
After different setting and trial-error approach it was realised that this acidic condition 
was not analytical significant to perform voltammetric study on this molecule.  
As performed for the calibration at pH5 shown before, the study of the calibration curve 
at pH7.4 was obtained starting with 10mL buffer adding aliquots of 200µL of 1µg/mL 
digoxin stock solution and making addition of 200µg each time. Six additions were 
performed and each addition was tested twice. The voltage of the peak used to follow 
the voltammetric response at the diverse concentrations was -1.390V.  
Following the previous procedure, to perform the analyses at pH10, 10mL of the 
carbonate-bicarbonate buffer (60mL Na2CO3 0.1M + 40mL NaHCO3) was added with 
serial aliquots of 200µL of the 1µg/mL digoxin stock solution. Six additions were 
performed and each addition was tested twice. 
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With the increase of the concentration of the solution under examination, a shift of the 
peak potential towards slight lower voltage was observed. It was speculated that it could 
have been caused by a chemical transformation.  
In order to select the best representative peak value at which refer for the calibration 
curve, two peaks have been selected, at -1.403V and -1.409V, chosen by visual analysis 
of the voltammograms and their correspondent current values utilise for the construction 
of the calibration curve. The calibration curve relative to the peak at -1.403V resulted to 
present a slight improved linear regression (r2) of 0.8766 with respect the linear 
regression of 0.8653 obtained at -0.1403V. 
As in the previous pH conditions, 10mL of pH11 buffer were spiked with aliquots of 
200µL of the 1µg/mL digoxin stock solution. Nine additions were performed and each 
addition was tested twice. Two peak values were preliminarily identified for the 
construction of the calibration curve, at -1.4796V and -1.4856V. 
The calibration curves built considering the two different potential peaks appeared to be 
nearly identical with same slope for the independent variable x. The curve originated 
from the peak at -1.4796V showed a slight better linear regression of 0.9684 against the 
one obtained from the peaks at -1.4856V with a r2 of 0.9625 and therefore was chosen 
as the analytical value to register the voltammetric signal. 
 
 
4.3.2. Investigation of the effect of time on hanging mercury voltammetry of 
digoxin 
During the execution of the voltammetric analyses at pH5, the solution after the scan 
was transferred in a vial and checked at set interval of time in order to investigated the 
action of the specific pH on the stability of the glycosides. It was noticed how, during 
the time, the peak obtained at the first scan (time=0) (-1.18V) tended to disappear, while 
a new peak (at -1.21V) was appearing and tending to increase with the time (Fig.5). It 
has been considered that a chemical process was happening, maybe a hydrolysis 
triggered by the slight acidic condition. In acidic condition, in the digoxin chemical 
structure, the bond that links the digitoxose sugar moiety to the digoxigenin part has 
been reported being separated by hydrolysis reaction [16]. This could lead to the release 
of a fraction of the original molecule with electrochemical behaviour. 
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Time: 0.5 h 
 
Time: 1h 
 
Time: 1.5h  
 
Time: 2h 
 
Time: 17.5h 
 
Time: 24.5h 
Fig.5. Variation of of digoxin mercury voltammograms obtained at pH5 tested at different interval of 
time 
 
The same investigations conducted at the other pHs (7, 10, 11) did not produced any 
changing in the voltammograms obtained, indicating that no chemical transformations 
were happening at those pHs. 
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4.3.3. Investigation of the effect of different pHs on hanging mercury voltammetry 
of digitoxin 
Digitoxin is characterised by an even lower solubility with respect digoxin, missing one 
hydroxyl group and being consequently less hydrophilic than digoxin. Because of this 
issue, the stock solution with higher concentration that it was possible to achieve was of 
1.001µg/mL, in methanol as solvent. As in the previous setting of experiments 
performed on digoxin, in order to replicate and validate the analytical approach, 10mL 
of the same four different buffers were spiked with aliquots of 200µL of the digitoxin 
stock solution and analysed voltammetrically. The analyses conducted at pH5, 7.4, 10 
did not show any variation from the baseline obtained from the voltammetric scan of the 
buffer on its own when the aliquots were added. Only the experiments performed at 
pH11 showed some electrolytic activity during the standard addition of the digitoxin 
aliquots. Eleven additions were performed and each addition was tested twice. In order 
to identify the lowest concentration traceable with this analytical approach, different 
concentrations obtained from the dilution of the original stock solution were tested and 
the lowest concentration that presented a relevant voltammetric response were of 
0.1001µg/mL As presented before for the digoxin analysis, two different potentials 
were identified as representative of the calibration curve (at -1.4737V and -1.4796V) 
and the two relative calibration curves were built accordingly. The two different values 
of the peak led to similar equation of the curve, with similar slope for the x and similar 
linear regression. Based on the slight better r2 of 0.9785 at -1.4796V, this value was 
chosen as analytical value to be used. 
In order to investigate the effect of the exposure to the different pH on the 
chemical structure of digitoxin, voltammetric scansions were performed at different 
interval of time. The voltammograms obtained indicating that no chemical 
transformations were happening at those pHs. 
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4.3.4. Investigation of the effect of different pHs on hanging mercury voltammetry 
of digoxigenin 
Digoxigenin presents as the digitoxin a reduced solubility, because of its lower polarity 
due to the lack of the hydrophilic sugar moiety. The maximum concentration that it was 
possible to reach in methanol was of 1.00µg/mL before to reach saturation. Exposing 
this digoxigenin stock solution to the same voltammetric approach defined previously 
for the other cardiac glycosides, as in the case of digitoxin, only pH11 was responsive to 
the test. Eleven additions were performed and each addition was tested twice. It was 
noticed that per each standard addition, the first scan gave always a peak higher than the 
following second scan, possibly due to a saturation process due to the alkaline condition 
of the buffer that reduce the polarity of the digoxigenin. 
Three peak values were preliminarily identified for the construction of the calibration 
curve, at E(V): a)-1.4120; b)-1.1472; c)-1.1531. The linear regressions of the calibration 
curves obtained from these signals resulted to be not particular significative. The 
calibration generated from the potential at -1.4120V was the best of the three when 
considering the whole set of measurements (with first and second scan per aliquot) but 
not analytically relevant, with a linear regression of just around 0.4. When considering 
only the results obtained from the first scan, the signals recorded at -1.1472V were the 
ones that produced the better calibration curve, but still with a low r2 of 0.8222. The 
second scan gave better results at -1.1531V, where the calibration curve resulted with a 
linear regression of 0.8637. 
 
 
4.3.5. Investigation of the effect of different pHs on the voltammetric 
characteristics of digoxin, digitoxin and digoxigenin using solid electrodes  
Examples of the use of electrochemical methods using solid electrodes for the 
determination of drugs in clinical [29, 30] or forensic applications [31-35] is not novel. 
Due to the selectivity and sensitivity achieved by the electrochemical techniques it is 
becoming more and more popular for their applications in sensors or sensing elements. 
Solid electrodes presents a range of advantages with respect the traditional mercury 
electrode. Solid metal electrodes, contrarily to mercury electrode, have no 
environmental implications and provide an accurate polishing phase at the end of each 
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analysis, which guarantees a constant analytical surface and in turn ensures 
reproducibility of results. Furthermore, despite the excellent cathodic potential range of 
mercury, its anodic range is severely limited with respect to main solid metal electrodes 
due to its ability to oxidise easily. Solid electrodes also have the potential to be used in 
portable analytical devices. 
Solid electrodes, such as glassy carbon, silver and gold, have not been previously 
reported being used in any voltammetric studies to analyse digoxin, digitoxin or 
digoxigenin,  representing a novelty in this area of research. 
The aim of this study, therefore, is to investigate the use of carbon glass, gold 
and silver electrodes to analyse these cardiac glycosides and compare the results with 
those obtained from Hg electrode. 
Investigation of the effect of different pHs on the voltammetric characteristics of 
digitoxin, and digoxigenin using carbon glass, gold and silver electrode did not produce 
any significative analytical results. 
 
 
4.3.6. Investigation of the effect of different pHs on the voltammetric 
characteristics of digoxin, using carbon glass electrode  
The electrochemical properties of the three cardiac glycosides were studied using solid 
electrodes replicating the same conditions adopted for the study using mercury 
electrode, with the same buffer solutions, of pH5, 7.4, 10 and 11. 
In general, the results have not been as reproducible as when using HDME and this 
electrode has shown to be not indicated for the analysis of those cardiac glycosides. The 
vast majority of all the voltammograms obtained resulted showing no trace of signals at 
all. It was considered the use of KCl as enhancer to increase conductivity in the 
electrolytic cell, but without any analytical benefit. Only digoxin has shown a slight 
responsive behavior when tested at pH5 (Fig.6).  
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Time: 0h  
 
Time: 0.5h 
 
 
Time: 1.5h 
 
 
Time: 2h 
  
Time 2.5h  
  
Time 18h 
 
Fig.6. Voltammograms of digoxin tested with carbon glass electrode at pH5, at different times. 
 
As in the identical case of the experiment conducted at this pH with mercury electrode, 
it has been noticed that when left the solution and re tested during the time a 
decomposition process seemed to occur, with a new peak gradually appearing and the 
initial one decreasing. 
The kinetic of the disappearing peak was y = 2×10'(() − 4×10', while the kinetic of 
the appearing peak was y = −8×10'(() − 5×10',. The rate of variation of the 
intensity of the peaks detected by carbon glass voltammetry was lower than the 
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correspondent rate noticed by mercury voltammetry. In the decomposition investigated 
by mercury electrode voltammetry, the disappearing trend line of the first peak and the 
formation of the second peak trend line had a coefficient of the time of the order of 10-
10. In the case of the results obtained by carbon glass, the same coefficients were of the 
order of 10-11, where at the same changing of the variable time (x) the effect on the 
correspondent intensity of the peak (y) was lower. 
 
 
4.3.7. Investigation of the effect of different pHs on the voltammetric 
characteristics of digoxin, using gold electrode 
At pH5 and pH7.4, gold electrode shows an analytical peak during the reduction process 
at -1.2138 and -1.2733V, leading to a linear regression of the calibration curve of 
0.9568 and 0.9072 respectively. At pH10, gold electrode shows good analytical signal 
both during the cycle RedOx in the reduction phase at 0.2322V, giving a linear 
regression of 0.976, and during the cycle OxRed, still during the reduction process at 
0.2019, with r2 of 0.9204. 
This electrode showed the best linearity of data (r2=0.9948) at pH11. At this pH, gold 
electrode showed to be able to analyse digoxin both in the RedOx cycle and in the 
OxRed cycle. In the RedOx cycle, actually, it was possible to use two different points of 
the RedOx curve at 0.601V in the anodic sweep and at 0.041V in the cathodic sweep 
respectively to build the calibration curve (with r2=0.9267 and 0.9948 respectively). In 
the OxRed cycle the analytical peak was at 0.5887 in oxidation phase, with r2=0.9792. 
The linear regression of the calibration curve obtained in these condition resulted to be 
of the order of 0.9, with a slope in order of 10-6. 
Figure 7 shows the oxidation of gold at different pHs from oxidation to reduction 
sweep. First, the gold electrode in a buffer solution (digoxin-free) was investigated in an 
oxidation-reduction scan cycle to explore the extent of its ability to oxidise and then 
return to its original state via a reduction process.  
In an acidic condition, such as that of pH=5, the gold electrode does not present a 
visible peak in the oxidation direction and presents a slight peak in the reduction 
direction. Pasta, Mantia and Cui [24] suggest a probable reaction for the oxidation of 
gold to be:  
CHAPTER 4                                                                                                                     Cardiac Glycosides 
!
 
 
101 
2Au+3H2O ↔ Au2O3 + 6H+ + 6e-  
 
Such reaction is driven by alkaline pHs where the H+ may link to the OH- of the 
solutions, driving the equilibrium of the reaction towards the formation of oxidised Au. 
 
 
Fig.7. Voltammogram obtained using a gold electrode as a working electrode and different buffer 
solutions at different pHs of  5, 7.4, 10 and 11. Scan direction from -0.5V to +1V.  Sweep rate = 0.05V/s; 
Voltage step = 0.0059V; T= 25°C. 
 
A reaction such as this would be driven by alkaline pHs because the H+ and OH- ions 
may come together in solution, in turn driving the equilibrium of the reaction towards 
the formation of oxidised Au. It can be noted that as the pH of the buffer solution moves 
from acidic to alkaline the reduction peak shifts towards the negative potential, whereas 
the oxidation peak remains more or less constant at a potential of between +0.6V. The 
cathodic shift from right to left as the pH becomes increasingly alkaline can be 
explained by the consideration that the basic pH seems to favour the stability of the 
oxidised gold, which explains the higher voltage gap for the reduction current peak at 
the higher pH’s [24]. This is in line with Kirk, Foulkes and Graydon [25] which 
reported the electrochemical formation of monolayers of Au(I) hydroxide in basic 
conditions close to pH=11. 
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Fig.8. Theoretical oxidation-reduction equilibria for Au at 25oC and 10µM Au at different pHs. 
 
Figure 8, obtained from Medusa software, shows the theoretical concentration of the 
different forms of oxidised Au as a function of pH at a fixed potential of 0.5V and a 
metal concentration of 10µM to simulate an equilibrium process using thermodynamic 
criteria.   
It is noticeable at pH9 a sudden conversion of Au in Au(OH)-2; at pH5 oxidation of Au 
from metallic state to oxidised AuOH. This is in line with the results obtained (Fig.7) 
and with the Pourbaix diagram (Fig.9) that reports the different oxidised species of Au 
at different potentials function of pH. 
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Fig.9. Pourbaix diagram of Au (extracted from Harris et al [24]) 
 
As the pH increases up to pH=9, a constant amount of gold is precipitating out of the 
solution and the concentration of H+ ions is steadily decreasing. From pH5, the 
concentration of OH- ions steadily increases. 
Across pH=7, the level of H+ and OH- ions are at equilibrium, which is to be expected 
as at a neutral pH the concentration of H+ and OH- ions should be consistent. It can be 
noted that at pH9, the concentration of gold decreases dramatically, demonstrating the 
sudden conversion of gold to Au(OH)-2 ions. It is possible to identify (Fig.7) the 
formation of broad peaks in both reductive and oxidative scans, due to the 
chemisorption of hydroxide ions to the gold surface, in line with the report from Kirk et 
al [25]. At pH=5, Figure 8 also shows oxidation of gold from its metallic state to 
AuOH. This supports the results obtained from the cyclic voltammetry (Fig.7) for which 
an increase on surface oxides were obtained with an increase in pH. Similar results were 
reported both by Pasta, Mantia and Cui [24] who visualised the different oxidised 
species of Au at different potentials as a function of pH in the form of a Pourbaix 
diagram and by Nicol [36] who shown as gold at pH=7-12 is oxidized to Au(III) 
hydroxides, confirming the shift of the potentials shows in Figure 7. The same Figure 
shows the oxidation of the gold at different pHs in the positive sweep, and the following 
reduction in the negative sweep. It is noticeable an appearance of oxidative current 
CHAPTER 4                                                                                                                     Cardiac Glycosides 
!
 
 
104 
peaks in the in the range of 0.5-0.6V, increasing the alkalinity of the buffer solution in 
the oxidation phase. 
This is in accordance with literature [24,25]. Y. Cui et al [24] speculate that in that 
condition the gold surface is covered by a layer of gold oxide subjected to the following 
reversible reaction: 
AunOm-1 ↔ AunOm+H2O+2e- 
In the reduction sweep it is the signal of reductions on the gold electrode surface with 
peaks at 0.49V for pH7.4, 0.22V for pH10 and nearly 0V for pH11. The alkaline pH 
favours the stability of the oxidised Au, this explains the higher voltage gap for the 
reduction current peak at higher pHs. In the cycle starting from reduction and ending 
with oxidation, Red-Ox (Fig.7) gold electrode shows the same features, giving 
reduction peaks pH dependent of the oxidised Au with peak voltages decreasing with 
the increase of the alkalinity, 0.5V at pH7.4, 0.27V at pH10 and 0V at pH11.  
The oxidation reactions appear at the same range of voltage applied in the cycle Ox-
Red, showing that the reactions occurring at the electrode surface are fully reversible. 
For the gold electrode the limit of detection (LOD) ranged from 55µg/mL at 
pH5 to 1.7µg/mL at pH11 (data reported in Appendix 1). This could be explained with 
the better response of the conversion of the equilibrium of oxidised Au in alkaline 
medium as discussed earlier. This assertion is corroborated by the values of the standard 
deviations (data reported in Appendix 1) showing the lower dispersions at this pH both 
in Red-Ox and in Ox-Red sweeps. The standard deviations and the coefficients of 
variation show that the results obtained are quite repeatable, as confirmed also by 
principal component analysis (PCA) as shown in Fig.10 and 11. PCA of the results 
shows how the data obtained are well grouped in isolated clusters, especially the ones 
obtained at pH11.  
Furthermore, the gold electrode was investigated in a reduction-oxidation scan cycle to 
discover the ability of the gold electrode to reduce and then revert back to its original 
state via oxidation. Similarly to the results observed in the oxidation-reduction scan, 
reduction peaks dependent on the pH of the oxidised gold are observed. The peak 
voltages decrease from 0.5V to 0V as the pH increases towards the alkaline region from 
pH=7.4 to pH=11. The oxidation reaction on the reduction sweep appears at the same 
range of voltages as those uncovered in the oxidation-reduction cycle. All of these 
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factors demonstrated that the reactions on the surface of a gold electrode are fully 
reversible as expected. 
By observing the chemical structure of digoxin, successful reduction and 
oxidation of the compound would be expected due to the presence of electroactive 
groups. As suggested by Ivanovskaya [20], the double bond conjugated to the carbonyl 
group of the molecule can be prone to reduction from an alkene to an alkane group, as 
well as oxidation as a result of the lactone ring being opened. 
When using a gold electrode, at pH=5 and pH=7.4, an analytical peak during the 
reduction process at -1.21 and -1.27V, can be respectively seen, producing linear 
calibration curves with correlation coefficients of r2=0.9568 and 0.9072, respectively.  
At pH=10, the gold electrode also showed a good analytical signal in the reduction 
phase at 0.23V, producing a linear regression of r2=0.976. This electrode showed the 
best linearity of data (r2=0.9948) at pH=11. At this pH, the gold electrode showed to be 
able to analyse digoxin in a reliable manner. It was possible to use two different points 
of the curve, at 0.601V in the anodic sweep and at 0.041V in the cathodic sweep 
respectively to build the calibration curve (with r2=0.9948). 
For the gold electrode the limit of detection (LoD) ranged from 55µg/mL at pH=5 to 
1.7µg/mL at pH=11. The optimum pH for analysis was chosen to be pH=11. 
This could be explained with the better response of the conversion of the equilibrium of 
the oxidised Au in alkaline medium as discussed earlier. This is also corroborated by 
lower values of the standard deviations at pH=11.  
The average Coefficient of Variation also followed this trend showing a higher 
precision of 2.07% and 4.13% for both the anodic and cathodic peaks respectively at 
pH=11. 
Principal Component Analyses of the different digoxin solutions were also performed, 
as shown in Figures 10 and 11 . This PCA analysis of the results showed how the data 
obtained are well grouped in isolated clusters, especially the ones obtained at pH=11 
where the points are closer to each other. The different clusters were helpful to 
discriminate the best pH conditions under any concentration, even blanks, to show any 
trends or surface behaviour and potential interactions. It is clear from the results 
achieved that pH is a key variable to determine the chemical reactions occurring on the 
surface of the electrode. Even the absence (blanks) or presence of digoxin in solution at 
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different concentrations seems to be a secondary factor in the clustering as 
demonstrated by the fact that all voltammograms clustered together. Different pHs will 
affect the position of the reduction and oxidation peaks and, as seen before, the 
reproducibility of these processes. Hence, to select the best possible analytical 
conditions for the analysis of digoxin on a gold electrode this is a factor that needs to be 
considered. The presence of surface oxides will greatly condition the electrochemical 
response. However, this is not a factor that prevents the analytical use of this electrode 
in the determination of digoxin as demonstrated by the calibration curves. The 
variability achieved in the analysis of each of the PCA plots was given by the 
percentage of variability for the different PCs. In this way for Fig.10 and Fig.11 this 
was PC1 (53.79%) and PC2 (26.86%) and PC1 (51.30%) and PC2 (29.94%), 
respectively.  
 
                     
 
Fig.10. PCA scatterplot of the electrochemistry RedOx of a gold electrode at different pHs of 5, 7.4, 10, 
11.  Percentage of variability: PC1=53.79%; PC2=26.86%. 
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Fig.11. PCA scatterplot of the electrochemistry OxRed of a gold electrode at different pHs of 5, 7.4, 10, 
11.  Percentage of variability: PC1=51.30%; PC2=29.94%.  
 
 
4.3.8. Investigation of the effect of different pHs on the voltammetric 
characteristics of digoxin, using silver electrode 
At pH5, silver electrode showed the possibility to analyse digoxin both in OxRed and 
RedOx cycles at 0.0055V in the reduction phase and 0.0121V in the reduction phase 
respectively, with calibration curves r2 correspondently of 0.9269 and 0.9874. 
pH7.4 was a non-ideal environment for silver electrode that was not be able to detect 
digoxin in neither the cycles.  
At pH10, silver electrode could analyse digoxin in in RedOx cycle at -0.0594V in the 
reduction phase (r2=0.8561) and in OxRed cycle at -0.1195V during the reduction 
phase, achieving a calibration curve with a r2=0.9104. 
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At pH11, this solid electrode was able to detect digoxin in both cycle, obtaining 
calibration curves with r2=0.9111 in RedOx cycle at -0.2736V in the reduction phase 
and r2=0.9923 in OxRed cycle at -0.2921V in the reduction phase.  
Silver electrode,  in the OxRed cycle (Fig.12), shows not particular evident signal of 
oxidation during the positive sweep at the acid environment of pH5, and at pH11,  while 
at pH7.4 and 10 an anodic peak is shown at 0.505 and 0.535V respectively. 
Reversing the potential scan, in the negative sweep at pH11 a weak signal is noticeable 
at -0.239V, while at the other pHs strong cathodic peaks are registered, with peaks at 
0.02V for pH5, 0.03V for pH7.4 and -0.10V for pH10. 
In the RedOx cycle (Fig.13), in the reduction sweep two peaks are visible for both 
pH7.4, at 0.012 and -0.149V, and pH10, at -0.053 and -0.357V. A single peak is 
noticeable at pH5, at 0.02V, and at pH11, at-0.405V. In the positive sweep, still two 
peaks are visible for pH7.4, at 0.560 and 0.815V, and for pH10, a weak one in the 
region around 0.350V and a stronger one at 0.590V. 
 
 
Fig.12. Voltammogram obtained using a silver electrode as a working electrode and different buffer 
solutions at different pHs of 5, 7.4, 10 and 11. Scan from -1V to +1V.  Sweep rate = 0.05V/s; Voltage 
step = 0.0059V; T= 25°C. 
 
Similarly to the investigation carried out for the gold electrode, the silver electrode was 
studied in an oxidation-reduction scan cycle first to discover the extent of its ability to 
oxidise and then reduce (Fig.12).  
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In the oxidation-reduction cycle where the silver electrode was employed, there is no 
evidence of an oxidation signal during the positive sweep in the acidic environment of 
pH=5. At the remaining pH levels of 7.4, 10 and 11, however, anodic peaks can be 
observed, in agreement with the results shown by Hassan et al [26]. When the scan is 
then reversed to reduce the products of the initial oxidation, only a weak signal was 
detected (-0.239V) in the alkaline conditions of pH11. The pH regions of 7.4 and 10 
registered strong cathodic peaks.  
Following this, the silver electrode was then studied by a reduction-oxidation scan cycle 
(Fig.13). In the reduction sweep of the silver electrode two peaks are visible at pH7.4 
(0.012V and -0.149V) and pH10 (-0.3905V and -0.04745V) and only one at pH5 (0V).  
When the scan then moves into the oxidation phase, sweeping towards the more 
positive potential, two peaks are present at pH=7.4, however at pH=10 only one 
oxidation peak is observed. No oxidation peaks were detected at pHs 5 and 11. 
 
 
Fig.13. Silver electrode voltammogram in a reduction-oxidation scan cycle at different pHs of 5, 7.4, 10 
and 11. Scan from +2V to -2V.  Sweep rate = 0.05V/s; Voltage step = 0.0059V; T= 25°C. 
 
Figure 14 shows the concentration of the different forms of oxidised silver as a function 
of the pH at a fixed potential of 0.5V and silver concentration of 10µM. As the pH 
increases up to pH10, a constant amount of silver is precipitating out of solution and the 
concentration of H+ ions steadily decreases (expected as the pH is moving towards the 
alkaline condition). 
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Fig.14. Theoretical oxidation-reduction equilibria for Ag at 25oC and 10µM Au at different pHs. 
 
At the time that this is happening, up to pH11, a constant amount of Ag+ ions are 
forming. It can be noted that at pH8 Ag2O also starts to precipitate out of solution.  
 
 
Fig.15. Pourbaix diagram of Silver (extracted from Hassan et al [26]) 
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Silver electrode at pH5 showed the possibility to analyse digoxin both in OX-RED  
(Fig.12) and RED-OX (Fig.13) cycles at 0.0055V in the reduction phase and 0.0121V 
in the reduction phase respectively, with calibration curves r2 correspondently of 0.9269 
and 0.9874. pH7.4 was a non-ideal environment for silver electrode that was not be able 
to detect digoxin in neither the cycles. At pH10, silver electrode could analyse digoxin 
in OxRed cycle at -0.1195V during the reduction phase, achieving a calibration curve 
with a r2=0.9104, and in RED-OX cycle at -0.0594V in the reduction phase 
(r2=0.8561). 
At pH11, this solid electrode was able to detect digoxin in both cycle, obtaining 
calibration curves with r2=0.9923 in OxRed cycle at -0.2921V in the reduction phase 
and r2=0.9111 in RED-OX cycle at -0.2736V in the reduction phase. For the silver 
electrode the LoD ranged from 16µg/mL at pH10 to 0.9µg/mL at pH5 and pH11.  
The concentration of both these ions begins to plateau at around pH11. From pH10 a 
sudden increase of Ag(OH)2- ions can be seen, followed by an appearance of AgOH 
ions between pH=11 and 12 (Fig.15). The presence of all of these ions at the differing 
pHs visually demonstrates the cyclic voltammetry results and the presence of surface 
oxides on the electrode, as well as supporting those results presented by Pasta, Mantia 
and Cui in the form of a Pourbaix diagram (Fig.15) [24] and [26]. It is clear, from the 
evidence supplied here, that an important factor to consider when digoxin is to be added 
to a solution and analised by an electrode system is the presence of metal oxides. 
Digoxin will have to compete with the electrode in both the oxidation and reduction 
processes occurring during cyclic voltammetry. This leads to a reduction in signal as the 
concentration of digoxin increases. There is a definite evidence of a linear dependence 
between the signal obtained and digoxin concentration.  
Digoxin solutions at pH=5 showed the possibility to be also analysed using 
silver electrodes yielding peaks at 0.0055V and 0.0121V (in the reduction phase), 
showing calibration curves with r2= 0.9269 and 0.9874, respectively. Solutions at 
pH=7.4 showed a non-ideal environment for the analytical use of silver electrodes as 
they were not able to detect digoxin in neither the cycles possibly due to the lack of 
interaction with surface oxides. At pH=10, silver electrodes could analyse digoxin at -
0.12V during the reduction phase, achieving a calibration curve with a r2=0.9104. 
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At pH=11, silver electrodes were able to detect digoxin obtaining calibration curves 
with r2=0.9923 at -0.29V. For the silver electrode the LoD ranged from 16µg/mL at 
pH=10 to 0.9 µg/mL at pH=5 and pH=11, respectively. The best percentage of recovery 
obtained using gold electrode in OxRed was at pH10 with 115%  and in RedOx it was 
at pH10 with 75% and at pH11 with 110%. An appreciative percentage of recovery 
resulting from the use of silver electrode was obtained only in OxRed condition at pH10 
and it was of 120%. 
The Standard deviation and the average Coefficient of Variation also followed the trend 
observed for gold electrodes showing a higher precision of -3.90% and -1.61% at pH=5 
and 11, respectively. 
Principal Component Analysis of the different digoxin solutions were also performed 
for silver electrodes, as shown in Figure 16 and 17.  
 
               
 
Fig.16. PCA scatterplot of the electrochemistry RedOx of a silver electrode at different pHs of 5, 7.4, 10, 
11.  Percentage of variability: PC1=51.30%; PC2=29.94%. 
 
The PCA analyses showed a similar behaviour to that observed in gold at pH=11 and 
showed a better clustering than other pHs. Hence, the best possible analytical conditions 
for the analysis of digoxin on a silver electrode should be conducted at pH=11. Also, 
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the variability achieved in the analysis of the PCA plot for Fig.16 was PC1 (51.30%) 
and PC2 (29.94%) and for Fig.17 was PC1 (54.02%) and PC2 (20.61%). 
 
 
Fig.17.  PCA scatterplot of the electrochemistry OxRed of a silver electrode at different pHs of 5, 7.4, 10, 
11.  Percentage of variability: PC1=54.02%; PC2=20.61%.  
 
For the gold electrode in RedOx sweeps, the voltage potential peaks selected as 
analytical signals to follow in quantitative determinations were: at pH 5, -1.2138V; at 
pH7.4, -1.2733V; at pH10, 0.2322V; at pH11, 0.0418V in the reduction phase and  
0.6012V in the oxidation phase. In OxRed sweeps, at pH5 and pH7.4 no signal was 
analytically significative; at pH10, 0.2018V; at pH11, 0.5886V. 
For the silver electrode in RedOx sweeps, the voltage potential peaks selected as 
analytical signals to follow in quantitative determinations were: at pH5, 0.0120V; at 
pH7.4 no signal was analytically significative; at pH10, -0.0593V; at pH11, -0.2735V 
In OxRed sweeps, at pH5, 0.0055V; at pH7.4 no signal was analytically significative; at 
pH10, -0.1194V; at pH11, -0.2920V. 
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4.4. Investigation of digoxin tablets by voltammetry  
After having assessed the suitability of this analytical technique to investigate the 
cardiac glycosides in their standard pure form, the investigation was extended to the real 
pharmaceutical samples. Digoxin tablets from one generic and one branded version 
were submitted to voltammetric investigations, reiterating the same procedure applied 
previously for the standards. The tablet of digoxin contained 250µg of active 
pharmaceutical ingredient and as excipient lactose and magnesium stearate. The 
information found on the excipients were only qualitative, no information on the 
quantity were disclosed, being protected by industrial patent. The weight of the tablets 
averaged around 212mg, both for the generic and for the branded ones, leading to an 
extremely low ratio API to excipients of 0.1%w/w. The low ratio represented a strong 
limitation in the analysis of the API, because of the potential strong shielding effect of 
the signals generated from the bulk of excipients, covering the specific response of the 
analyte, as previously reported [24]. This could have been the reason of the poor results 
obtained in the voltammetric analyses of the digoxin in tablet form. In fact, when 
digoxin tablets have been submitted to the same analytical procedure of the 
correspondent standards, they showed a scarce response, of no analytical significance, 
to the voltammetric investigations both with mercury and with solid electrodes. 
 
 
4.5. Raman characterization of digoxin, digitoxin and digoxigenin pure standards 
In the light of the unsatisfactory results obtained from the voltammetry of the 
pharmaceutical formulations, in order to adjust the project design of the research, the 
possibility to use a different analytical technique to analyse the same previous sample 
was investigated. 
Raman spectroscopy was chosen as a potential more appropriate analytical technique. 
Raman is a non destructive analytical method used in the last decades in the 
pharmaceutical sector with advantages to test in-situ solid pharmaceutical forms, often 
not even requiring to extract the tablets or capsules off from their original containing 
blisters and this has made Raman spectroscopy a valid candidate analytical method for 
quality control purposes [25-27]. 
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4.5.1. Examination of the cardiac glycosides by Raman spectroscopy 
The three pure standards of cardiac glycosides (digoxin, digitoxin and digoxigenin) 
investigated by Raman spectroscopy exhibited a good response to this analytical 
technique. Particularly, digoxigenin showed a quick significative response to Raman 
spectroscopy (Fig.18), while digoxin and digitoxin when exposed to conventional 
Raman analysis did not produced analytical results, 
 
 
Fig.18. Comparison of SERS (blue line) and conventional Raman analysis (red line) of digoxigenin 
(spectra are shown offset in order to distinguish each other) 
 
In order to amplify the Raman signals of the two non-responsive molecules, SERS 
analysis was performed on the standards of digoxin and digitoxin. When expose to 
SERS, the spectra obtained from the two compounds resulted changed, characterised by 
characteristic peaks (Fig.19, 20). Both digoxin and digitoxin showed a dramatic 
increase of the response to this analytical technique. 
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Fig.19. Comparison of SERS (blue line) and conventional Raman analysis (red line) of digoxin 
 
On the contrary, when digoxigenin was submitted to SERS analysis the correspondent 
spectrum resulted to be very similar to the one obtained with conventional Raman 
spectroscopy.  
SERS amplifies the signals produced by nucleophilic functional groups which have 
electron-rich atoms able to donate a pair of electrons to the silver colloid to form a new 
covalent bond. It is possible that the sugar moiety covers the Raman scattering of the 
steroid glycoside in digoxin and digitoxin, which benefit from a dramatic enhancement 
with the SERS, that shows a increase of the signals obtained from functional groups 
present in the steroid glycoside moiety. In Fig.20 it is possible to notice the sharp peak 
at 1470cm-1possibly due to the the stretching of the double bonds C=C conjugated to the 
carboxylic group. At 1630cm-1 a strong signals probably attributable to the carboxylic 
group. 
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Fig.20. Comparison of SERS (blue line) and conventional Raman analysis (red line) of digitoxin. 
 
In Fig.21 are plotted the spectrograms obtained for the three pure standards of cardiac 
glycosides investigated. In the region from 800 to 1000cm-1, only digoxigenin seemed to 
show a significative Raman activity. The peak at 850cm-1 could be assigned to the 
stretching of the C-O-C in the cyclobutenolide ring. 
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Fig.21. SERS Comparison of pure standards of Digoxin (red line), Digitoxin (blue line), and Digoxigenin 
(green line). (Spectra reported with baseline correction). At 1020cm-1 peaks due to asymmetric stretching 
C-O-C; at 1180cm-1 peaks due to CH2 twisting; at 1470cm-1 stretching of the conjugated double bond 
C=C; at 1660cm-1 stretching of the carboxylic group; at 1750cm-1 the alicyclic ester stretching 
 
The peaks in the range from 850 to 970cm-1 can be referred to the stretching of the 
diverse C-C alicyclic bonds (Fig.20). At 1020cm-1, both digoxin and digitoxin, showed 
a sharp signal characteristic of asymmetric stretching C-O-C. Slightly shifted to 
1040cm-1 digoxigenin presented a peak that can be associated to the same stretching. At 
1100cm-1 digitoxin only presented a peak attributable to the OH rocking. At 1180cm-1 
digoxigenin and digitoxin showed sharp signals, referable to CH2 twisting, while 
digitoxin seemed not to present the same spectroscopic behavior. In the region from 
1220 to 1250cm-1 all the three glycosides showed two sharp peaks, probably due to the 
OH scissoring of the hydroxyl groups both on the aglicone core and on the glycoside 
moieties. Digoxigenin showed a peak at 1320cm-1 and a prominent peak at 1360cm-1 
due to bending of methyl groups. In the region between 1470 and 1490cm-1 all the three 
cardiac glycosides produced a sharp peak, possibly due to the stretching of the double 
bond C=C. In the region between 1640 and 1660cm-1 the three compounds emitted very 
strong signals attributable to the the stretching of the carboxylic group. At 1750cm-1 the 
alicyclic ester stretching is shown for digoxigenin and digoxin. 
Raman spectroscopy resulted to be a valid technique to analyse the pure standards of 
cardiac glycosides. The extension of signals obtained were sufficient to identify and 
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differentiate the three samples. Particularly, digoxigenin seemed to respond directly to 
normal Raman investigation, without the aide of the metal colloids used to perform 
SERS investigation. However, SERS analysis was instead necessary for the digoxin and 
digitoxin, non responding to normal Raman analysis. Being the presence of the sugar 
moiety the main difference between the chemical structure of the digoxigenin and 
digoxin and digitoxin, it may be speculated that the presence of the hydroxyl groups in 
the sugar moiety seemed to interfere with the response of the steroid core alone, 
attenuating the intensity of the signals. Nevertheless, this attenuation has been resolved 
efficiently by the use of SERS for the analyses of the three cardiac glycosides, 
enhancing the signals of the nucleophilic functional groups, showing that this technique 
can be effectively adopted to investigate such products. 
 
 
4.5.2. Raman characterization of digoxin tablets 
Eight tablets of digoxin, generic and branded, were analysed with conventional Raman 
and SERS in order to explore the possibility to use this analytical technique to 
investigate this analyte in its pharmaceutical formulations. The signals obtained 
submitting the two different kind of digoxin tablets to both normal Raman and SERS 
analysis resulted analytically significative (Fig.22). 
Lactose is the main excipient used in the manufacturing of the digoxin tablets tested. It 
presents a structure that can resemble the one of the polysaccharides side of the digoxin 
interfering with the analysis. The SERS spectrum of the main excipient lactose has been 
compared with the digoxin-tablet. The digoxin tablets and the lactose show different 
Raman spectra features, with some common peaks, and some peculiar ones.  
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Fig.22. SERS spectroscopy of digoxin tablet (blue line) and lactose (green line). 
 
The peaks in the range from 850 to 970cm-1 can be referred to the stretching of the 
diverse C-C alicyclic bonds present both int structure of the digoxin and in the lactose. 
At 1080cm-1 a sharp signal probably characteristic of asymmetric stretching C-O-C of 
the cyclobutenolide ring in digoxin is evident. At 1140cm-1 lactose showed a peak 
referable to CH2 twisting, while digoxin seemed not to present the same spectroscopic 
behavior. In the region from 1220 to 1250cm-1 digoxin showed two sharp peaks, 
probably due to the OH scissoring of the hydroxyl groups both on the aglicone core and 
on the glycoside moieties. Digoxin showed a peak at 1330cm-1 due probably to bending 
of methyl groups. In the region around 1470cm-1 digoxin produced a sharp peak, 
possibly due to the stretching of the conjugated double bond C=C. At around 1630cm-1 
digoxin produced a strong signals attributable to the the stretching of the carboxylic 
group.  
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4.6. Conclusions 
Digoxin, digitoxin and digoxigenin were used in a comparison study of the 
electrochemical interactions of carbon glass, gold and silver solid metal electrodes in 
different pH buffer solutions of pH5, 7.4, 10 and 11,  using cyclic voltammetry.  
A good comprehension of the features of the different electrodes under different pH 
conditions was key to understand the electrochemical behaviour of these cardiac 
glycosides and their interactions with the different solid electrode surfaces. The results 
obtained shown that only digoxin could be investigated with a significant analytical 
response using this voltammetric approach. 
The results obtained studying pure standards of these cardiac glycosides with solid 
electrodes carbon glass, gold and silver showed that only digoxin results offer sufficient 
value to be analytically investigated by voltammetry analysis using solid electrodes, 
particularly in gold and silver electrodes. In fact, carbon glass electrode resulted not 
able to register signals with analytical significance. 
Nevertheless, the results obtained from the analysis of digoxin standard with Ag and Au 
electrodes showed that both electrodes were suitable for this investigation. Furthermore, 
in most of the cases, digoxin could be investigated, for the same pH, both in RedOx and 
in OxRed conditions. pH7.4 has shown to be a critical condition for both electrodes: the 
silver electrode has shown not to be sensitive at all, while the gold one has shown a 
response only in RedOx cycle. 
When digoxin standard is added to the solution, competition with the electrode in the 
oxidations and reductions processes occurs the electro-activity of the electrode goes in 
competition with the electro-activity of digoxin, leading to a reduction of the signal with 
the increasing of the concentration of digoxin. This current peaks intensities, both at 
anodic and cathodic potentials, are highly correlated to a linear dependence on digoxin 
concentration.  
Studying the chemical structure of digoxin, the double bond conjugate to the carbonyl 
group of the molecule seems to be prone to reduction from alkene to alkane group and 
to oxidation with opening of the lactone ring. 
In terms of sensitivity, the better conditions have been for the Ag-electrode at pH10.  
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The very narrow solubility of digitoxin and digoxigenin it has been considered the 
major limiting factor to perform an adequate investigation in liquid condition of these 
molecules.  
The results obtained on digoxin with the carbon glass electrode were overall 
inconclusive.  Only digoxin has shown a slight responsive behavior when tested at pH5, 
as in the identical case of the experiments conducted at this pH with mercury electrode. 
On the other hand, the results obtained by studying digoxin with Ag and Au electrodes 
in solution at different pHs showed that both electrodes were suitable for the analytical 
determination of digoxin in solution in the range of concentrations from 3.92 to 
14.81µg/mL. 
Using a gold electrode, the best analytical conditions, given by the LoD and the 
linearity of the calibration curve, showed that the alkaline environment at pH11 is the 
ideal one.  
For this the LoD was 1.7µg/mL, with a corresponding average coefficient of variation 
of 2.09% and 4.13% at pH11 for both RedOx and OxRed sweeps, respectively. 
For the gold electrode, the best percentage of recovery obtained in OxRed was at pH10 
with 115% while in RedOx it was at pH10 with 75% and at pH11 with 110%. 
Silver electrodes showed the best LoD (0.9µg/mL) at pH5 and at pH11. The results 
obtained characterised by an average coefficient of variation of -3.90% and -1.61% at 
pH5 and 11, respectively. For silver electrode, a significative rate of recovery was 
obtained only in OxRed condition at pH10 and it was of 120%. 
The metal electrodes, gold and silver, studied seem to be good candidates in the analysis 
of digoxin via cyclic voltammetry replacing the mercury one and being able to quantify 
trace of this alkaloid in the range in optimum alkaline solutions at pH11. It is also 
important to emphasize the role that the surface oxides may play in digoxin redox 
behaviour and the catalytic influence in the electrochemical behaviour of this molecule 
in solid electrodes.   
Micromole sensitivity has been achieved for both of the electrodes, showing that the use 
of these sensors could represent an alternative choice, more practical and less 
environmental impacting than using mercury electrodes. 
Having confirmed that voltammetry analysis was indicated for the digoxin pure 
standard, the same investigation was extended to the tablet formulation of digoxin. Poor 
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results, not analytically representative, were obtained in the voltammetric analysis of the 
digoxin tablets.  
The low solubility of the digoxin represented a strong limitation in the analysis 
of the digoxin tablets. The bulk of excipients is not electroactive, consequently the 
strong shielding effect of the signals showed in the spectroscopic analysis should not 
represent a limitation in voltammetry. When digoxin tablets were submitted to the same 
analytical procedure of the correspondent standards, they showed a scarce 
electrochemical response, of no analytical significance, to the voltammetric 
investigations both with mercury and with solid electrodes. 
In view of the inadequate results obtained from the voltammetry analysis of the 
pharmaceutical formulations, in order to adjust the project design of the research, the 
possibility to use a different analytical technique to analyse the same previous sample 
was investigated.  
Since cardiac glycosides have not been particularly studied using Raman spectroscopy, 
it seemed there were elements of novelty to undertake this study. The three pure 
standards of cardiac glycosides investigated by Raman spectroscopy exhibited a good 
response to this analytical technique. Particularly, digoxigenin showed a quick 
significative response to conventional Raman spectroscopy, while digoxin and digitoxin 
required SERS investigation to produce a significant analytical response. The response 
obtained submitting the two different kind of digoxin tablets to both normal Raman and 
SERS analysis resulted analytically significative. Even though the structure of the 
excipients used in the manufacturing of the digoxin tablets resembles the structure of 
the sugar moiety of digoxin, interfering with the analysis, some specific peaks 
attributable to the digoxin were registered.  
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5. Differences Observed among Amlodipine Salts used in Medicine through 
Raman and FT-IR Spectroscopy with Chemometric Analysis 
 
 
5.1 Introduction 
A significant paradigm continuously frequented in pharmacology is the confliction 
between views on generic medications. As introduced earlier, “generics” are drugs 
comparable to their patented predecessors in terms of dosage, form, route of 
administration, quality and performance characteristics, and intended use [1, 2]. For a 
generic drug to be accepted by the appropriate authorities, the manufacturer must 
demonstrate that the replicate meets bioequivalence expectations whilst containing the 
same quantity of active pharmaceutical ingredient (API) [3]. Generic drugs should be 
used interchangeably with the innovators drug; however, generic substitution has 
become common practise amongst healthcare professionals [1]. Despite this 
commonplace normality there are concerns in the healthcare sector as well as amid 
patients that not all generic preparations are equally clinically effective as their brand 
siblings, and that brand-name drugs may be clinically superior [5-7]. In order to 
introduce into the market a generic medication, pharmaceutical companies have 
previously produced different salts of an approved patented medication [4]. The 
different salt forms of a molecule can change its pharmacokinetic and stability features, 
which leads to needs for more exhaustive regulatory considerations [8, 9]. 
Kesselheim et al. raised the issue of generic drug substitution in the cardiovascular area 
[10]. They reported how 23 of 43 publications expressed negative views of generic drug 
substitution within cardiovascular science, and advised against the interchangeability of 
generic medications. Dong et al., however, studied the effect of different generics of 
Levothyroxine on a hypothyroidism condition, and concluded that there was not a 
considerable difference in the therapeutic properties [11]. In the area of epileptic 
medications, Burkhardt et al. suggest that phenytoin-branded drugs and their generics 
do not produce equivalent therapeutic effects in some patients and therefore substitution 
was not advised [12]. Borgheini and Guberman et al., also within the epileptic 
discipline, reported a general level of discomfort among neurologists with regards to 
their views towards generic medications [13, 14].  
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Amlodipine provides an interesting example of a drug that pharmaceutical companies 
have introduced in different salt forms of the same active pharmaceutical ingredient 
moiety in order to attempt replication of an approved patented medication. Currently in 
therapy, amlodipine is available in the maleate, mesylate and besylate salt forms (Fig.1) 
[15,16].  
 
 
(A)  
 
(B)  
(C)  (D)  
Fig.1. Chemical structure of (A) Amlodipine with relevant salt moieties; (B) Besylate, (C) Maleate and 
(D) Mesylate.  
 
Amlodipine is a calcium channel blocker that acts on the cardiac muscle and its 
peripheral vessels. Acting on the myocardial cells, which are responsible for the 
conduction of the electric stimuli of the heart, amlodipine causes a decrease of the 
myocardial contractility [1]. Amlodipine causes dilation of coronary and peripheral 
arteries which is an important treatment of hypertension, as well as increasing blood 
flow to the cardiac muscle which aids angina [2]. 
The Food and Drug Administration has already raised concern that the maleate salt of 
amlodipine, unlike the besylate and mesylate salts, suffer from intrinsic chemical 
instability resulting in the formation of a biologically active degradation product [17]. 
Some studies, including that by Suh et al., report how one of the by-products obtained 
by the degradation of the maleate salt moiety is a derivate of aspartic acid [18-20]. A 
citizen’s petition was organised in 2002 to revoke acceptance of amlodipine maleate as 
a clinically equivalent option to amlodipine besylate, due to the high biological activity 
of the impurities obtained from the degradation of the maleate moiety [21]. This was 
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acknowledged by the United States Court of Appeals for the Federal Circuit which 
temporarily prevented the generic maleate version from entering the market while it 
underwent further investigation [22]. 
The amlodipine salts are available to purchase in the solid-state form of tablet. The 
majority of medications currently developed and prescribed are in the form of tablets or 
capsules due to their ease of consumption by the patient. The identification and 
characterisation of tablets and capsules is a vital process within the drug development 
timeline, as the pharmaceutical form of a substance can impact significantly its stability 
and bioavailability [23]. Taylor & Langkildl explain how useful it could be to be able to 
identify these solid-state medications in situ, particularly where different salts are 
present. Furthermore, tablets often contain low doses of API, which can present 
analytical challenges. [24]. The design of the pharmaceutical industry has demonstrated 
considerable challenges in the need for new analytical systems that can discriminate 
between salt forms of a single drug moiety for quality control purposes, especially when 
doubts on the nature of the source of manufacturing and distribution are raised. 
Since the interchangeability of amlodipine medications has been questioned, here we 
explore differentiation of three salts of amlodipine, namely besylate, maleate and 
mesylate, in tablet formulation. Raman spectroscopy was chosen as one technique for 
this investigation as it has previously been selected to evaluate substances of abuse in 
combination with statistic aids. O'Connell et al reported how Raman spectroscopy, 
coupled with chemometric methods, can be used for on site analysis, both qualitative 
and quantitative, of narcotics deriving from illegitimate distribution chains [25]. In this 
study, O'Connell et al demonstrated that the first derivative of the Raman spectra from 
the fingerprint region yielded the best classifications and using cross-validation applied 
only on the fingerprint region between 750–1900cm−1 a correct classification rates of 
better than 90% was achieved. They showed that even with very high degrees of 
sample variance it was possible to gain accurate identification. In a different study, 
Ryder explained how using PCA and Raman spectroscopy it is possible to discriminate 
between cocaine, heroin, and MDMA mixtures even with very similar and complex 
Raman spectra [26]. Moreover, restricting the variables for principal component 
analysis to the most intense peaks in the Raman spectrum of the pure narcotic resulted 
in a rapid discrimination method for classifying samples according to the narcotic type. 
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At the present time no similar published study has been extended towards PPIs 
medications. FT-IR was chosen as the second technique for this investigation, as it is 
usually coupled to Raman spectroscopy given complementary correlated results, but, 
similarly as for the Raman spectroscopy, its use on the three salts of amlodipine 
medications result to be innovative. Furthermore, Raman spectroscopy was chosen as 
one technique for this investigation as it has previously been selected to evaluate the co-
action of amlodipine on cardio-vascular conditions, as well as for amlodipine tablet 
dissolution testing [27, 28] but not yet used to investigate the three therapeutic salts. FT-
Raman has been previously used for the characterisation of various solid-state forms, 
including salts [29] but not for these amlodipine salts. FT-IR was chosen as the second 
technique for this investigation, as it is an instrument frequently deemed suitable for the 
analysis of tablets [30]. FTIR has previously been used to analyse crystal forms of 
amlodipine besylate as well as amlodipine inclusion complexes [31, 32] but not 
extended to a comparison study of the three salts. The application of these two 
analytical techniques in the examination of the three different salts of amlodipine with a 
subsequent chemometric evaluation presents an element of novelty in pharmaceutical 
analysis. 
 
 
5.2. Materials and Methods 
 
5.2.1. Materials 
-Amlodipine maleate tablets ((Z)-but -2- enedioic acid; 3-O-ethyl 5-O-methyl 2-(2-
aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-
dicarboxylate) were purchased from Discovery Pharmaceuticals;  
-Amlodipine mesylate tablets (3-ethyl 5-methyl 2-[(2-aminoethoxy) methyl] -4-(2-
chlorophenyl) -6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; methanesulfonic acid) 
were purchased from Actavis; 
-Amlodipine besylate tablets (benzenesulfonic acid;3-O-ethyl 5-O-methyl 2-(2-
aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-
dicarboxylate) were purchased from Sandoz. Sixteen tablets of each Amlodipine salts 
were analysed internally and externally by Raman and FT-IR. 
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5.2.2. Methods 
Spectroscopic analysis was carried out by Raman spectroscopy, surface-enhanced 
Raman spectroscopy (SERS) and FT-IR. Raman analysis was performed on a FORAM 
685-2 instrument with a laser operating at 532nm, to ensure high levels of sensitivity. 
The Raman instrument was also equipped with an integral video microscope. Analyses 
were performed between the wavenumbers 800 and 2000cm-1.  
A Perkin-Elmer Spectrum 100 was used for the FT-IR analysis. This was supported by 
a Motorola DSP56303 Digital Signal Processor and a near infrared detector. The FT-IR 
was equipped with a Perkin-Elmer Autoimage microscope, with a IR performance of 
9000:1 p/p signal to noise ratio and a resolution greater than 10µm. The range of 
wavenumbers investigated was between 4000 and 500cm-1. 
Sample Preparation: eight tablets were taken for Raman analysis. To test the external 
side of the tablets using Raman spectroscopy the tablets were exposed to the laser at 
five points for each tablet, to achieve 40 repeated representative analyses for each 
amlodipine salt. To test the internal side, the tablets were broken in half and again 
exposed to the laser five times for each tablet. 
SERS enhances the sensitivity of standard Raman scattering by depositing a metal 
colloid on the surface of the sample being analysed. For this part of the investigation, 
silver colloids were prepared as follows: silver nitrate was reduced using sodium citrate 
in water, and concentrated by centrifuging at 5000rpm. The eight tablets for SERS 
analysis were covered with 2µL of the prepared colloid solution and 2µL of NaCl 1M 
after analysis by normal Raman, and analysed immediately. To test the external side of 
the tablets using Raman spectroscopy the tablets were coated in the silver colloid 
preparation and exposed to the laser. This was again repeated five times for each tablet, 
with the laser directed at a variation of external sites, to achieve the 40 representative 
analyses for each amlodipine salt. To test the internal side, the tablets were broken in 
half prior to the addition of the silver colloid, and again exposed to the laser five times 
for each tablet.  
Eight tablets were also taken for FT-IR analysis. To study the external side of 
the tablets by FT-IR the samples were prepared by scratching the surface of the tablets 
onto the ATR plate with a small spatula. This was done in order to attain adequate 
contact of the sample on the ATR crystal, so a successful spectrum could be produced. 
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Due to the shape of the tablets this contact would not have been achieved if the tablet 
was kept intact, and would have resulted in poor transmittance. To study the internal 
side, the tablets were ground to ensure homogenisation and subjected to the 
aforementioned procedure. Each tablet was analysed individually using a scan cycle of 
40. 
Principal Component Analysis (PCA), Factor Loadings, Cross Validation, 
Leave-one-out  were performed using Tanagra™ data mining software (University of 
Lyon, France). Analytical data were exported from the correspondent analytical 
apparatus to an excel spreadsheet and subsequently uploaded onto Tanagra.  
 
 
5.3. Results 
 
5.3.1. Raman Spectroscopy of Amlodipine Salts 
The conventional Raman analysis of the three salts of amlodipine examined, both 
internally and externally, resulted to produce spectra with broad peaks, not analytically 
significant (Fig.2, 3). 
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Fig.2. Raman analysis of tablets of amlodipine besylate (blue line), amlodipine maleate (purple line), 
amlodipine mesylate (yellow line), external sides 
 
 
Fig.3. Raman analysis of tablets of amlodipine besylate (blue line), amlodipine maleate (purple line), 
amlodipine mesylate (yellow line), internal sides 
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Baseline correction is a significant pre-processing technique of the obtained spectrum, 
aiming to separate true spectroscopic signals from several type of interferences. 
Baseline correction attempts to remove mainly the spectral contributions originated by 
fluorescence effects associated to the Raman scattering, and the laser fluctuations 
contribution, which will be reflected in the process data as an overall intensity shift. In 
fact, Raman intensity of the peaks obtained can often vary sensibly amongst replicates 
(Fig.4) and this fluctuation can have a profound influence on the associated 
chemometric model by causing extra factors to appear. On the contrary, adopting 
preprocessing techniques, such as baseline correction, allows to improve the 
performance and robustness of the statistical models adopted.  
 
 
Fig.4. Raman analysis of tablets of six replicates of amlodipine besylate), internal sides, showed as 
example to highlight the variation of intensities of the generated spectra. 
 
Opposite to the results obtained by conventional Raman, SERS analyses generated 
remarkably distinctive spectra thanks to the presence of several nucleophilic functional 
groups in the chemical structure of both the anionic and the cationic moieties of the 
amlodipine salts. The SERS spectra obtained from the analysis of the surfaces and of 
the internal areas of the samples, after their breakage, of the three salts investigated 
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have been displayed together in Fig.5 and 6. The spectra clearly show the similarity 
between forms with structure specific peaks obtained for each of the amlodipine salt.  
 
 
Fig.5. SERS analysis of tablets of amlodipine besylate (blue line), amlodipine maleate (pink line), 
amlodipine mesylate (yellow line), external sides. Peak at 851cm-1 due to stretching of the carboxylic 
group of the maleate; at 1024cm-1 peak due to the asymmetric stretching of the ether group; at 1097cm-1 
the stretching vibration of the C-C aliphatic chain is shown;  at 1240cm-1 peak due to the stretching of the 
C-C aliphatic chain; at 1260cm-1 peak due to the presence of multiple C-N stretching vibrations; at 
1390cm-1 peak due to the cationic aromatic ring moiety which emits C-C vibrations; at 1480cm-1 peaks 
are related to the aromatic C=C stretching; at around 1600cm-1 it is observed that a small peak associated 
to asymmetric in plane bending for a NH2 group; at 1640cm-1 sharp peaks related to the C=O stretching. 
 
From Fig.1 it is clear that the cationic moiety is linked by its primary amine to the acid 
group of each of the anionic counterpart, respectively. In Tab.1 the tentative band 
assignment of the peaks obtained from SERS analysis is reported. 
Starting at 1024cm-1, all salts present a peak which correlates to the asymmetric 
stretching of the ether group in the cationic moiety. In the spectra of all three salts, the 
stretching vibration of the C-C aliphatic chain is demonstrated at 1097cm-1. In the 
region of 1200-1250cm-1 there are two peaks present. The first at 1240cm-1 is also as a 
result of the stretching of the C-C aliphatic chain, and the second at 1260cm-1 is due to 
1480cm-1 
1097cm-1 1640cm-1 
1600cm-1 
1024cm-1 
1260cm-1 1240cm-1 
1390cm-1 
851cm-1 
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the presence of multiple C-N stretching vibrations. All amlodipine salts present a peak 
at 1390cm-1 due to the C-C vibrations of the cationic aromatic ring moiety. 
 
 
Fig.6. SERS analysis of tablets of amlodipine besylate (blue line), amlodipine maleate (pink line), 
amlodipine mesylate (yellow line), internal sides. Peak at 851cm-1 due to stretching of the carboxylic 
group of the maleate; peaks at 998cm-1 are related to sulfonic group stretching; at 1024cm-1 peak due to 
the asymmetric stretching of the ether group; at 1097cm-1 the stretching vibration of the C-C aliphatic 
chain is shown;  at 1240cm-1 peak due to the stretching of the C-C aliphatic chain; at 1260cm-1 peak due 
to the presence of multiple C-N stretching vibrations; at 1390cm-1 peak due to the cationic aromatic ring 
moiety which emits C-C vibrations; peaks at 1480cm-1 are related to the aromatic C=C stretching; at 
around 1600cm-1 it is observed that a small peak associated to asymmetric in plane bending for a NH2 
group peaks at 1640cm-1 are related to the characteristic carboxylic group stretching. 
 
The characteristic peak at 1480cm-1 is relative to the C=C stretching resultant from 
sections of the aromatic ring. The C-N group within the amlodipine molecule is 
accounted for by the broad C-N stretching aromatic peak at 1570cm-1 and 1610cm-1. 
Around 1600cm-1 it is observed that a small peak is present for all salts, which has 
previously been associated to asymmetric in plane bending for a NH2 group [28]. At 
1640cm-1 all spectra produce a sharp signal, which is justified by the presence of the 
C=O unit in the carboxylic and ester groups. This has been selected in some studies as a 
reference peak for validation models [35]. The peaks mentioned here can be associated 
1600cm-1 
998cm-1 
851cm-1 
1480cm-1 
1640cm-1 
1097cm-1 
1024cm-1 
1260cm-1 
1240cm-1 
1390cm-1 
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to amlodipine itself, as the salt part of the molecule and any excipients between the 
different tablet types are different.   
In addition to these peaks, there are spectral regions where differences between the salt 
forms are pronounced. In the amlodipine maleate spectrum, there is a prominent peak at 
851cm-1, in both external and internal analyses, that is not present in the mesylate and 
besylate spectra. This is due to the additional stretching of the carboxylic group of the 
maleate salts structure (Fig 1), not present in the besylate and mesylate structures. 
Furthermore, in both internal and external set of experiments (Fig.5, 6) the mesylate and 
besylate spectra show a peak evident at 998cm-1 which is not as strong in the maleate 
spectra. This wavenumber is often related to stretching of the aromatic C=C but also to 
the the stretching of the sulfonic group, presented only in the besylate and mesylate but 
not on the maleate moiety.  
 
Tab.1. Tentative band assignment of SERS spectra of different salts of amlodipine tablets 
Wavenumber [cm-1] Functional group 
851 C=O maleate stretch 
998 S=O besylate/mesylate 
1024 COC asym stretch 
1097, 1240 C-C aliphatic chain stretch 
1260 CN stretch 
1390, 1480 CC aromatic ring stretch 
1570 CN aromatic stretch 
1600 NH2 bending 
1640 CO stretch 
 
To aid the interpretation of the vast amount of wavenumbers generated by the 
spectroscopic techniques, both SERS and conventional Raman, PCA was used. PCA of 
the SERS data obtained by analysis of the external side of the amlodipine tablets shows 
identifiable distribution profiles for each salt (Fig.7).  
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Fig.7. Principal Component Analysis of the results obtained by SERS analysis of the external side of 
amlodipine besylate, amlodipine maleate, amlodipine mesylate tablets. PCA1=97.91%, PCA1+2=99.27% 
 
Principal component PC1 accounted for 97.91% of variation, with PC2 and PC3 being 
responsible for 1.36% and 0.65% respectively. The Kaiser-Guttman criteria advises to 
only use PCs greater than 1, for which PC3 has a score of 1.66, however as PC3 is 
accountable for less than 1% variation it was dismissed. PC1 and PC2 are therefore 
responsible for an accumulative 99.27% of the variation. The salts were separated due 
to their individual association with the two main components. All three salts gave a 
positive correlation across the two PC axis’ but can be seen to separate over the value of 
PC2. Amlodipine besylate clusters at a lower PC2 value, the maleate salt at a high PC2 
value whilst the mesylate salt clusters centrally around 0 for both components. 
Predictive accuracy of the PCA model obtained was validated via cross validation and 
leave-one-out approach (Tab.2, 3). 
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Tab.2 Cross validation of the PCA shown in Fig.7 on SERS spectroscopy obtained from the surface 
analyses of the amlodipine salts 
Error rate 0.043 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  BES MAL MES Sum 
BES 0.01 0.03 BES 39 0 1 40 
MAL 0.03 0.05 MAL 0 38 2 40 
MES 0.03 0.05 MES 0 2 38 40 
!! Sum 39 40 41 120 
 
 
The total error rate of the predictive model evaluated via cross validation accounted for 
around 4%. From the confusion matrix, it is possible to notice that out of 40 specimens 
per each salts analysed, besylate gave 39 samples correctly classified, correspondent to 
97.5% of the total; maleate and mesylate salts gave 38 samples correctly classified, 
equivalent to 95%. These data reflect the visual representation on the PCA (Fig.7) were 
the three classes of samples are separated in three distinctive clusters, even if spread 
within each group. 
 
Tab.3. Leave-one-out validation of the PCA shown in Fig.7 on SERS spectroscopy obtained from the 
surface analyses of the amlodipine salts 
Error rate 0.041 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  BES MAL MES Sum 
BES 0.12 0.026 BES 39 0 1 40 
MAL 0.14 0.051 MAL 0 38 2 40 
MES 0.07 0.05 MES 0 2 38 40 
!! Sum 39 40 41 120 
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Furthermore, the predictive accuracy of the model was tested via leave-one-out 
validation. The cumulative error rate accounted for around 4%, with similar results in 
terms of predictions than the ones obtained from correspondent the cross validation. 
From the confusion matrix, it is also possible to observe that the correct classification 
for all the specimens analysed is comparable to the cross validation data. 
 PCA of the SERS data obtained by analysis of the internal side of the tablets 
(Fig.8) shows distribution profiles for each salt, but without the same clarification.  
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Fig.8. Principal Component Analysis of the results obtained by SERS analysis of the internal side of 
amlodipine besylate, amlodipine maleate, amlodipine mesylate tablets. PCA1=99.68%, 
PCA1+2=99.92%. 
 
For this analysis, PC1 determines 99.68% of variability and PC2 0.24%. Here, 
amlodipine mesylate and besylate seem to have changed positions, with mesylate 
appearing to cluster at a lower PC2 value. As before, the model prediction of the 
principal component analysis model was validated by cross validation leave-one-out 
processing (Tab.4, 5). 
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Tab.4 Cross validation of the PCA from Fig.8 on SERS spectroscopy obtained from the internal analyses 
of the amlodipine salts 
Error rate 0.5221 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  BES MAL MES Sum 
BES 0.375 0.4 BES 15 4 21 40 
MAL 0.35 0.3944 MAL 8 22 10 40 
MES 0.35 0.3615 MES 19 9 12 40 
!! Sum 42 35 43 120 
 
The PCA model for the internal analyses performed by SERS gave a total error rate of 
52%, with the error rates similar for the individual class of sample. From the confusion 
matrix it possible to observe that 22 of the 40 samples of maleate salts were correctly 
classified. This is accordance with the PCA (Fig.8) that shows the cluster for the 
maleate well separated from the others, even if with the individual maleate analyses 
resulted to be spread within the group. Besylate and mesylate data resulted to be less 
well classified, confirming the overlapping of their two clusters visible on the PCA 
scatterplot 
 
Tab.5. Leave-one-out validation of the PCA from Fig.8 on SERS spectroscopy obtained from the internal 
analyses of the amlodipine salts 
Error rate 0.5117 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  BES MAL MES Sum 
BES 0.375 0.455 BES 14 9 17 40 
MAL 0.25 0.29 MAL 8 23 9 40 
MES 0.38 0.4116 MES 6 20 14 40 
!! Sum 28 52 40 120 
 
The total error rate of the predictive model estimated by leave-one-out validation 
accounted for 51%. Besylate and mesylate salts presented again the highest error rate, 
(Tab.5) in line with the correspondent cross validation and the visual representation on 
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the PCA scatterplot. From the confusion matrix, it is possible to notice that for all the 
classes of samples, the classification reflects the one obtained by cross validation. 
The similarity in chemical structure of the amlodipine salts and the bulk agents used to 
manufacture the tablets (see list of excipients in chapter 2) could justify the results 
obtained, finding, on average, half of the samples correctly classified. 
PCA of the conventional Raman data obtained by analysis of the external side of 
the tablets show clear distribution profiles (Fig.9). Principal component PC1 accounted 
for 99.37% of variation, with PC2 being responsible for 0.59%.  
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Fig.9. Principal Component Analysis of the results obtained by Raman analysis of the external side of 
amlodipine besylate, amlodipine maleate, amlodipine mesylate tablets. PCA1 explains 99.37% of the 
variability and the difference between PCA1 and PCA2 is 99.96%. 
 
As before, the model prediction of the principal component analysis model was 
validated by cross validation leave-one-out processing. In Tab.6 and 7 the two 
prediction model validation are illustrated. 
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Tab.6. Cross validation of the PCA from Fig.9 on conventional Raman spectroscopy obtained from the 
surface analyses of the amlodipine salts 
Error rate 0.3082 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  BES MAL MES Sum 
BES 0.175 0.249 BES 33 0 7 40 
MAL 0.21 0.3112 MAL 2 34 4 40 
MES 0.18 0.3011 MES 7 1 32 40 
!! Sum 42 35 43 120 
The cross validation reported in Tab.5 shown a total error rate of the predictive model 
evaluated accounting for around 31%. The three salts presented a similar error, data 
which is supported visually by the PCA (Fig.9) that shows the three classes of samples 
grouped in separated but spread clusters. From the confusion matrix, it is visible that out 
of 40 specimens per each salts analysed, besylate gave 33 samples correctly classified, 
maleate and mesylate salts gave 34 and 32 samples correctly classified, respectively. 
Apart from the comparable chemical composition already mentioned, the similarity in 
classification obtained by the cross validation for this dataset could be explained taking 
into consideration that conventional Raman analysis was maybe not powerful enough, 
or less powerful with respect the correspondent SERS analysis, in its ability to identify 
minor details for the differentiation of the three salts. 
Tab.7. Leave-one-out validation of the PCA from Fig.9 on conventional Raman spectroscopy obtained 
from the surface analyses of the amlodipine salts 
Error rate 0.2945 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  BES MAL MES Sum 
BES 0.16 0.238 BES 32 0 8 40 
MAL 0.24 0.3056 MAL 1 33 6 40 
MES 0.19 0.32977 MES 8 1 31 40 
!! Sum 41 34 45 120 
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The predictive accuracy of the model tested via leave-one-out validation gave a 
cumulative error rate accounted around 29% with results in agreement with the ones 
obtained from the correspondent cross validation (Tab.7). The validations of this 
predictive model supported the visual representation data in the spreadsheet, with good 
rate of classification per class of samples analysed. 
PCA results generated by normal Raman analysis for the internal side of the 
tablets also shows distribution profiles for each salt (Fig.10). With this investigation, the 
majority of the data points have clustered together more tightly in separate salt 
groupings with respected the previous analyses. 
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Fig.10. Principal Component Analysis of the results obtained by Raman analysis of the internal side of 
amlodipine besylate, amlodipine maleate, amlodipine mesylate tablets. PCA1 explains 98.04% of the 
variability and the difference between PCA1 and PCA2 is 99.82% 
 
For this analysis, PC1 determined 98.04% of variability and PC2 1.78%. Amlodipine 
maleate still appears to favour a higher PC2 value, however this salt has a main cluster 
with several outlying points. The besylate salt has formed the tightest cluster of the 
three, and sits around a central 0 value for both components, with mesylate generating 
negative PC1 and PC2 scores as in the previous PCA.  
Validation of this predictive model is shown in Tab.8 and 9, as seen before. 
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Tab.8. Cross validation of the PCA from Fig.10 on normal Raman spectroscopy obtained from the 
internal analyses of the amlodipine salts 
Error rate 0.46872 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  BES MAL MES Sum 
BES 0.175 0.2711 BES 27 5 8 40 
MAL 0.325 0.3292 MAL 11 19 10 40 
MES 0.125 0.2744 MES 7 9 24 40 
!! Sum 45 33 42 120 
 
In Tab.8 the relative cross validation is reported. The predictive model is associated to 
an amount of error of around 47%. Besylate and mesylate salts present a similar 
individual error rate, with 27 and 24 out of 40 besylate samples correctly classified, 
respectively. This data reflects the PCA correspondent, with visual grouping of the three 
class of samples. Maleate salts resulted to be more spread around the belonging cluster, 
this justifies the 19 maleate samples classified correctly shown in the confusion matrix. 
 
Tab.9. Leave-one-out validation of the PCA from Fig.10 on normal Raman spectroscopy obtained from 
the internal analyses of the amlodipine salts 
Error rate 0.4312 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  BES MAL MES Sum 
BES 0.18 0.14 BES 29 6 5 40 
MAL 0.35 0.3771 MAL 11 16 13 40 
MES 0.21 0.201 MES 8 7 25 40 
!! Sum 48 29 43 120 
 
The predictive accuracy of the model tested via leave-one-out validation (Tab.9) gave 
an error rate around 43%, with the smallest error rate for the besylate group. This 
reflects the visual representation on the PCA scatterplot where besylate cluster formed 
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the tightest group. Furthermore, besylate cluster presents 29 of the 40 samples correctly 
classified. Maleate samples were more spread out in their own group, this is consistent 
with the confusion matrix data where only 16 samples result to be correctly classified. 
Mesylate samples present as well a consistent match between the validation data, with 
25 samples out of 40 correctly classified, and the visual representation on the PCA 
scatterplot. 
Factor loading was also employed, and demonstrated a very similar picture to that of the 
PCA. Each wavenumber gave a factor value of 0.80 or above, with most giving a value 
superseding 0.95. This suggests that each wavelength, and therefore each PC, is 
accountable for the majority of variability in the data.  
 
 
Fig.11. Factor Loadings of the three amlodipine salts versus attributed wavenumbers in Raman analysis 
of external area of samples. Amlodipine besylate (blue line), maleate (orange line), mesylate (grey line) 
 
The factor loadings calculated against PC1 were then plotted against the 
correspondent wavenumbers in an attempt to identify a significant signal or signals that 
could be utilised for distinct characterisation between the amlodipine salts All the 
wavenumbers resulted to present a factor loading close to one with the exception of 
sharp peaks at 1480cm-1 for the external and internal and in the region around 1890cm-1 
for the internal (Fig.11, 12).   
 
←Besylate 
↑Mesylate 
↑Maleate 
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Fig.12. Factor Loadings of the three amlodipine salts versus attributed wavenumbers in Raman analysis 
of internal area of samples. Amlodipine besylate (blue line), maleate (orange line), mesylate (grey line) 
 
Two peaks identify sources of potential separation power. Wavenumbers between 1465-
1488cm-1 overlap for the three salts, however, and were discredited as possibilities. 
Amlodipine besylate shows a peak around wavenumber 1635cm-1 which could be used 
to separate it from the other two salts.  
 
 
5.3.2. FT-IR Spectroscopy of Amlodipine Salts 
The FT-IR spectra of the three Amlodipine salts have been overlaid in Fig.13 for the 
analysis of the external part of the samples and Fig.14 for the analysis of the internal 
sides. The spectra have been represented off-set on the figures in order to facilitate the 
band identifications. 
 
 
 
Besylate→ ←Mesylate 
↑Maleate 
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Fig.13. FT-IR analysis of tablets of amlodipine besylate (blue line), amlodipine maleate (red line), 
amlodipine mesylate (green line), external sides (spectra are shown offset in order to visualise the 
differences). At 3300cm-1 broad peaks due to the symmetric stretching of N-H and OH groups; at 
2900cm-1 peak due to C-H stretching; at 1650cm-1 peaks due to carboxyl group stretching; at 1450cm-1 
peak due asymmetrical in plane bending of CH2 groups; at 1380cm-1 there is a peak descriptive of methyl 
CH3 bending; at 900-1100cm-1 symmetrical and asymmetrical stretching of the ethyl group 
 
Each spectrum contains structurally characteristic peaks which can be associated to 
certain parts of the Amlodipine molecule. The FT-IR analysis of both part of the 
specimens seemed to provide same peak location. 
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Fig.14. FT-IR analysis of tablets of amlodipine besylate (blue line), amlodipine maleate (purple line), 
amlodipine mesylate (yellow line), internal sides (spectra are shown offset in order to visualise the 
differences). At 3300cm-1 broad peaks due to the symmetric stretching of N-H and OH groups; at 
2900cm-1 peak due to C-H stretching; at 1650cm-1 peaks due to carboxyl group stretching; at 1450cm-1 
peak due asymmetrical in plane bending of CH2 groups; at 1380cm-1 there is a peak descriptive of methyl 
CH3 bending; between 1300cm-1 a strong peak for the ether group attached to the primary amine chain; at 
900-1100cm-1 symmetrical and asymmetrical stretching of the ethyl group 
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In Tab.10 the tentative band assignment of the peaks obtained from FT-IR analysis is 
reported. 
 
Tab.10.  Tentative band assignment of FT-IR spectra of different types of amlodipine tablets 
Wavenumber [cm-1] Functional group 
3520 OH stretching 
3300 NH  asym stretching 
3100 CH asym stretching 
2900 CH stretching 
1740 Ester CO stretching 
1650 C=C aromatic stretching 
1450 CH2 bending 
1380 CH3 bending 
1300 C-C alicyclic stretchng 
1300-1000 COC stretchng 
1100 Ethyl asym stretching 
900 Ethyl stretching 
558 CCl stretching 
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Starting at 3520cm-1, peaks are observed for all three salts as a result of the 
hydroxyl O-H stretching. At 3300cm-1 broad peaks are generated due to the asymmetric 
stretching of N-H groups, as seen by Szabó et al [36]. Between 2900 and 3100cm-1 a 
small but sharp dual set of peaks are seen for each salt. The first at 3100cm-1 is 
accounted for by asymmetric C-H stretching and the latter at 2900cm-1 by standard C-H 
stretching. Within the recognised ‘fingerprint region’ of the spectra, at 1740cm-1 a small 
but sharp peak is recognised as a C=O stretch of an ester group. At 1650cm-1 a peak 
characteristic for aromatic group stretching is noted. In the region of 1450cm-1 peaks 
associated with asymmetrical in plane bending of CH2 groups are present. At 1380cm-1 
there is a peak descriptive of methyl CH3 bending. At 1300cm-1 the stretching vibration 
of C-C alicyclic and aliphatic chains are generated. Between 1300-1000cm-1 there is a 
strong peak for the ether group attached to the primary amine chain. The symmetrical 
and asymmetrical stretching of the ethyl group is found at 900-1100cm-1 [37]. The C-Cl 
in the cationic moiety is responsible for the peak at 558cm-1. The similarities in peaks 
mentioned here can be associated to the amlodipine core. Variances in salt type and 
excipients amid all three tablet types would therefore be expected to generate 
differences.  
In addition to these FT-IR peaks, there are points of interest where differences between 
the salt forms are noted.  In the amlodipine maleate spectrum, it is noted that the 
transmittance for the peak at 3540cm-1 is higher, due to the presence of extra O-H 
moieties as part of the carboxylic group in its structure. Again, at the peak at 1650cm-1, 
the maleate salt has a greater transmittance than the other salts, and the peak itself is 
sharper due to the extra carbonyl groups attached to its form. Finally, the asymmetric C-
H stretching of the benzene sulphonate ring of the besylate salt is slightly visible at 
around 3100cm-1. 
PCA of the FT-IR data obtained by analysis of the external side of the tablets 
show clear distribution profiles (Fig.13). Principal component (PC)1 accounted for 
97.73% of variation, with PC2 being responsible for an additional 1.28%.  
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Fig.15. Principal Component Analysis of the results obtained by FT-IR analysis of the external side of 
amlodipine besylate, amlodipine maleate, amlodipine mesylate tablets. PCA1= 97.73%, PCA2=99.01%  
 
The visual interpretation of the PCA scatterplot, shows how the three classes of samples 
resulted to be separated each others and tightly clustered, especially the besylate and 
maleate groups. Validation of this predictive model is shown in Tab.11 and 12, as seen 
before with cross validation and leave-one-out, respectively. 
The leave-one-out validation (Tab.12) was in accordance with the results produced by 
the cross validation, showing the same trend confirming the good level of separation of 
the dataset. 
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Tab.11. Cross validation of the PCA from Fig.13 on FT-IR spectroscopy obtained from the surface 
analyses of the amlodipine salts 
Error rate 0 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  BES MAL MES Sum 
BES 0 0 BES 40 0 0 40 
MAL 0.01 0 MAL 0 40 0 40 
MES 0.02 0 MES 0 0 40 40 
!! Sum 40 40 40 120 
 
 
In Tab.11. the relative cross validation of the PCA scatterplot of Fig.13 is reported. The 
predictive model is associated to an amount of error of 0% with all the three data set 
points correctly classified.  
 
Tab.12. Leave-one-out validation of the PCA from Fig.13 on FT-IR spectroscopy obtained from the 
surface analyses of the amlodipine salts 
Error rate 0 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  BES MAL MES Sum 
BES 0 0 BES 40 0 0 40 
MAL 0 0 MAL 0 40 0 40 
MES 0.03 0 MES 0 0 40 40 
!! Sum 40 40 40 120 
 
 
The leave-one-out validation (Tab.12) was in accordance with the results produced by 
the cross validation, showing the same trend confirming the good level of separation of 
the dataset. 
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 PCA results for the internal side of the tablets by FT-IR analysis also shows 
distribution profiles for each salt, although without the high level of clarity (Fig.16).  
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Fig.16. Principal Component Analysis of the results obtained by FT-IR analysis of the internal side of 
amlodipine besylate, amlodipine maleate, amlodipine mesylate tablets. PCA1= 97.11%, PCA2=98.77% 
 
For this analysis, PC1 determined 97.11% of variability and PC2 a further 1.66%. The 
three different classes of samples resulted to be well separated each other and clustered 
together, better for the maleate specimens and less for the mesylate.  
 
 
 
 
 
 
 
 
 
 
 
Besylate 
Maleate 
Mesylate 
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Tab.13. Cross validation of the PCA from Fig.16 on FT-IR spectroscopy obtained from the internal 
analyses of the amlodipine salts 
Error rate 0 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  BES MAL MES Sum 
BES 0 0 BES 40 0 0 40 
MAL 0 0 MAL 0 40 0 40 
MES 0.02 0 MES 0 0 40 40 
!! Sum 40 40 40 120 
 
 
The cross validation reported in Tab.13 shown a total error rate of the predictive model 
evaluated accounting for 0%, with all the dataset points correctly separated.  
 
Tab.14. Leave-one-out validation of the PCA from Fig 16 on FT-IR spectroscopy obtained from the 
internal analyses of the amlodipine salts 
Error rate 0 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  BES MAL MES Sum 
BES 0 0 BES 40 0 0 40 
MAL 0 0 MAL 0 40 0 40 
MES 0 0 MES 0 0 40 40 
!! Sum 40 40 40 120 
 
 
The leave-one-out validation (Tab.14) of the predictive model, presents similar results 
obtained from the correspondent cross validation, confirming the good percentage of 
data classification. 
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Factor loading was utilised for FT-IR statistical interpretation and, similarly to the 
Raman data, demonstrated a similar result to the PCA (Fig.17, 18).  
 
 
Fig.17. Amlodipine Salts Factor Loading vs 3700-2700cm-1. Amlodipine besylate (blue line), maleate 
(brown line), mesylate (grey line).  
 
A large portion of the wavenumbers studied gave a factor value of 0.80 or above. The 
factor loadings were again plotted against the correspondent wavenumbers in an attempt 
to identify a significant signal or signals that could be utilised for distinct 
characterisation between the amlodipine salts The large amount of data are reported in 
two different Figures (Fig.17, 18) for clarity.  
 
 
 
 
←Besylate 
Mesylate 
Maleate 
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Fig.18. Amlodipine Salts Factor Loading vs 1750-800cm-1. Amlodipine besylate (blue line), maleate 
(brown line), mesylate (grey line).  
 
FT-IR plots generate surplus peaks which could be used to potentially separate the three 
salts. These wavenumbers, however, are all within areas of a spectrum where there are 
broad peaks, resulting in any small differences between the salts spectra being 
insignificant. Subsequently, separation of the three Amlodipine salts would be entirely 
using PCA clustering. 
 
 
5.4. Discussion 
 
5.4.1. Raman spectroscopy of Amlodipine. 
The analysis of the three different amlodipine salts does not give a remarkably 
distinctive spectrum when studied via conventional Raman spectroscopy, both 
internally and externally. Using SERS, however, it was possible to observe 
characteristic peaks of the main amlodipine molecule.  
Amlodipine anionic moiety presents an abundance of electronic clouds from 
nucleophilic groups such as primary amine, two different ester groups, ether group and 
aromatic structure able to link with the silver colloid and enhance the correspondent 
signal on the spectrum. Equally, the cationic counterparts of the amlodipine salts are 
characterised by electron donating groups. 
←Besylate 
Mesylate 
Maleate 
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Although an amlodipine standard was not used in this study, previously reported spectra 
compared to those achieved here demonstrate that there are variances that can be 
attributed to the excipients added to the tablets and the differences in the salt forms [28]. 
Results from the internal and external analyses are very similar although some 
differences in quality and resolution could be due to a possible coating effect on the 
tablets. Han & Faulkner noted that, using spectroscopic techniques, the external surface 
of the tablets appeared to accrue the signal from the API in the tablet core, and 
discussed what implications this effect could have on the measurement of API content 
between batches of tablets [38]. SERS analyses of the external side seem to show the 
same peaks but more pronounced than the internal area. This could be due to how the 
tablets are compressed in manufacture, effectively giving a higher concentration at the 
external surface compared to that of the internal examination [38]. 
Although the main amlodipine core gives a representative spectrum, the three salts do 
not appear at first glance to produce any evident differences in their spectra. This was a 
hypothesised result as it was realised that the chosen techniques needed to be powerful 
and sensitive enough to detect differences in salt forms despite the low dose of API in 
the tablet, the high excipient content, the near complete similarities in salt forms and 
possibility of a non-homogenous solid-state medication. The table reported in chapter 2, 
with the list of excipients present in the formulation of the tablets, shows as for all the 
three different classes of amlodipine investigated, cellulose and starch represent the 
main ingredients. 
An explanation for the lack in differences could be provided from the additional 
chemical structure of the three salts to the main molecule. The differences in the 
structures of the three salts themselves are not eminent enough to separate, for example; 
the besylate and the mesylate salts both contain SO3 groups. In the besylate form, the 
sulfonate is linked to an aromatic ring, while in the mesylate it is linked to a methyl 
group. The Raman signal of these sulfonic groups are not distinguished enough to 
separate the two different salts [36]. Furthermore, the maleate salt presents conjugated 
carboxyl groups which absorb in the same region of the aromatic ring, making difficult 
its traceability [37].  
Despite the great similarities between the spectra of the three salts the 
application of chemometric methods, namely PCA and factor loading analysis, allowed 
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for the minor differences to be exploited. The PCA algorithm used within the Tanagra 
software generated score plots which meant visual clustering of the different amlodipine 
forms could be observed. Throughout PCA analysis of both Raman and SERS data, 
amlodipine besylate separated and clustered more tightly than the other salts. In addition 
to this, it was seen that the best separation power occurred from the data collected by 
analysis of the external side of the tablets.  
There are many advantages of SERS over normal Raman, not least being its 
enhanced sensitivity and therefore selectivity, which would lead one to hypothesise that 
SERS data would allow for better discriminatory abilities [41, 42]. Interestingly, 
however, the PCA demonstrates that using data from standard Raman analysis provides 
this superior separation. One reason for this could be the intensity of background signal 
and noise peaks from contamination with regards to the bulking agents and excipients 
present in the tablets or to different polymorphs presenting different analytical response. 
Some studies have reported that compared to normal Raman, SERS actually 
considerably increases background noise compared with the transmittance from the 
analyte signal peaks [43]. If this is the case here, the explanation for this 
aforementioned phenomenon could be that the SERS analysis is actually too sensitive 
for this analysis and Raman is a more suited technique. This would, however, need to be 
investigated in much more depth. 
Predictive accuracy of the model validated with both cross validation and leave-one-out 
gave a positive report on the accuracy of the prediction models with acceptable amount 
of error. The total error rates for all the PCAs performed on the Raman spectroscopies 
performed were around or below 50%, both from cross validation and from leave-one-
out evaluation. The prediction model that was associated with the best validation was 
the one obtained from SERS investigation of the external parts of the tablets, with error 
rate ranging around 25%. 
 
 
5.4.2. FT-IR spectroscopy of Amlodipine. 
Analysis of the Amlodipine salts by FT-IR, similarly to Raman and SERS, does not 
produce three vastly unique spectra. The backbone of amlodipine generates several 
main peaks of interest which can be linked back to its structure, but there are limited 
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regions that can be associated with the individual salt forms. This could be because the 
core of the molecules is the same, or that the excipients within the tablets are covering 
any of the more noticeable differences, or perhaps the addition of the salt moiety simply 
adds to a stronger transmittance of already existing peaks. The high concentration of 
hydroxyl functional groups presents in these two sugar could, in principle, create a 
covering effect of the signals originated from the amlodipine molecules. However, 
despite the excess of signals originated from the excipients, the amlodipine salts shown 
to be detectable from FT-IR technique, revealing the proper distinctive peaks. 
Prior to statistical interpretation, each spectrum was processed to attempt unambiguous 
identification of the salts by removing the main peaks concomitant with the Amlodipine 
backbone. These residual peaks would, in theory, match those of the salt molecule but 
this was unsuccessful as so similar. Lactose is one of the main bulking agents in all of 
the purchased tablets, which could be masking components of the API due to its broad 
sugar associated peaks. This is evidenced by the stretching C-O-C and C-OH peaks at 
1100cm-1 from the sugar ring of the lactose [39]. Additionally, there have been reports 
that mention drug-excipient interactions which could suggest an alternative to the 
masking effect [40]. 
The differences that can be established include the stretching of the carboxylic groups at 
1650cm-1 in the maleate spectra, which can be associated to the additional carbonyl 
groups attached to the structure of the salt. Also in the spectra of the maleate salt, there 
are three peaks in the internal analysis at 1660cm-1, 1430cm-1 and 1290cm-1 which are 
more prominent than in the mesylate and besylate salts. These can be attributed to 
stretching of C=O and C=C bonding. In the 1500cm-1 region of the besylate salt there is 
evidence of N-H stretching, as previously reported by Koradia et al [44].  Assumptions 
may be made that these discrepancies between the spectra, which allow for 
differentiation, will all be located in the molecular fingerprint region [45]. Although 
there are these small differences in this area, in this case we are also presented with 
some minor variances in the left side of the spectra. In data for all three salts there is a 
major peak at 3520cm-1 due to the stretching of O-H bonding. Amlodipine maleate, 
however, has noticeably better transmittance for this peak due to the presence of an 
extra O-H moiety within the carboxylic group in its structure. In addition, there is a 
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visible presence of asymmetric C-H stretching at 3100cm-1 due to the benzene 
sulphonate ring of the besylate moiety. 
Supporting the results of the Raman and SERS chemometric analysis, PCA of the FT-
IR data also shows how the three salts can be successfully separated. The multivariate 
analysis here presented good discrimination power, although less than Raman and 
SERS, but some loss as error can be associated to the physical similarities in the salt 
compounds, the low dosage of API and the high proportion of excipients.  
Some will argue that Raman is better and a more useful technique than FT-IR in this 
situation as the spectra here are so similar. Raman peaks are mostly sharper than those 
seen in FT-IR analysis and therefore makes it easier to spot spectral differences [26]. It 
has been reported that in pharmaceutical analysis, in many occasions it is not feasible to 
identify and characterise entire formulations using a single spectroscopic technique 
[46]. Clarke et al. combined Raman and IR spectroscopies in thoroughly determining 
the heterogeneous make up of solid-state dosage forms [47]. While Raman directly 
targets each part of the molecular structure of a given compound, IR presents the analyst 
with a subtler approach to the existing combinations of molecular functional groups and 
bonding patterns. Taylor & Langkilde support this notion by explaining that vibrations 
producing strong IR absorptions typically produce faint Raman signals, and vice versa 
[26]. The correlations that present themselves between the salt spectra and the 
calculated factor loadings are more difficult to establish in the FT-IR data due to the 
broad bands present in the spectra. As a result of the peaks encompassing a wider range 
of wavenumbers, it leads the factor loading algorithm to believe that more wavelengths 
are of necessity than in the Raman analysis. There is no clear spectroscopic evidence in 
the factor loadings for any salt. This is not surprising given the broad peaks, which 
make it problematic to detect a loading that contains a signature for one of the salt 
forms without spectral interferences from the excess material within the tablets. 
Previously single intensities and integrated areas from SERS data sets have been plotted 
against analyte or API concentrations to produce a univariate calibration [48, 49].  
The validations of the chemometric model gave error rate around 20% for the analyses 
conducted on the external area of the specimens, and around 30% for the ones 
conducted on the internal areas of the tablets, with consequently good separation 
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amongst the different classes of samples, with besylate samples presented the best rate 
of correct classification. 
 
 
5.5. Conclusions 
It is inferred from the analyses that there are enough spectral differences, when coupled 
with chemometric methods, to successfully separate the three salts. Despite the minimal 
samples used and similarity in chemical structure, separation of the Amlodipine salts 
has been statistically proven successful. The proposed method gives a level of 
sensitivity and selectivity never before achieved with alternative techniques, as well as 
being fast and requiring minimal sample preparation. This study presents a method that 
could have large applications in the pharmaceutical industry, distinguishing between 
three salt forms of a pharmacologically active compound, for which some argue can 
produce unrequited side effects.  
The combination of the two analytical techniques employed were successful in 
separating the besylate, maleate and besylate salts. Each technique provided peaks 
indicative of the Amlodipine backbone, as well as minor differences for each of the salt 
forms. These were extrapolated further with the use of PCA which allowed separation 
to be visually presented by clustering groups. Raman generated the best statistical 
separation of the salts with PC1 and PC2 accounting for an accumulative 99.96% of all 
variability within the data set. Cross validation and leave-one-out validation technique 
proved that the predictive models produced were reliable, allowing separation amongst 
the classes of samples studied. 
The non-destructive nature of the technique, plus the minimal sample 
preparation and speed of analysis presents this as a very attractive choice for this type of 
investigation. Despite this, the FT-IR clusters visually appear to separate with the most 
clarity.  
This is the first report to successfully identify and characterise amlodipine besylate, 
maleate and mesylate by Raman, SERS and FT-IR spectroscopy. 
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An Investigation of different Esomeprazole and Omeprazole generic medications 
obtained from traditional and internet market using FT-IR, Raman, NMR 
spectroscopies and Chemometric Analysis 
 
 
6.1 Introduction 
Proton pump inhibitors (PPIs) are a family of medications that block or diminish the 
production of gastric acid acting on the proton pump present in the parietal cells of the 
stomach [1]. Omeprazole (Fig.1) and esomeprazole belong to such a family, being the 
first a racemic mixture and the second the related levo-enantiomer [2]. In the 
intracellular canaliculi of the parietal cell, particularly acidic, omeprazole is 
concentrated and converted to the active form, being a weak base, and interacts with H+-
K+-ATPase, the proton pump, reversibly reducing or blocking its activity [3]. This 
influences the final step of the gastric acid secretion process and act irrespectively both 
in the basal acid secretion and in the one instigated by stimulus. PPIs are quickly active 
and with a unique daily dose can maintain control of the inhibition of the gastric acid 
secretion [2]. 
 
 
Fig.1 Omeprazole, chemical structure. 
 
Because the reflux of the acidic gastric content into the esophagus plays a major role in 
the pathogenesis of symptoms of GERD (gastro-esophageal reflux disease) and lesions 
of erosive esophagitis, acid suppression with a PPI is currently a mainstay of anti-reflux 
therapy [3,4]. There is a strong correlation between the degree of acid suppression 
provided by a given drug and its efficacy. The superiority of PPIs over other drugs 
(antacids, prokinetics and H2-receptor antagonists) has now been established beyond 
doubt, both for short- and long-term treatment [5]. Nevertheless, patient with erosive 
esophagitis are more reactive to PPIs than those with non-erosive reflux. Sometimes the 
action of PPIs in patients with atypical gastric condition is reduced to a reduction of the 
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symptomatology of heartburn. Different studies conducted on the safety of use of PPIs 
both in short and long periods have provided reassuring conclusions on their safety [6-
9]. PPIs have shown improved healing yield in case of severe erosive esophagitis, with 
quicker relief of the associated symptomatology [9]. The successful results obtained 
with the use of PPIs for the treatment of erosive esophagitis is having an important 
reflection on the prescribing habits of clinicians of primary and secondary care 
organizations in the United Kingdom [10]. The vast therapeutic success of PPIs has 
incredibly increased their use both in primary and in secondary care. With the attempt to 
reduce their financial impact on the health system, generic medications, obtained both 
from tradition distribution chain  and from parallel import, have represented the main 
type of PPIs used in clinics recently [11, 12]. This is one of the clinical areas previously 
cited, where there are concerns among health-care professionals and patients that not all 
generic and brand preparations can be equally clinically effective [6, 7]. Different 
clinical trials have been performed comparing brand medications versus generics, in 
order to evaluate any therapeutic differences. In [8, 9] Shimatania et al compared, in 
prospective, randomized, open-label, crossover studies, the acid-suppressive effect of 
generic omeprazole [8] and lansoprazole [9] with that of the original brand, measuring 
the intragastric pH at the regular interval of time, drawing the conclusion that acid-
suppressive effects of some brands of generic omeprazole and lansoprazole are not the 
same as the original ones. Besides these clinical studies, no information has been found 
in the literature concerning the chemical characterization of PPIs generics, aimed to 
investigate if different clinical features are associated with specific chemical 
characteristics. In fact, generic drugs are actually chemically equivalent to their brand-
name counterparts or among them just in terms of active ingredients, but they may 
differ in peripheral features, such as different polymorph forms of the same API, inert 
binders and fillers, shape, color and the specific manufacturing process, which could 
lead to diverse clinical responses [13-15]. This scenario highlights the need for a 
development of an analytical approach capable of discriminating amongst the different 
PPIs generic medications.  
Since the interchangeability of omeprazole medications has been questioned, in this 
study, it was used Raman and FT-IR spectroscopies to characterize different omeprazole 
and esomeprazole generic formulation produced by different manufactures and obtained 
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from traditional pharmacies and from the internet market in order to establish what kind 
of differences could be found to substantiate any different clinical performances.  
 
 
6.2 Materials and Methods 
 
6.2.1 Materials 
Omeprazole, (5-methyl-2-{[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfonyl}-
1H-benzimidazole) 
In order to characterise omeprazole and esomeprazole generics, seven different PPIs 
medications have been tested:  five of these were 20mg omeprazole (Dexcel and Losec 
obtained from traditional pharmacies, and GPO, Hycid and Olzep obtained from 
internet websites) and two were 10mg esomeprazole Rambaxy and Esopral, obtained 
from traditional pharmacies.  
Sixteen tablets of each PPIs were analysed internally and externally by Raman, FT-IR 
and NMR and the results submitted to chemometric evaluations. 
 
6.2.2. Methods 
Spectroscopic analysis was carried out by Raman spectroscopy, surface-enhanced 
Raman spectroscopy (SERS) and FT-IR. Raman analysis was performed on a FORAM 
685-2 instrument with a laser operating at 532nm, to ensure high levels of sensitivity. 
The Raman instrument was also equipped with an integral video microscope. Analyses 
were performed between the wavenumbers 800 and 2000cm-1.  
A Perkin-Elmer Spectrum 100 was used for the FT-IR analysis. This was supported by a 
Motorola DSP56303 Digital Signal Processor and a near infrared detector. The FT-IR 
was equipped with a Perkin-Elmer Autoimage microscope, with a IR performance of 
9000:1 p/p signal to noise ratio and a resolution greater than 10µm. The range of 
wavenumbers investigated was between 4000 and 500cm-1. 
Sample Preparation: eight tablets were taken for Raman analysis. To test the external 
side of the tablets using Raman spectroscopy the tablets were exposed to the laser at 
five points for each tablet, to achieve 40 repeated representative analyses for each 
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amlodipine salt. To test the internal side, the tablets were broken in half and again 
exposed to the laser five times for each tablet. 
SERS enhances the sensitivity of standard Raman scattering by depositing a metal 
colloid on the surface of the sample being analysed. For this part of the investigation, 
silver colloids were prepared as follows: silver nitrate was reduced using sodium citrate 
in water, and concentrated by centrifuging at 5000rpm. The eight tablets for SERS 
analysis were covered with 2µL of the prepared colloid solution and 2µL of NaCl 1M 
after analysis by normal Raman, and analysed immediately. To test the external side of 
the tablets using Raman spectroscopy the tablets were coated in the silver colloid 
preparation and exposed to the laser. This was again repeated five times for each tablet, 
with the laser directed at a variation of external sites, to achieve the 40 representative 
analyses for each amlodipine salt. To test the internal side, the tablets were broken in 
half prior to the addition of the silver colloid, and again exposed to the laser five times 
for each tablet. Eight tablets were also taken for FT-IR analysis. To study the external 
side of the tablets by FT-IR the samples were prepared by scratching the surface of the 
tablets onto the ATR plate with a small spatula. This was done in order to attain 
adequate contact of the sample on the ATR crystal, so a successful spectrum could be 
produced. Due to the shape of the tablets this contact would not have been achieved if 
the tablet was kept intact, and would have resulted in poor transmittance. To study the 
internal side, the tablets were ground to ensure homogenisation and subjected to the 
aforementioned procedure. Each tablet was analysed individually using a scan cycle of 
40. 
1H NMR spectra were obtained from a Bruker Avance 500 at 500.1MHz using TMS as 
internal standard. Chemical shifts for proton resonances were given inppm (δ). Signal 
multiplicity was characterized by s (singlet), d (doublet) and dd (double doublet). 
NMR spectra were recorded using 128k complex points and a recovery time of 4 
seconds 16 transients were generally sufficient to achieve good signal-to-noise. 
Principal Component Analysis (PCA), Factor Loadings, Cross Validation, 
Leave-one-out  were performed using Tanagra™ data mining software (University of 
Lyon, France). Analytical data were exported from the correspondent analytical 
apparatus to an excel spreadsheet and subsequently uploaded onto Tanagra.  
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6.3. Results 
 
6.3.1. Raman spectroscopy of omeprazole generic medications  
The SERS spectra related to the analysis of the surfaces of the omeprazole tablets 
investigated are reported in Fig.2. Tablets from all the seven different formulations have 
been submitted to the preparation for SERS analysis as introduced earlier. The spectra 
obtained from the SERS analyses of the surfaces showed both similar features and few 
distinctions for all the classes of samples. Hycid, indicated with the red line and GPO in 
purple, resulted to be overlapped. 
 
 
 
Fig.2. SERS analysis of omeprazole generic medications, external sides. Spectra have been off-set in 
order to avoid overlapping and facilitate observation. Rambaxy (black), Losec (yellow), Olsep (light 
blue), Esopral (green), Dexcel (brown). Hycid (red) and GPO (purple). At 890cm-1 and 1100cm-1 
stretching of the ether groups present in the two aromatic rings; 1300cm-1 symmetric stretching of the 
chain vibrations of the two aromatic rings; at 1470cm-1 methyl asymmetric bending. 
 
At 890cm-1 Esopral presents a more defined peak than the others, possibly related to the 
stretching of the ether groups present in the two aromatic rings of the omeprazole 
molecule. In the region around 950cm-1 Esopral and Losec produce smooth peaks, while 
the others do not present any peak, possibly attributable to the stretching of the C-C. In 
the region around 1100cm-1 all formulations produce signals with different intensity 
which might be assigned to the stretching of the ether groups. Hycid and GPO spectra 
890cm-1 
1100cm-1 
1300cm-1 
1470cm-1 
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looked overall overlapped. In the region around 1260cm-1 all samples produce peaks 
which may be referred to the stretching of the thiocarbonyl group. In the region of 
1300cm-1 all samples show peaks, possibly attributable to the symmetric stretching of 
the chain vibrations of the two aromatic rings. At 1380cm-1 strong peak for Esopral, 
small for the others and non for Dexcel possibly due to the symmetric bending of 
methyl groups. The asymmetric bending of the same groups laid in the region between 
1440 and 1500cm-1 can explain the signals recorded in the region 1460-1475cm-1 for all 
formulations. At 1500cm-1, Losec presents a peak probably to be referred to the 
asymmetric bending of the CH3. At 1632cm-1 all samples present peaks with different 
intensity possibly related to the stretching of the aromatic rings. 
To perform the investigation of the internal parts of the samples, the tablets of 
the seven different formulations have been broken in half manually and then submitted 
to the preparation for SERS analysis as indicated previously. The spectrum of GPO, 
shown with purple line, and Hycid, in red line, resulted to be overlapped, as also seen 
previously in the SERS analyses of the surfaces. Starting at 860cm-1, all formulations 
present signals (Fig.3), more prominent for Dexcel, GPO and Hycid, which might be 
referred to the stretching of a ether groups present in the aromatic rings of the 
omeprazole molecule. At 880cm-1 Dexcel, GPO and Hycid present marked signals 
while the others show all smooth peaks. These signals may be attributable to the 
stretching of the different C-O-C linked to the other aromatic ring. 
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Fig.3. SERS analysis of omeprazole generic medications, internal sides. Spectra have been off-set in 
order to avoid overlapping and facilitate observation. Rambaxy (black), Losec (yellow), Olsep (light 
blue), Esopral (green), Dexcel (brown). Hycid (red) and GPO (purple). At 880cm-1 peak due to ether 
groups stretching; at 1025cm-1 peaks due to the stretching of the thiocarbonyl group C=S; at 1260cm-1 
peak due to the stretching of the thiocarbonyl group; at 1480cm-1 peaks due to bending asymmetric of the 
methyl groups; at 1640cm-1 due to CN aromatic stretching.  
 
At 970cm-1 Dexcel and Hycid present sharp peaks while Olsep at the same wavenumber 
shown a smaller peak, possibly related to the stretching of the C-C. At 1000cm-1 all 
formulations present a small peak followed by another at 1025cm-1, which may be 
referred to the stretching of the thiocarbonyl group C=S. The stretching signals from the 
two aromatic rings are accounted for by the peaks in the region around 1100cm-1. At 
1160cm-1 all formulations present a broad signal that could be related to the asymmetric 
stretching of the ether group, C-O-C. The C=S stretching is demonstrated at 1260cm-1 
with peaks for all the formulations with the exclusion of GPO and Hycid. At 1280cm-1 
all formulations produce a signal even if with different intensity, possible to relate to the 
CC stretching of the aromatic chains. At 1395cm-1 it was noticed the presence of peaks 
for all formulations, with exclusion of Losec, due to bending symmetric of the methyl 
1260cm-
1 
880cm-1 
1640cm-1 
1025cm-1 
1480cm-1 
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groups. At 1480cm-1 all samples present sharp peaks, due to bending asymmetric of the 
methyl groups. At 1530cm-1 peak for Dexcel, Olsep, Hycid, GPO; at 1610cm-1 peak for 
Hycid, Olsep, GPO, Dexcel, with Losec presenting two peaks at 1590 and 1610cm-1 
possibly to be referred to the stretching of the aromatic rings. At 1640cm-1 all 
formulations produce signals with different intensity, due to stretching of CN in the 
aromatic rings. 
The conventional Raman spectrograms of the analyses of the surfaces of the 
omeprazole tablets under investigation are reported in Fig.4. As for the analyses of the 
internal sides shown earlier in SERS investigation, the spectra obtained from the surface 
analyses show common tracts and dissimilarities within the different tablets of 
omeprazole studied. 
 
 
 
 
 
 
 
 
 
CHAPTER 6                                                                                                                                 Omeprazole 
 
 178 
 
 
Fig.4. Raman analysis of omeprazole generic medications, external sides. Spectra have been off-set in 
order to avoid overlapping and facilitate observation. Rambaxy (black), Losec (yellow), Olsep (light 
blue), Esopral (green), Dexcel (brown). Hycid (red) and GPO (purple). At 1130cm-1 peaks due to the 
asymmetric stretching of C-O-C in the benzimidazole and in the pyridinylic rings; at 1300cm-1 symmetric 
stretching of the aromatic ring chain vibrations; at 1380cm-1 peaks due to symmetric bending of the 
methyl groups; at 1460cm-1 peaks due to the asymmetric bending of the CH3. 
 
At 840 and 890cm-1 sharp peaks are noticeable for Losec, and less prominent for the 
others, possibly due to the stretching of C-O-C in both the pyridinylic and 
benzimidazole rings. At 950cm-1 a sharp peak for Losec and a broad one for Dexcel 
tablets are noticeable, possibly due to the stretching of the C-C. The stretching of CS is 
accounted for by the peak at 1025cm-1 in Losec’s spectrum. At 1065cm-1 Esopral and 
Olsep present sharp peaks possibly due to the symmetric stretching of the aromatic 
rings. At 1130cm-1 sharp peaks for Esopral, Olsep, and Losec possibly to be attributable 
to the asymmetric stretching of C-O-C in the benzimidazole and in the pyridinylic rings. 
At 1175cm-1 a small peak might be assigned to the stretching of CS. At 1245cm-1 small 
peak for Losec and at 1300cm-1 shifted peaks for all formulations, sharp for Esopral, 
possibly related to symmetric stretching of the aromatic ring chain vibrations. The 
symmetric bending of the methyl groups is demonstrated at 1380cm-1 with a sharp peak 
for Losec and medium for Esopral, Olsep. At 1430cm-1 small peak for Losec, and sharp 
for Olsep, Esop, possibly due to symmetric bending of CH3. At 1450-1470cm-1 sharp 
1130cm-1 
1300cm-1 
1380cm-1 
1460cm-1 
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peak for Esopral, Olsep. Losec presents a sharp peak slightly shifted at 1460cm-1, 
possibly related to the asymmetric bending of the CH3. 
The Raman spectra of the analysis of the internal side of the tablets are reported 
in Fig.5. The spectra show the similarities and differences amongst the different 
formulations of omeprazole under investigation. Structure specific peaks are clearly 
observed in the spectra obtained for each omeprazole formulation. 
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Fig.5. Raman analysis of omeprazole generic medications, internal sides. Spectra have been off-set in 
order to avoid overlapping and facilitate observation. Rambaxy (black), Losec (yellow), Olsep (light 
blue), Esopral (green), Dexcel (brown). Hycid (red) and GPO (purple). At 880cm-1 peak due to the 
symmetric stretching of C-O-C of the ether groups in the aromatic chains; at 1090cm-1of the stretching of 
C=S of the sulphur conjugated to the benzimidazole ring; at 1240cm-1 peak due to the stretching of the 
aromatic ring chains; at 1630cm-1 peak due to the stretching of CN in the benzimidazole 
 
Starting at the spectral region around 800cm-1, Dexcel presents a strong peak at 850cm-1 
and a second one at 880cm-1. These peaks may be attributed to the symmetric stretching 
of C-O-C of the ether groups in the aromatic chains [18]. At 880cm-1, Hycid presents a 
small peak possibly due to the same previous group but shifted. In this interval, the 
other formulations present minor peaks at around 850cm-1 which correlates possibly to 
the stretching of O-O from the lactose used as excipient. At 920 and 965cm-1, two 
strong peaks for Dexcel are shown, possibly due to C-O-C asymmetric stretching 
shifted at different value than GPO and Hycid. The other formulations present a broad 
peak at 990cm-1 possibly related to the C-C stretching. At 1020cm-1 all present a peak, 
more remarkable for Dexcel and less for Rambaxy. The stretching C-C of the aromatic 
rings is demonstrated at at 1060cm-1. In this area of the spectra, Dexcel presents a sharp 
peak, while all the other formulations only a minor one. At 1090cm-1 Dexcel presents a 
880cm-1 
1090cm-1 
1240cm-1 1630cm-1 
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peak, the others show similar peak at higher wavenumbers, with the exclusion of 
Rambaxy, as a result of the stretching of C=S of the sulphur conjugated to the 
benzimidazole ring. At 1125cm-1 all present substantial peaks, with the exclusion of 
Rambaxy and weak peak for Dexcel, possibly related to the asymmetric stretching of 
the ether groups present in the pyridinylic ring. At 1150cm-1 Dexcel present a weak 
peak that may be referred to the previous group shifted at higher wavenumbers. At 
1155cm-1 all formulations, with the exclusion of Rambaxy and Dexcel, produced a 
peak, possibly due to the asymmetric stretching of C-O-C in both the aromatic rings of 
the omeprazole molecule. At 1190cm-1 it was present a strong peak for Dexcel, small 
for GPO, Hycid, Olsep, Esopral, absent for Rambaxy and Losec, possibly to be assigned 
to the stretching of the CS. At 1240cm-1 a peak present for all, with the exclusion of 
Rambaxy, due possibly to the stretching of the aromatic ring chains. At 1270cm-1 
Dexcel presents a sharp peak, possibly due to a shifted signal from the aromatic rings. 
At 1365cm-1 and 1380cm-1 peaks possibly due to the symmetric bending of methyl 
groups, while the asymmetric bending of the same groups laid in the region between 
1440 and 1500cm-1. The CN in the pyridinylic ring is accounted for by stretching peaks 
at 1530 and 1600cm-1. At 1630cm-1 a peak probably due to the stretching of CN in the 
benzimidazole ring [18] can be also observed. This has been selected in some studies as 
a reference peak for validation models based on the consideration that excipients 
generally do not interfere in this region of the spectrum not containing functional groups 
that emit at these wavenumbers [19]. 
To aid the interpretation of the vast amount of wavenumbers generated by the 
spectroscopic techniques, both SERS and conventional Raman, PCA was used. PCA of 
the SERS data obtained by analysis of the external side of the omeprazole tablets shows 
a partial identifiable distribution profiles for some of the classes of samples investigated 
(Fig.6).  
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Fig.6. Principal Component Analysis of the results obtained by SERS analysis of the external side of 
omeprazole samples. PCA1=93.22%, PCA2=98.53%. From top to bottom, the circled clusters identify 
Losec, Rambaxy and Esopral. 
 
Principal component (PC) 1 accounted for 93.22% of variation, with PC2 and PC3 
being responsible for 5.31% and 0.65% respectively. PC1 and PC2 were therefore 
responsible for an accumulative 98.53% of the variation. The omeprazole generic 
medications were separated due to their individual association with the two main 
components.  
Losec, Rambaxy and Esopral can be seen to partially separate over the value of PC2. 
Esopral is sparse at lower PC2 value, Rambaxy is located at a central PC2 value whilst 
Losec clusters at higher value of PC2. The cloud of data incorporating the overlap of 
other classes of samples is located in positive areas for both components. Predictive 
accuracy of the PCA model obtained was validated via cross validation and leave-one-
out approach (Tab.1 and 2, respectively). 
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Table.1. Cross validation of the PCA from Fig.6 on SERS spectroscopy obtained from the surface 
analyses of the omeprazole generic medications. 
Error rate 0.7786 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  ESOP RAM LOS DEX HYC OLZ GPO Sum 
ESOP 0.4872 0.6667 ESOP 19 4 16 0 0 0 0 40 
RAM 0.3415 0.7667 RAM 18 14 3 6 0 0 0 40 
LOS 0.275 0.8778 LOS 20 5 11 2 0 0 2 40 
DEX 0.375 0.6512 DEX 0 11 13 15 0 1 0 40 
HYC 0 1 HYC 0 5 13 3 0 4 16 40 
OLZ 0.025 0.875 OLZ 0 5 22 10 0 1 2 40 
GPO 0.0513 0.9091 GPO 0 16 12 7 0 2 2 40 
!! Sum 57 60 90 43 0 8 22 280 
 
The total error rate of the predictive model evaluated via cross validation accounted for 
78%. GPO and Hycid presented the higher error rate, while the Dexcel showed the 
lowest error, but still high with a value prediction of 65%. From the confusion matrix, it 
is possible to notice that out of 40 specimens per each class of samples analysed, 
Esopral gave the best classification, with 19 samples correctly classified, corresponding 
to 47.5% of the total. 
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Table.2. Leave-one-out of the PCA from Fig.6 on SERS spectroscopy obtained from the surface analyses 
of the omeprazole generic medications. 
Error rate 0.7987 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  ESOP RAM LOS DEX HYC OLZ GPO Sum 
ESOP 0.3872 0.6922 ESOP 18 3 16 2 1 0 0 40 
RAM 0.3815 0.7896 RAM 16 15 1 7 0 0 1 40 
LOS 0.275 0.8898 LOS 19 4 10 2 0 3 2 40 
DEX 0.475 0.6120 DEX 1 10 12 15 1 1 0 40 
HYC 0.05 0.9601 HYC 1 4 14 4 1 4 12 40 
OLZ 0.075 0.8965 OLZ 2 5 21 9 0 2 1 40 
GPO 0.0613 0.9385 GPO 2 14 11 8 1 2 2 40 
!! Sum 59 55 85 47 4 12 18 280 
 
Furthermore, the predictive accuracy of the model was also tested via leave-one-out 
validation. The cumulative error rate accounted for around 80%, with worse results in 
terms of predictions than the ones obtained from the cross validation. From the 
confusion matrix, it is also possible to observe that the correct classification for all the 
specimens analysed was quite low.  
PCA of the SERS data obtained by analysis of the internal side of the 
omeprazole tablets shows a not clear distribution profiles for the classes of samples 
studied (Fig.7).  
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Fig.7. Principal Component Analysis of the results obtained by SERS analysis of the internal side of 
omeprazole samples. PCA1=95.83%, PCA2=99.59%.  
 
Principal component (PC)1 accounted for 95.83% of variation, with PC2 and PC3 being 
responsible for 3.76% and 0.45% respectively. PC1 and PC2 were therefore responsible 
for an accumulative 99.59% of the variation. Only Dexcel samples resulted to cluster 
together in a sparse group but well separated over the values of PC2, in negative field, 
from the rest, all gathered together. 
Predictive accuracy of the PCA model obtained was validated via cross validation and 
leave-one-out approach (Tab.3 and 4, respectively). 
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Table.3. Cross validation of the PCA from Fig.7 on SERS spectroscopy obtained from the internal 
analyses of the omeprazole generic medications. 
Error rate 0.6977 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  ESOP RAM LOS DEX HYC OLZ GPO Sum 
ESOP 0.4872 0.6167 ESOP 20 3 15 1 0 0 1 40 
RAM 0.3415 0.6667 RAM 19 13 2 5 0 0 1 40 
LOS 0.275 0.8078 LOS 21 4 12 2 0 0 1 40 
DEX 0.375 0.5912 DEX 1 10 11 16 1 1 0 40 
HYC 0 0.94 HYC 1 4 12 2 2 3 16 40 
OLZ 0.025 0.884 OLZ 2 4 18 10 1 3 2 40 
GPO 0.0513 0.8933 GPO 2 13 13 6 1 2 3 40 
!! Sum 66 51 83 42 5 9 24 280 
 
The total error rate of the predictive model evaluated via cross validation accounted for 
70%. The set of error rates was comparable with the ones originated from cross 
validation, with Hycid and GPO at the higher error rate, and Dexcel with the lowest 
error. From the confusion matrix, it is possible to notice that out of 40 specimens per 
each class of samples analysed, Esopral gave again the better classification. 
Leave-one-out validation on this set of data reported a cumulative error rate 
accounted for 75%, with results comparable with the ones obtained from the cross 
validation. From the confusion matrix, it is also possible to observe the same trend in 
the classification.  
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Table.4. Leave-one-out of the PCA from Fig.7 on SERS spectroscopy obtained from the internal analyses 
of the omeprazole generic medications. 
Error rate 0.7522 
Values prediction Confusion matrix 
Value Recall 
1-
Precision 
  ESOP RAM LOS DEX HYC OLZ GPO Sum 
ESOP 0.45133 0.6654 ESOP 18 5 14 1 1 1 0 40 
RAM 0.3674 0.6874 RAM 18 11 2 5 3 1 0 40 
LOS 0.376 0.7988 LOS 18 7 10 2 2 0 1 40 
DEX 0.381 0.6123 DEX 0 11 11 14 1 1 2 40 
HYC 0 0.9103 HYC 2 3 10 2 2 3 18 40 
OLZ 0.035 0.9041 OLZ 4 4 16 8 1 3 4 40 
GPO 0.0663 0.8103 GPO 4 11 14 6 0 3 2 40 
!! Sum 64 52 77 38 10 12 27 280 
 
Chemometric assessments were performed on the all remainder set of experiments, both 
with Raman and by FT-IR, showing very similar results in terms of PCAs and 
correlated model validations. 
Factor loading was also utilised, and each wavenumber gave factor values of 
0.75 or above, with most giving value superseding 0.90. This suggests that each 
wavenumber, and therefore each PC, was accountable for the majority of variability in 
the data demonstrating a very similar representation to that of the PCA. In order to to 
identify significant wavenumbers that could be employed for distinct characterisation 
between the omeprazole generic medications, the factor loadings were plotted against 
the correspondent wavenumbers (Fig.8-10).  
All the wavenumbers resulted to be clustered together for all the classes of 
samples with few exceptions. In the SERS analyses of the external sides of the sample 
(Fig.8), two main significant peaks identify sources of potential separation power. 
Losec and Rambaxy present a peak at 1500cm-1; Rambaxy showed a peak at 1700cm-1.  
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Fig.8. Factor Loadings of the omeprazole generic medications versus attributed wavenumbers in SERS 
analysis of external area of omeprazole generic medications. From top to bottom, Esopral (blue), Hycid 
(red), GPO (blue), Rambaxy (dark brown), Olzep (brown), Dexcel (purple), Losec (green). 
 
 
 
 
Fig.9. Factor Loadings of the omeprazole generic medications versus attributed wavenumbers in SERS 
analysis of internal areas of omeprazole generic medications. From top to bottom, Esopral (light blue), 
Hycid (red), GPO (blue), Rambaxy (dark brown), Olzep (brown), Dexcel (yellow), Losec (green). 
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In the SERS analyses of the internal sides of the sample (Fig.9), Hycid and GPO 
showed more characteristic spectra, with peaks at 1080, 1150, 1480, 1650cm-1; Dexcel 
showed also characteristic peaks at 1220, 1290 and 1480cm-1 which could be used to 
separate them from the other omeprazole generic medications. 
 
 
Fig.10. Factor Loadings of the omeprazole generic medications versus attributed wavenumbers in Raman 
analysis of external areas of omeprazole generic medications. From top to bottom, Esopral (blue), Hycid 
(red), GPO (blue), Rambaxy (dark brown), Olzep (brown), Dexcel (purple), Losec (green) 
 
In the conventional Raman analyses of the surface sides of the samples (Fig.10), 
Esopral presented two peaks at 1090 and 1110cm-1. 
The other Raman analysis did not produce relevant representation with the majority of 
the wavenumbers all gathered close to Factor Loading 1. 
 
 
6.3.2. FT-IR spectroscopy of omeprazole generic medications  
The FT-IR spectra of the seven omeprazole generic medications salts have been 
overlaid in Fig.11. for the analysis of the external part of the samples and Fig.12 for the 
analysis of the internal sides. Both sides resulted to provide very similar spectra. 
Starting at 3500cm-1, broad peaks are observed for all seven omeprazole generic 
medications as a result of the hydroxyl O-H stretching from the excipients that overlap 
with the asymmetric stretching of N-H groups at 3300cm-1. 
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Fig.11. FT-IR analysis of omeprazole generic medications, external sides. Spectra have been off-set in 
order to avoid overlapping and facilitate observation. Rambaxy (black), Losec (yellow), Olsep (light 
blue), Esopral (green), Dexcel (brown). Hycid (red) and GPO (purple). Peak at 2900cm-1 could be 
accounted for by asymmetric C-H stretching; at 2850cm-1 peak due to the symmetric C-H stretching; at 
1650cm-1 small but sharp peaks are recognised as a C=C aromatic stretching; at 1590cm-1 peak due to CN 
stretching; at 1075cm-1 peak due to the CS stretching 
 
Between 2900 and 2850cm-1 a sharp dual set of peaks are seen for all the 
samples. The first at 2900cm-1 could be accounted for by asymmetric C-H stretching 
and the latter at 2850cm-1 by symmetric C-H stretching. Within the recognised 
‘fingerprint region’ of the spectra, at 1650cm-1 small but sharp peaks are recognised as a 
C=C aromatic stretching and at 1590cm-1 as a CN stretching. The sharp peaks at 
1075cm-1 are related to the CS stretching of the thiocarbonyl group. 
 
 
 
 
 
2900-2850cm-1 
1590cm-1 
1075cm-1 
1650cm-1 
CHAPTER 6                                                                                                                                 Omeprazole 
 
 191 
 
 
Fig.12. FT-IR analysis of omeprazole generic medications, internal sides. Spectra have been off-set in 
order to avoid overlapping and facilitate observation. Rambaxy (black), Losec (yellow), Olsep (light 
blue), Esopral (green), Dexcel (brown). Hycid (red) and GPO (purple). Peak at 2900cm-1 could be 
accounted for by asymmetric C-H stretching; at 2850cm-1 peak due to the symmetric C-H stretching; at 
1650cm-1 small but sharp peaks are recognised as a C=C aromatic stretching at 1590cm-1 peak due to CN 
stretching; at 1075cm-1 peak due to the CS stretching 
 
 
6.3.3. 1H-NMR of omeprazole generic medications  
In light of the similarity of the Raman and FT-IR spectra obtained which did not make 
possible to analytically discriminate amongst the seven different classes of samples, in 
order to gather additional information on the chemical structures of the samples the use 
of proton NMR was considered to elucidate more chemical diversities. 
In its molecular structure, omeprazole presents two sources of structural differentiation 
when performing proton NMR. Firstly, omeprazole is a chiral molecule since it has a 
diastereogenic center located on the thiocarbonyl sulfur atom. The second source of 
diversity is that it presents tautomerisms. 
 
 
2900-2850cm-1 1590cm-1 
1075cm-1 
1650cm-1 
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Fig.13. Omeprazole, molecular structure nomenclature used for peak assignment . 
 
In the assignment of the NMR peaks it is important to follow clear conventions on the 
numbering system adopted to identify the location of the protons in the carbon 
backbone of the chemical structure. According to IUPAC nomenclature [20], for 
omeprazole, numbering starts from nitrogen atom of the NH in the benzimidazole 
moiety, however for instrument requirement the numbering adopted is as shown in 
Fig.13 and in Fig.14 is shown the NMR spectrum obtained from Olzep analysis, used to 
start the peak assignment.  Proton nuclear magnetic resonance of the whole seven 
different omeprazole generic medications analysed is reported in Fig.15. 
While spectroscopy gives information on the functional groups present in the 
compound, to go into the structure of the compounds NMR has been performed. 
Omeprazole molecule present two different aromatic moiety, benzimidazole and 
pyridinylic moieties. 
 
 
1 4 
3 7 
2 
5 
8 
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Fig.14. 1H NMR of omeprazole OLZEP used to represent in details the peaks assignment (500 MHz, 
MeOD, 298K).  
 
The NMR spectra for the specimens analysed (analyses kindly performed by Dr Steven 
Prior, University of Lincoln) resulted to be as expected similar but with few elements of 
differentiation. As reported by Claramunt et al in an assessment study conducted 
omeprazole standard, the peak at 8.2ppm (Fig.14) is related to the proton in position 7 
in the pyridinylic moiety (Fig.13). This peak is present in all the seven different classes 
of samples. 
Hycid and GPO showed two singlets at 7.6 and 7.7ppm, respectively, close to a doublet 
at 7.5ppm. While the doublet at 7.5ppm, present in each analyte’s spectrum, is probably 
to assign to the protons in position 3 and 4, as reported by Claramunt et al, in the two 
aromatic moieties of the omeprazole molecule linked  together, the two separate singlets 
are indicative of additional aromatic molecules present as impurities. The region 
between 6.5 and 4.75ppm is where the strongly de-shielded methyl/ methylene protons 
directly attached on the pyridinylic moieties could be found. The peaks located in the 
area of 5ppm are related to the hydroxyl groups present in the excipients, mainly 
7 
2 
4 
3 
5 
1 and 9 
6 and 8 
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lactose, cellulose and starch for all the formulations studied (see chart of excipient 
reported in chapter 2.). 
 
Fig.15. Nuclear Magnetic Resonance of the omeprazole generic medications. From top to bottom: 
Dexcel, Esopral, Rambaxy, Losec, Olzep, GPO, Hycid.. A: At 7.6 and 7.7ppm, Hycid and GPO present 
two singlets associated to aromatic compounds different than omeprazole structure; B: lactose; C: 
cellulose; D: aliphatic compound; 
 
NMR analyses of the seven classes of omeprazole investigated present some remarkable 
differentiation (Fig.15). Olzep and Losec showed same formulation, with slightly 
different ratios. GPO and Hycid resulted to be identical in every way. GPO, Hycid, 
Olzep and Losec resulted to be very similar, with similar amount of both lactose and 
cellulose, however GPO and Hycid contain an extra aromatic compound, as indicated 
by the arrow A in Fig.15. Dexcel seemed to be the only one not containing cellulose, 
lacking the peaks indicated by arrow C in Fig.15. Rambaxy and Esopral, both isomers, 
contained the same chemicals, however Esopral contained significantly less API in the 
formulation. Both presented presence of lactose and cellulose. Esopral and Rambaxy 
contain another aliphatic compound, indicated with arrow D, with respect the other 
classes of samples. Hycid and GPO spectra presented elements of differentiation above 
7ppm. At 7.6 and 7.7ppm, Hycid and GPO present two singlets associated to aromatic 
compounds different than omeprazole structure. 
Dexcel 
Esopral 
Rambaxy 
Losec 
Olzep 
GPO 
Hycid 
A 
A 
B 
D 
D 
C 
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6.3.3.1. Hycid and GPO, internet samples 
Two singlets have been identified in the spectra obtained from Hycid and GPO not 
found in the other spectra that can be related to additional aromatic substances not 
present in the other formulations. It could be speculated that these two aromatic 
compounds could be the two separated moieties, benzimidazole and pyridinylic 
moieties, of the omeprazole molecule that for unknown reason split or never linked 
together during the synthetic process. Another logical cause of the presence of these 
impurities is that they originated as contamination from the specific manufacturing 
process that Hycid and GPO have gone through.  Notwithstanding the possible causes 
that have produced the two aromatic impurities, their presence in the composition of the 
final pharmaceutical products, ready to be used by patients, raises suspects on the 
quality of the medications themselves.  These two set of samples have been both 
purchased off internet market from un-official websites, not regulated by any 
government authorization for the dispensing of medications. The origin of both websites 
where Hycid and GPO were purchased from are Asian regions. In this geographic area,  
between 1999 and 2004, the ratio of fraudulent medications boosted drastically, with an 
increased of forged medications sales range from 10% to more than 30% of the national 
legal market. Because of the anonymous nature of the online market, the risks of entry 
into the market of medications of uncertain quality is remarkably high, being the quality 
control performed by the government authorities significantly more difficult and 
consequently less effective. 
The manufacturing production of medicines is extremely articulated but it can be 
divided into two principal stages: the primary manufacturing stage, where the active 
pharmaceutical ingredient (API) is manufactured, and the secondary manufacturing 
stage, where the API is mixed with other ingredients to prepare the final pharmaceutic 
formulation. Hycid and GPO impurities could have derived from one or both of these 
stages. 
During the very last World Health Assembly, it was agreed to embrace the definition of 
‘Substandard and Falsified medical products’ as official term to be used by the member 
states with a most recent change in terminology introducing the the classification of 
‘substandard’ and ‘falsified’. The first, defines those official medical products that lack 
of reaching the required standards of quality and/or to meet the necessary specifications. 
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Falsified identifies those medical products that intentionally give false information on 
their nature, origin and structure. It is not clear at this stage of research if Hycid and 
GPO could be classified as substandard or, worse, as falsified, but it seems probable that 
the lack of quality control that has allowed to input into the market these medicinal, 
containing aromatic products, and as such usually biochemically active, suggests to 
address these products with caution. 
 
 
6.4. Discussion 
The analysis of the seven different omeprazole generic medications does not give 
significantly distinctive spectra when studied via conventional Raman spectroscopy and 
FT-IR, both internally and externally. Using SERS, however, it was possible to observe 
an improvement in the characterisation of the spectra, because of the nucleophilic nature 
of the omeprazole’s chemical structure, especially on the analyses of the surfaces of the 
specimens. Although an omeprazole standard was not used in this study, previously 
published spectra compared to those obtained in this investigation shown that there are 
differences that can be accredited to the excipients added to the formulations [23, 24]. 
All the spectroscopic analyses obtained from the internal and external parts of the 
samples were quite alike although some differences in quality and resolution could be 
noticed, due to a possible coating effect on the tablets. Previous spectroscopic studies 
reported that the concentration of active ingredient in solid formulations resulted to be 
non-homogeneously spread across from external to internal areas. [25, 26]. SERS 
analyses of the internal side seem to show the same peaks but more pronounced than the 
external area. This could be related to the manufacturing processing, effectively giving a 
higher concentration at the internal area compared to that of the surfaces. 
The spectra obtained from all the spectroscopic investigations did not produce a neat 
visual differentiation amongst the seven classes of samples investigated. It could be 
speculative to suggest that solid formulations often contain very low doses of API in 
comparison with the dosage of excipients used, which can present analytical challenges 
in terms of differentiation [26]. The weights of the tablets for all the different 
formulations were ranging between 399 and 410mg, leading to a ratio API/excipients of 
only 0.05. The limited differentiation in the results obtained from the spectroscopic 
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analyses was taken into consideration as a possible result obtained, because of the 
similar nature of the samples investigated. 
Cellulose, lactose and starch are the main excipients used in all of the formulation 
studied and all present a high ratio of hydroxyl groups, which in the FT-IR analyses 
could have been masked with their broad peaks components of the omeprazole 
molecules, as reported in the chart of excipients in chapter 2. This is substantiated by 
the asymmetric stretching C-O-C and C-OH peaks found in the region around 1100cm-1 
from the sugar rings of the excipients [27, 28]. Notwithstanding the great resemblances 
amongst the spectra of the seven different classes of analytes, the statistical analysis of 
these spectroscopic data allowed the minor differences to be significative, even though 
only very few differences could be effectively being exploited. There were limited 
regions of the spectra obtained that could be associated with the individual omeprazole 
core structure. This could be because both the core of the molecules for all the classes of 
omeprazole is the same and that the excipients employed in the manufacturing of the 
solid formulations, covering any of the more noticeable differences, are indeed the same 
or belonging to sugar classes with same functional groups. 
The principal component analyses used within the Tanagra software generated 
score plots which meant to give visual clustering of the different omeprazole generic 
medicines but indeed only few separations could be observed. Throughout PCA 
analysis of all spectroscopic investigations, the omeprazole generic medications did not 
separate and clustered tightly, but they were rather spread in the same areas, 
overlapping. Only in the PCA algorithm obtained from the SERS analysis of the 
external areas, Losec, Rambaxy and Esopral showed to be clustered in separated groups, 
even if not tightly, presenting then the best separation power. This consideration is in 
line with previous articles that reported how the enhanced sensitivity of SERS over 
conventional Raman leads to an improved selectivity which would allow for better 
discriminatory abilities [29, 30]. The PCA results obtained ranged around 98-99% of 
variability for all the categories of set of experiments performed. 
In this case, cross validation and leave-one-out used to validate the accuracy of 
the predictive models gave non-positive outcomes, with a considerable amount of error. 
The total error rates for all the PCAs executed were well over 75%, both from cross 
validation and from leave-one-out evaluation, showing that the multivariate analysis in 
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this study did not presented good discrimination power. There was no strong 
spectroscopic evidence in the factor loadings for omeprazole generic medications. This 
is not unexpected given spectral interferences from the excess bulk agents present in the 
formulation already mentioned. These results substantiate the fact that the classes of 
omeprazole studied are extremely similar. 
Because of the need of additional information on the chemical structures of these 
samples to be able to discriminate differences amongst them, the use of NMR was 
considered to elucidate more chemical diversities. While Raman and FT-IR 
spectroscopies directly target each part of the molecular structure of a given compound 
providing information related to the functional groups present, NMR gives information 
on the chemical structure of the analyte. NMR analyses of the seven classes of 
omeprazole investigated present some remarkable point of discrimination. Olzep and 
Losec showed same formulation, with slightly different ratios. GPO, Hycid, Olzep and 
Losec resulted to be very similar, with similar amount of both lactose and cellulose. On 
the contrary, Dexcel seemed to be the only one not containing cellulose. Rambaxy and 
Esopral, both levo-isomers of omeprazole racemate, contained the same chemicals, 
however Esopral contained considerably less API in the formulation. Both presented 
presence of lactose and cellulose. Esopral and Rambaxy contain another aliphatic 
compound, not found in the other classes of samples. GPO and Hycid resulted to be 
identical in each other, however GPO and Hycid contain an extra aromatic compound. 
Two singlets were identified in their NMR spectra which could be due to aromatic 
impurities not otherwise found in the other formulations. Hycid and GPO were 
purchased from uncertified online websites, and the parcels received were both coming 
from Asian regions. Because of the nature of the impurities tracked in these two generic 
medications, it is plausible to consider them as suspicious and potentially fraudulent 
products.  
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6.5. Conclusions  
In this study it was shown that Raman and FT-IR investigations with the aid of 
chemometric methods did not provide a valid analytical tool robust enough to 
differentiate the different generic PPIs studied.  
Sixteen tablets of five different omeprazole generic medications and two different 
esomeprazole generic medications were analysed with each spectroscopic technique, 
both at their surface and after breaking, internally, in order to evaluate the possible 
coating effect influencing the response to the analytical examination. The spectroscopic 
results were then exposed to chemometric investigations. The predictive models 
produced by multivariate analysis were then submitted to validation via cross validation 
and leave-one-out processing. The validations showed that the prediction models were 
not successfully able to separate the PPIs analysed through spectroscopic investigations. 
This result could be attributed to the extreme similarity of the samples investigated in 
terms of active pharmaceutical ingredient and of excipients.  
Further investigation by proton NMR of the backbone of the molecular structure of the 
omeprazole formulation highlighted the similarity of the samples, with GPO and Hycid 
being in effect the same product, probably manufactured by the same plant and then 
commercialised under two different marketing names. Olzep and Losec resulted nearly 
identical, showing a very similar NMR spectrum, as well. 
NMR investigation allowed to notice in the internet samples GPO and Hycid the 
presence of aromatic impurities, not detected during the Raman and FT-IR analyses. 
The problem of the uncertain quality of medications purchased online has been 
previously emphasised in this study, showing how probable it could be to obtain low 
quality medications when bought from un-authorised online sources. 
 This results are particularly relevant, highlighting the fact that while 
spectroscopic techniques such as Raman and FT-IR, are typically used in standard 
quality control tests in the pharmaceutical industry, they may miss impurities in 
medications produced in different manufacturer plants under different quality regimes, 
opening the possibility to adopt NMR in the list of analytical technique that can help to 
assure the quality of medicines, tackling the problem of counterfeit and substandard 
medications.  
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7. Antiepileptic and anti-allergic medications  
 
7.1.  Carbamazepine as an anti-convulsive medication 
In the cure of epileptic conditions, as in all areas of medicine therapy, generic 
preparations usage is becoming more prominent as pressure to control drug costs 
increases. In common clinical practice, the interchangeability of proprietary and generic 
formulations is habitually assumed. However, in individual patients for medications 
with a narrow therapeutic range, switching to another formulation of an antiepileptic 
drug with different pharmacokinetics may lead to a diverse response to the treatment. 
Mayer et al reported how breakthrough seizures or toxicity may originate from 
switching from one antiepileptic to a generic equivalent version [1]. Rahman et al.  
evaluated the rate of drug adverse reports related to the antiepileptic generic 
medications usage in the period range between January 2004 and March 2015. Their 
conclusion was that proof of bioequivalence between original and generic preparations 
for the treatment of epilepsy does not imply that they are liberally interchangeable 
because of their narrow therapeutic index [2].  
 
 
Fig.1. Carbamazepine, chemical structure 
 
Nevertheless, the same authors reported that generic preparations with established 
bioequivalence to the original formulations used as reference can still be used, for 
example, at the beginning of the treatment or in not well-controlled patients with mid-
range serum concentrations. The overall conclusion of their review was that the results 
demonstrate that current regulations for bioequivalence and the range of acceptability 
for interchangeability of generic preparations of carbamazepine are problematic [3]. A 
study conducted by the School of Medicine of the University of Miami on two children 
of age six, treated with carbamazepine, reported that after a switch from Tegretol, one 
main brand for carbamazepine, to a different generic carbamazepine, the serum levels of 
the drug increased to 22% and 41% per each patient respectively. This showed how, 
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despite the two formulations had been considered bioequivalent, the pharmacokinetics 
profile was different, leading to different rate of serum concentrations. The switch 
caused to the patients the insurgence of side effects such as lethargy, ataxia, slurred 
speech, and nystagmus. When dosage was adjusted and re-established the previous 
regime, symptoms of toxicity resolved [4]. It has been reported how, because of the 
potential for breakthrough seizures and adverse reaction related to generic substitution, 
prescribers need to be more attentive in their prescription-writing practices, prescribing 
per brand and not per generic name, to preclude unwanted substitution with generic 
medications [5]. In a dissolution test run on six different generic carbamazepine 
formulations, it has been reported how the generic formulation of carbamazepine 
presented extensively differences in their dissolution rate [6]. There is significative 
concern to recommend generic switching, and if necessary it should be performed on an 
individual patient basis with tight control on efficacy and adverse event throughout the 
changeover [7, 8]. In therapy conducted with carbamazepine, the evaluation of the rate 
of absorption is essential in light of the related side effects associated with different 
concentration as much as the effects of fluctuations and the flatness of the 
carbamazepine plasma concentration curve relative to the drug efficacy and tolerability 
[9]. Because of the narrow therapeutic index and the specific literature that highlight 
how important it is for the exact brand of carbamazepine to be employed in therapy, an 
investigation of these medications including Tegretol, the main original brand, and a 
generic carbamazepine, has been performed in order to evaluate if this technique could 
be able to differentiate the two different formulations. 
 
 
7.2. Cetirizine and levocetirizine as anti-allergic medications 
Histamine is one of the principal mediators involved in the pathophysiology of allergic 
conditions, including hay fever, rhinitis, urticaria, asthma and anaphylaxis [10]. 
Histamine, released from basophils and mast cells, exerts its actions interacting with 
one of four specific receptors, defined as H1, H2, H3, H4. In allergic disease, it is the H1 
receptor which is the pharmacological target to reduce the allergic reactions, although 
H2 antihistamines may also play a therapeutic role. The main effects of the new 
generations of antihistamine are mediated via selective inhibition of peripheral H1 
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receptors, with a reduced crossing of the blood–brain barrier, thus diminishing the 
sedative side-effect common with older antihistamines. H1 antihistamines drugs remain 
first-line medications for the treatment of urticaria and allergic rhinoconjunctivitis. 
Newer generation of antihistamines, based on the use of the levorotary stereoisomers, 
rather than the whole racemic formulation, are preferred to their predecessors because 
of a better benefit-to-risk profile [10]. This second generation of antihistamines are not 
only more effective, but also present a reduced quota of undesired effects. Chang et al 
reported a clinical study conducted in South Corea where a challenge test was 
performed on side effects of different antihistamines [11]. A challenge test is a 
procedure in which patients are challenged by exposure to specified types of allergenes 
to determine whether they are reactive to them. In the study reported by Chang et al, 
urticaria resulted being induced by hydroxyzine and cetirizine (Fig.2), two first 
generation antihistamine, but not by levocetirizine, the levo stereoisomere of cetirizine.  
 
 
Fig. 2.  Cetirizine, chemical structure 
 
The challenge test conducted on levocetirizine resulted negative. Chang et al concluded 
that although the newer antihistamines are more expensive than the first generation, the 
cost is considerably offset by their higher potency and safety profile when used in 
therapeutic dosages [11]. A study conducted by Chih-Fang et al, instead, cetirizine 
seemed to show slight better results than the levo-isomeric formulation [12]. In the 
study, 74 paediatric patients affected by perennial allergic rhinitis, where split in three 
groups and treated with one of three treatment agents (cetirizine, levocetirizine and 
placebo) for twelve weeks. Nasal peak expiratory flow rate (nPEFR) and hematologic 
analysis in nasal smears were conducted and compared among the three groups. The 
results revealed that both cetirizine and levocetirizine improved the symptomatology in 
comparison with the placebo group, and cetirizine resulted to be more effective than 
levocetirizine. The eosinophil ratio in the nasal smears considerably declined among the 
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cetirizine treated group in comparison with the placebo group but there was no statistic 
significant in the levocetirizine groups [12]. Levocetirizine, which is not expose to 
racemization after administration, is quickly and extensively absorbed with a low rate of 
metabolism, resulted being a more potent antihistamine than loratadine in the treatment 
of human skin allergic reactions [13]. The levocetirizine’s pharmacokinetic main 
features appear to be superior to the racemic ones. Its apparent that volume of 
distribution is smaller than that of dextrocetirizine, and the mostly hepatic clearance of 
levocetirizine is also significantly lower than that of dextrocetirizine, suggesting that the 
racemate should be replaced by the levo-stereoisomer [14].  
In this work, cetirizine and levocetirizine, produced by the generic manufacturers 
Somex Pharma and Glenmark, respectively have been studied by Raman spectroscopy, 
in order to assess if this technique could be able to separate and differentiate the two 
different formulations. 
 
 
7.3. Materials and methods 
 
7.3.1 Materials 
-Carbamazepine, 5H-Dibenzo[b,f]azepine-5-carboxamide, was obtained from obtained 
from Novartis, as brand name Tegretol, and from GenericUK manufacturer, as a 
generic. 
–cetirizine, (2-(4-((4-Chlorophenyl) phenylmethyl)-1-piperazinyl) ethoxy) acetic acid,  
and levocetirizine, were obtained from the generic manufacturers Somex Pharma and 
Glenmark respectively. 
 
7.3.2. Methods 
Spectroscopic analysis was carried out by Raman spectroscopy, surface-enhanced 
Raman spectroscopy (SERS) and FT-IR. Raman analysis was performed on a FORAM 
685-2 instrument with a laser operating at 532nm, to ensure high levels of sensitivity. 
The Raman instrument was also equipped with an integral video microscope. Analyses 
were performed between the wavenumbers 800 and 2000cm-1.  
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A Perkin-Elmer Spectrum 100 was used for the FT-IR analysis. This was supported by 
a Motorola DSP56303 Digital Signal Processor and a near infrared detector. The FT-IR 
was equipped with a Perkin-Elmer Autoimage microscope, with a IR performance of 
9000:1 p/p signal to noise ratio and a resolution greater than 10µm. The range of 
wavenumbers investigated was between 4000 and 500cm-1. 
Sample Preparation: eight tablets were taken for Raman analysis. To test the external 
side of the tablets using Raman spectroscopy the tablets were exposed to the laser at 
five points for each tablet, to achieve 40 repeated representative analyses for each 
amlodipine salt. To test the internal side, the tablets were broken in half and again 
exposed to the laser five times for each tablet. 
SERS enhances the sensitivity of standard Raman scattering by depositing a metal 
colloid on the surface of the sample being analysed. For this part of the investigation, 
silver colloids were prepared as follows: silver nitrate was reduced using sodium citrate 
in water, and concentrated by centrifuging at 5000rpm. The eight tablets for SERS 
analysis were covered with 2µL of the prepared colloid solution and 2µL of NaCl 1M 
after analysis by normal Raman, and analysed immediately. To test the external side of 
the tablets using Raman spectroscopy the tablets were coated in the silver colloid 
preparation and exposed to the laser. This was again repeated five times for each tablet, 
with the laser directed at a variation of external sites, to achieve the 40 representative 
analyses for each amlodipine salt. To test the internal side, the tablets were broken in 
half prior to the addition of the silver colloid, and again exposed to the laser five times 
for each tablet.  
Eight tablets were also taken for FT-IR analysis. To study the external side of 
the tablets by FT-IR the samples were prepared by scratching the surface of the tablets 
onto the ATR plate with a small spatula. This was done in order to attain adequate 
contact of the sample on the ATR crystal, so a successful spectrum could be produced. 
Due to the shape of the tablets this contact would not have been achieved if the tablet 
was kept intact, and would have resulted in poor transmittance. To study the internal 
side, the tablets were ground to ensure homogenisation and subjected to the 
aforementioned procedure. Each tablet was analysed individually using a scan cycle of 
40. 
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Principal Component Analysis (PCA), Factor Loadings, Cross Validation, 
Leave-one-out  were performed using Tanagra™ data mining software (University of 
Lyon, France). Analytical data were exported from the correspondent analytical 
apparatus to an excel spreadsheet and subsequently uploaded onto Tanagra.  
 
 
7.4. Results and discussion 
 
7.4.1. Raman spectroscopy of carbamazepine  
Carbamazepine, whose IUPAC name is 5H-Dibenzo[b,f]azepine-5-carboxamide, 
presents a tricyclic aromatic molecular structure characterised by the presence of a 
carboxamide group (Fig.1). 
In this study, eight tablets of 200mg Tegretol, from Novartis, and 200mg of generic 
carbamazepine, from GenericUK, were exposed to Raman and SERS analysis, as 
showed in the previous chapters, in order to evaluate the response of these samples to 
this analytical technique. Tablets have been tested on their surface and inside, to test 
possible coating interaction with the investigation and then the spectroscopic results 
were submitted to statistical analysis. 
The spectra obtained from the traditional Raman analyses of the external and internal 
sides of the tablets of generic and branded carbamazepine are reported in Fig.3, while 
the SERS analyses are shown in Fig. 4. All the spectra resulted being not significantly 
differentiated. The analyses of the internal sides of the tablets performed by Raman 
produced identical spectra to the ones obtained from surface analyses. The same 
consideration could be express in reference to the SERS analyses. Structure specific 
peaks observed in the spectra were attributable to the molecule of carbamazepine and 
other signals related to the structure of the lactose used as a main excipient. 
Analysing the spectra, at 873cm-1 it is possible to notice signals possibly corresponding 
to the C-C stretching of lactose, used as main excipients for the manufacturing of the 
tablets. The aromatic ring chain vibrations may be demonstrated by the signals visible at 
985cm-1, while the peak at 1027 and 1043cm-1 could be assigned to the carboxamide 
symmetrical stretching. The carbonyl group is linked to two well different nitrogen 
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substitute, one being a primary amine and the other a tertiary amine, the incorporated in 
the tricyclic structure.  
 
 
Fig. 3. Baseline corrected conventinal Raman comparison generic and Tegretol. Tegretol external (light 
blue line), carbamazepine generic external (dark blue line), Tegretol internal (yellow line), carbamazepine 
generic internal (purple line). At 1123cm-1 the vibrations C-O-H bending mode of lactose. At 1165cm-1 
the NH2 twisting peak group within the carboxamide group. At 1257cm-1 peak due to the =CH symmetric 
rocketing. At 1315cm-1 peak due the CH2 in plane twist of the sugar excipient. At 1570cm-1 peak due to 
the aromatic C=C stretching of the three aromatic rings. At 1640cm-1 peak at carbonyl C=O unit 
stretching in the carboxamide group. 
 
The diversity of the two different amines can generate the production of two distinctive 
emission signals [15]. Clearly visible is the intense band 1123cm-1 which could be 
corresponding to the vibrations C-O-H bending mode of lactose.  
The NH2 group within the carboxamide group is accounted for by the NH2 twisting 
peak at 1165cm-1. The peak at 1257cm-1 could be attributable to the =CH symmetric 
rocketing. The signal at 1315cm-1 could be related to the CH2 in plane twist of the sugar 
excipient. Furthermore, at 1424cm-1 the CH2 scissoring of the lactose could be noticed. 
The signals in the region of 1570cm-1 could be referred to the aromatic C=C stretching 
of the three aromatic rings, while the peak at 1613cm-1 may be related to the scissoring 
of the primary amine. The sharp signals in the region around 1640cm-1are justified by 
the presence of carbonyl C=O unit in the carboxamide group. 
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Fig. 4. Baseline corrected SERS comparison generic and Tegretol. Tegretol external (orange line), 
carbamazepine generic external (red line), Tegretol internal (green line), carbamazepine generic internal 
(blue line)(Baseline corrected). At 1123cm-1 the vibrations C-O-H bending mode of lactose. At 1165cm-1 
the NH2 twisting peak group within the carboxamide group. At 1257cm-1 peak due to the =CH symmetric 
rocketing. At 1315cm-1 peak due the CH2 in plane twist of the sugar excipient. At 1570cm-1 peak due to 
the aromatic C=C stretching of the three aromatic rings. At 1640cm-1 peak at carbonyl C=O unit 
stretching in the carboxamide group. 
 
As seen before, to aid the interpretation of the large amount of data generated by the 
Raman and SERS spectroscopic techniques, chemometric analysis was applied.  
Chemometric measurements of the conventional Raman results, led to a 
Principal component (PC) 1 explained 94.47% of the variability, with PC2 and PC3 
being accountable for 4.2% and 0.2% respectively. Based on the The Kaiser-Guttman 
criteria, which advises to only use PCs with variation greater than 1,  PC3, being 
responsible for less than 1% of the variation was not taken into account. PC1 and PC2 
are therefore responsible for an accumulative 98.67% of the variation. Visually it was 
not possible to cluster in defined separate groups the  samples analysed. This 
observation confirms the overlapping of the spectra produced by normal Raman (Fig. 
2). The lack of visual separation in the PCA results could give some information on the 
extremely high similarity in the composition of the two different classes of samples. 
The list of excipients, reported in chapter 3., reflects this similarity of the two different 
carbamazepine, prepared with the same bulk agents.  
When the PCA model was submitted to validation, the cross validation 
generated an error rate around  86% and leave-one-out around 84% to reiterate that this 
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specific model was not producing a significant separation of the two classes of samples 
and more specific setting of the analytical approach was necessary.  
Chemometric measurements of the SERS results, led to a PC1 which explained 
95.63% of the variability, with PC2 and PC3 being accountable for 2.2% and 0.5% 
respectively. PC1 and PC2 are therefore responsible for an accumulative 97.83% of the 
variation. The PCA representation was very similar to the one obtained by conventional 
Raman and the subsequent validation gave similar error rates in terms of cross 
validation and leave-one-out, around 84% and 79%, respectively. 
 
 
7.4.2. Raman spectroscopy of cetirizine  
Conventional Raman and SERS spectroscopy of the cetirizine and levocetirizine 
samples are reported in Fig 5 and 6, respectively. The spectra obtained from the 
conventional Raman analyses of cetirizine and levocetirizine are reported in Fig. 5, 
while the correspondent SERS analyses are shown in Fig. 6. Cetirizine chemical 
structure is characterised by the presence of two phenyl rings, a piperazine ring and a 
carboxylic group (Fig.2). All the spectra resulted being not significantly differentiated 
one from each other. The analyses of the racemic cetirizine and the levo-isomer 
levocetirizine performed produced virtually identical spectra both in conventional 
Raman and in SERS. Structure specific peaks observed in the spectra were attributable 
to the molecule of cetirizine and other signals might be related to the structure the main 
excipients used in the formulation of the tablets analysed. 
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Fig. 5. Typical spectrum obtained from conventional Raman analyses of cetirizine (blue line) and 
levocetirizine (orange line)  
 
A broad peak possibly attributable to the CN stretching of the piperazine is visible at 
1050cm-1. At 1424cm-1 the CH2 scissoring of the lactose used as excipient could be 
noticed 1450cm-1. A broad peak typical of C=C stretching of the phenyl ring are evident 
at 1630cm-1. 
This results were quite unexpected, considering that from the chemical structure (Fig. 2) 
cetirizine, as racemic or isomeric, is Raman active. Nevertheless, chemometric analysis 
was applied as aid for the interpretation of such spectrograms, both for the ones 
generated by normal Raman and for the others obtained by SERS.  
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Fig. 6. Typical spectrum obtained from SERS analyses of cetirizine (grey line) and levocetirizine (orange 
line)  
 
In conventional Raman, Principal component (PC) 1 explained  96.2% of the variation, 
with PC2 and PC3 being accountable for 2.2% and 0.6% respectively. PC1 and PC2 
were consequently responsible for an accumulative 98.4% of the variability (Fig. 7). 
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Fig 7. Principal Component Analysis scatterplot of the results obtained from conventional Raman 
spectroscopic analyses performed on cetirizine (A: cetirizine external; B: cetirizine internal) and 
levocetirizine (E: levocetirizine external; F: levocetirizine internal). 
 
Visually it was possible to find clusters to separate the groups of the cetirizine samples, 
while the levocetirizine samples grouped in two overlapped clusters.. Nevertheless, 
these results were expected because of the overlapping spectra. Cross validation gave an 
error rate of around was of 88% and leave-one-out of 84%.  
The method setting for the Raman analysis needs to be improved with different data 
acquisitions by adjusting the exposure time. 
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Fig 8. Principal Component Analysis scatterplot of the results obtained from SERS spectroscopic 
analyses performed on cetirizine (C: cetirizine external; D: cetirizine internal) and levocetirizine (G: 
levocetirizine external; H: levocetirizine internal). 
 
In SERS, Principal component (PC) 1 explained  95.1% of the variation, with PC2 and 
PC3 being accountable for 1.8% and 0.5% respectively. PC1 and PC2 were 
consequently responsible for an accumulative 96.9% of the variability (Fig. 8). 
Visually, the clusters of the cetirizine samples resulted to be seprated, while the 
levocetirizine samples grouped in two overlapped clusters, similarly to the conventional 
Raman model. Validation error rates of the model were very similar to the previous one, 
with cross validation which gave an error rate of around was of 82% and leave-one-out 
of 83%.  
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7.5. Conclusions 
 
7.5.1. Raman spectroscopy of carbamazepine  
It is supposed from the results obtained by the spectroscopic analyses of samples of 
carbamazepine, that there are not enough spectral differences between the two different 
classes samples of carbamazepine generic and branded to successfully separate the two 
different formulations. Nevertheless, both normal Raman and SERS technique provided 
peaks characteristic of the carbamazepine backbone. An improvement in the 
investigation of these sample is therefore required, concentrating on the analyses of the 
correspondent excipients under the same analytical condition to be able to interpreter 
the interferences deriving from the bulk agents used in the manufacturing of the tablets. 
An improvement in the analytical setting it is also required, to  explore the possibility to 
increase the sensitivity of the method in order to detect more discriminant bands. 
Furthermore, it would be worth to consider to extend the range of generic 
carbamazepine manufactured by different companies to submit to examination in order 
to enhance the  statistical value of the investigation. 
 
7.5.2. Raman spectroscopy of cetirizine  
Cetirizine and levocetirizine did not give a strong analytical response to the Raman 
investigations. This was an unexpected outcome, considering the structure of cetirizine, 
equipped with Raman sensitive functional groups. The chemometric of the 
spectroscopic instigations gave good report, but it was not supported by the validation 
of the predictive model. This negative results needs to be explored more in depth, 
giving a good opportunity to improve the development of the analytical setting for the 
analysis of medications in tablet form. 
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8. Conclusion 
 
A significant paradigm continuously frequented in pharmacology is the confliction 
between views on generic medications. Generic substitution has become common 
practise amongst healthcare professionals since generic medications can be used 
interchangeably with the original medicines. Despite this conventional normality, there 
are concerns in the healthcare sector, as well as amid patients, that not all generic 
preparations are equally clinically effective amongst themselves and their brand 
siblings. 
Counterfeiting of medications is a serious and rapid growing danger for the patient’s 
health and the pharmaceutical industry around the globe, with medications 
counterfeiting embracing not only replicas of branded drugs but also of generic 
medications. Fraudulent medications range from products without any active 
therapeutic ingredients to those with unsafe toxicological contents. Because of the 
anonymous nature of the internet web-sites, the risks of entry into the market of 
medications of uncertain quality is remarkably high, being the quality control performed 
by the government authorities significantly more difficult and consequently less 
effective. 
The main aim of this research was to develop a non-destructive quick qualitative 
analytical methodology, a flagging system, to be able to discriminate differences in the 
chemical composition from generic medicines, that have been reported not presenting 
similar therapeutic equivalence in previous clinical comparison studies, originated from 
the same brand-name medications and also obtained from different sources, such as 
authorised pharmacies and non-authorised internet sellers. 
 
 
This work has matched the aims initially set, generating novel methods of analysis to 
investigate differences in the chemical composition within groups of generic 
medications. 
 
Digoxin, one of the main cardiac glycosides medication with narrow therapeutic 
index, has shown to have a strong analytical response under investigation by 
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voltammetric analysis. In this study we have investigated the suitability of solid 
electrodes as carbon glass, gold and silver electrodes in voltammetric analysis of this 
active pharmaceutical ingredient. The study of digoxin with Au and Ag electrodes in 
solution at different pHs, not reported to have been performed before, showed that both 
electrodes are suitable for the analytical determination of digoxin standard in solution in 
the range of concentrations from 3.92 to 14.81µg/mL, which considering that syrup of 
digoxin solution used in therapy are typically of a concentration of 50 µg/mL, resulted 
to be in the normal therapeutic regime. Micromole sensitivity has been achieved for 
gold and silver electrodes, showing that the use of these sensors could represent a 
preliminary analytical approach when the more accurate alternative choice is not 
necessary, being more practical and less environmental impacting than using mercury.  
 
In the study of amlodipine, Raman spectroscopy and FT-IR have produced 
evidences to produce enough spectral differences, when coupled with chemometric 
methods, to successfully separate generics. The proposed method gives a level of 
sensitivity and selectivity never before achieved with alternative techniques, as well as 
being fast and requiring minimal sample preparation. This study presents a method that 
could have large applications in the pharmaceutical industry, distinguishing between 
three salt forms of a pharmacologically active compound, for which some argue can 
produce unrequited side effects. This is the first report to successfully identify and 
characterise amlodipine besylate, maleate and mesylate by Raman, SERS and FT-IR 
spectroscopy. 
 
In the PPIs study it was shown that Raman and FT-IR investigations with the aid 
of chemometric methods did not provide an immediate valid analytical tool, robust 
enough to differentiate the different generic PPIs studied. The validations showed that 
the prediction models were not successfully able to successfully separate the PPIs 
analysed through spectroscopic investigations. These results could be attributed to the 
strong similarity of the samples investigated in terms of active pharmaceutical 
ingredient and of excipients showing that neither Raman nor FT-IR were analytically 
powerful enough to discriminate the subtle differences in the samples. Investigation by 
1H NMR of the backbone of the molecular structure of the omeprazole formulations 
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proved to be a valid and technique to utilise when the results from the Raman and FT-
IR resulted not be adequate. By the use of 1H NMR it was possible to discover that the 
samples obtained from unauthorised websites, showed aromatic impurities, not detected 
during the Raman and FT-IR analyses. These aromatic impurities were not found in the 
other omeprazole generic medications, obtained from authorised pharmacies. These 
results led to the consideration that while spectroscopic techniques such as Raman and 
FT-IR, are typically used in standard quality control tests in the pharmaceutical 
industry, they may miss impurities in medications produced in different manufacturer 
plants under different quality regimes.  
 
This study has led to the creation and interpretation of novel knowledge, through 
a systematic acquisition and understanding of a substantial body of knowledge and 
through original research, and adjusting the project design in the light of unforeseen 
problems, conceptualizing, designing and implementing the research project for the 
generation of new knowledge. 
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9. Future work 
 
Using the analytical approaches optimized, plan for future work will include: 
1.! Medications will be acquired through different internet websites and analysed in 
order to investigate on their authenticity. Internet pharmacy market is an up-
coming concern for UK official authority. The Medicine and Health care 
products Regulatory Agency is strongly campaigning to raise attention on the 
risk of an unregulated pharmaceutical market. Recently worldwide, countries 
have granted permission to e-pharmacies to legitimate dispense medications 
through the internet market. Most of the e-pharmacies have passed all the strict 
regulations applied and have started to offer their service on-line, allowing 
patient to benefit of the convenience to buy online medications. Unfortunately, 
aside the legally recognised e-pharmacies, on the web operate unscrupulous 
online pharmacies that represent a major concern to the sector. 
 
2.! Use of Raman and FT-IR to possibly investigate on cardiac glycosides to 
differentiate generic and branded medications. At the present time, no study of 
this matter has been developed yet.  
 
3.! A structural comparison study of the three different salts of amlodipine currently 
used in cardio-vascular clinic, extended to more amlodipine generic medicines 
procured online from un-official websites in order to investigate the issue of 
fraudulent medications commercialised on line. 
 
4.! A study of omeprazole, esomeprazole generic medications characterized by 
Raman and FT-IR, and NMR showing how these two medications can be 
investigated with these three techniques, not mentioned in literature, so far. The 
study will be extended to more omeprazole generic medications procured online 
from un-official websites.  
 
5.! Clinical studies on anticonvulsants generic medications have reported having 
shown different therapeutic performances. Generic carbamazepine and Tegretol 
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as anticonvulsant will be analysed using the set of analytical methods shown 
before, extended to medications purchased from internet. 
 
6. Extended the analysis of the aforementioned medications to other analytical 
techniques as X-Ray Fluorescence (XRF) and X-Ray Diffraction (XRD) 
spectroscopies in order to expand the characterization of these medications with 
the aim to find more differential elements able to discriminate genuine from 
fraudulent products. In fact, counterfeit medicines are often not only adulterated 
with organic chemical substances of different crystallographic structures but 
some samples may be contaminated by the presence of harmful mineral 
compounds. XRF and XRD spectroscopies are multi-elemental fast analytical 
methods which requires a minimal sample preparation. While XRF allows 
identification and quantitation of the inorganic compounds, X-ray diffraction has 
the ability to distinguish between various polymorphic structures both of the 
active principal ingredient and of the excipients allowing the crystalline phases 
in various pharmaceutical mixtures to be clearly resolved. 
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Glossary of terms 
 
API 
Active Pharmaceutical Ingredient, it is the molecule present in a pharmaceutical 
formulation responsible for the pharmacological activity exerted. 
 
Bioavailability 
It is the relative amount and the rate at which the API which enters into the systemic 
circulation. 
 
Bioequivalence 
Two o more pharmaceutical products are deemed to be bioequivalent when, administered 
at same molar dosage, their rate and extent of absorption lay within predetermined limits 
from those of the reference product. 
 
Clinical Trial 
Organised study of pharmaceutical products in human subjects with the object of acquire 
clinical information on the clinical, pharmacodynamic, pharmacokinetic, toxicological 
features, with the aim of determining their efficacy and safety. 
 
Cmax 
This is the maximum drug concentration achieved in systemic circulation following drug 
administration. 
 
Cmin 
This is the minimum drug concentration achieved in systemic circulation following 
multiple dosing at steady state. 
 
GERD 
Gastro-Esophageal Reflux Disease 
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Good Clinical Practices (GCP) Guidelines 
Good clinical practices guidelines issued by national health authorities.  
 
Narrow Therapeutic Index The therapeutic index (TI) is the range of doses at which a 
medication is effective without unacceptable adverse events. Drugs with a narrow TI 
(NTIDs) have a narrow window between their effective doses and those at which they 
produce adverse toxic effects (e.g. digoxin) 
 
Pharmaceutical Alternatives 
Pharmaceutical alternatives are drug products that contain the identical therapeutic 
moiety but not necessarily in the same amount. 
 
Pharmaceutical Equivalents 
Pharmaceutical equivalents are drug products that contain identical amount of identical 
active drug ingredient in identical dosage forms, but not necessarily containing the same 
inactive ingredients. 
 
Pharmacodynamic Evaluation 
Pharmaceutical evaluation is a measurement of the effect on patho! physiological process 
as a function of time, after administration of two different products to serve as a basis for 
bioequivalence assessment. 
 
Pharmacokinetics 
It refers to the absorption, distribution, metabolism and excretion the drug in the body. 
 
PPIs 
Proton Pump Inhibitors  
 
Reference Product 
It refers to the pharmaceutical product which is licensed by the relevant authorities as a 
reference for comparing with the generic product in bio-equivalence studies. 
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SERS 
Surface-enhanced Raman spectroscopy  
 
Steady State 
Steady state is the state when the plasma concentration of drug at any time point during 
any dosing interval should be identical to the concentration at the same time during any 
other dosing interval. 
 
Supra Bioavailability 
It is the term used when the test product shows appreciable large bioavailability than the 
reference product. 
 
T1/2 
Elimination half life of a drug is the time necessary to reduce the drug concentration in 
the blood, plasma, or serum to one!half of its initial concentration. 
 
Therapeutic Equivalent 
Therapeutic equivalents are drug products that contain the same active substance or 
therapeutic moiety and, clinically show the same efficacy and safety. 
 
Tmax 
It is the time required to achieve maximum drug concentration in 
systemic circulation. 
 
 
